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Resumo
Impacto de proteínas virais imunomoduladoras ao nível da 
célula e do animal inteiro 
Cerca de 50% do genoma dos vírus de DNA evoluiu direcionado para 
a manipulação de importantes funções celulares do hospedeiro. 
Estas estratégias são muito diversas e conferem ao vírus vantagens 
importantes sobre o sistema imunitário do hospedeiro. Esses genes são, 
por isso, potenciais fontes de informação para a geração de novos fármacos 
dirigidos à manipulação da resposta imunológica na saúde e na doença. 
Esta tese centra-se na análise da função de dois genes virais distintos, 
ambos com funções imunomoduladoras. O gene do Vírus da Peste 
Suína Africana codificado pela “open reading frame” I329L (ORF I329L), e 
o gene do vírus herpes-gama-68 de murino codificado pela “open reading 
frame” M2 (ORF M2). Ambos os vírus são conhecidos por codificar várias 
proteínas capazes de manipular componentes vitais da resposta antiviral. 
Neste trabalho nós demonstramos que tanto a ORF I329L quanto ORF 
M2 são capazes de manipular a imunidade inata ou adquirida.
O vírus da peste suína africana (ASFV) é o único membro da nova 
família Asfarviridae. Pode dizer-se que este vírus atingiu um equilíbrio 
com o hospedeiro na qual causa sintomas mínimos de doença sendo no 
entanto capaz de evitar sua eliminação através da manipulação do 
sistema imunológico. 
Com tropismo para os macrófagos, o vírus causa uma infeção persistente 
e assintomática nos seus hospedeiros naturais – potamoqueros e javalis 
selvagens. Em contraste, a infecção de porcos domésticos com o vírus da 
peste suína africana resulta numa doença hemorrágica fatal com apoptose 
linfoide massiva. A peste suína africana é, por isso, considerada como 
uma “doença veterinária emergente”.
Além de infetar suínos, o vírus da Peste Suína Africana infecta também a 
carraça, o seu vector de transmissão invertebrado. A replicação do vírus 
da Peste Suína Africana em organismos vertebrados e invertebrados 
sugere que o vírus terá desenvolvido estratégias de evasão imunológica 
para ambos os hospedeiros.
Para além disso, o facto de que em hospedeiros vertebrados o vírus da 
peste suína africana infectar unicamente uma célula tão importante na 
resposta imunitária inata, os macrófagos, sugere a presença de genes 
antagonistas da sinalização via TLR no genoma do ASFV.
A primeira parte desta tese descreve a procura por um gene capaz de 
manipular um importante componente da resposta controlada pelos 
receptores “Toll” e “Toll-like” no genoma do vírus da peste suína africana. 
Para tal, foi efetuada uma procura bioinformática por um gene/proteína 
com homologia com algum interveniente das vias acima citadas. Esta 
procura resultou na identificação da ORF I329L, uma glicoproteína 
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hipotética com um domínio transmembranar simples. Esta hipótese foi 
confirmada por ensaios bioquímicos e de biologia celular.
Usando um sistema de gene repórter foi possível demonstrar que a 
proteína codificada pela ORF I329L inibe a ativação do NFkB e IFN-β 
desencadeada pela estimulação do TLR3. Este mesmo sistema revelou 
que o mecanismo de inibição é independente de MyD88 e que é dirigido 
para a manipulação do intermediário de sinalização TRIF. 
Alvos celulares adicionais não foram excluídos já que muitos genes de 
evasão virais são multifuncionais. Finalmente, a expressão do gene I329L 
em células de mamífero resulta na inibição da expressão de RANTES 
após estimulação do TLR3 com um análogo do RNA de cadeia dupla, Poly 
I:C. Em suma, foi identificado e caracterizado um novo gene de evasão 
viral do Vírus da Peste Suína Africana, a ORF I329L, com a função de 
inibir a resposta desencadeada pelo receptor TLR3.
O vírus herpes-gama-68 de murino (MHV-68) é um membro do 
omnipresente e bem-sucedido grupo de vírus herpes. O MHV-68 é muito 
semelhante as outros vírus que causam infecções em humanos, como 
o vírus Epstein-Barr (EBV) e o vírus associado ao sarcoma de Kaposi 
(KSHV), produzindo um tipo de doença conhecida como mononucleose 
infeciosa aguda. Em ratinhos este vírus persiste latente em linfócitos B.
Muitos dos estudos sobre a resposta imunológica a infeções virais com 
vírus herpes-gama-68 de murino, provém da análise da patogénese 
viral em diferentes ratinhos geneticamente modificados. Estes são, na 
sua maioria, desprovidos de um ou de vários componentes do sistema 
imunológico adaptativo.
A construção de ratinhos transgénicos é uma estratégia poderosa para 
estudar os mecanismos de imunidade in vivo. O uso de promotores 
específicos que restringem a expressão do gene de interesse a 
determinado tipo de células é um refinamento que ajuda a superar os 
efeitos indesejáveis de uma transgenesis global, presente em todas as 
células do organismo.
Assim, a expressão restrita da ORF M2 em linfócitos B constitui uma 
nova abordagem in vivo para estudar o mecanismo de manipulação das 
defesas do hospedeiro por este gene.
Esta abordagem tem a vantagem de possibilitar estudos em contexto de 
infeção e constitui um novo sistema para o estudo do impacto de uma 
única proteína viral in vivo, com expressão restrita durante as fases aguda 
e latente do ciclo de infeção viral.
O gene M2 do vírus MHV-68 está envolvido no estabelecimento, 
manutenção e reativação da latência em células B. Mais ainda, está descrito 
que a proteína M2 interage com o sistema de sinalização VAV, o que 
sugere a manipulação dos receptores de células B através desta via 
para regular a ativação, proliferação e, ou sobrevivência das células B 
infetadas. Após analisar os marcadores de superfície dos linfócitos B de 
ratinhos transgénicos não se verificaram diferenças significativas nas 
subpopulações de células B da medula óssea ou do baço sugerindo 
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assim que a ORF M2 não tem qualquer impacto ndesenvolvimento destas 
células. Por sua vez, ratinhos transgénicos imunizados com o antigénio 
T-dependente (DNP-KLH) obtiveram níveis elevados, e estatisticamente 
significativos, de anticorpos IgM e IgG2a quando comparados com 
animais não modificados. Em particular, é importante salientar que, após 
a imunização com hemácias de carneiro, foi observado um decréscimo 
significativo da taxa de apoptose em linfócitos B. Estas observações 
sugerem que a ORF M2 possa ter funções ao nível do ciclo celular, em 
particular no aumento da sobrevivência das células.
A resposta do ratinho transgénico M2 à infeção com o vírus MHV-68 
foi também explorada neste modelo. Para isso, ratinhos transgénicos e 
controles foram infectados com vírus não modificados ou com vírus 
mutantes, em que a ORF M2 foi eliminada. De seguida o número de 
células B com MHV-68 em latência no baço foi quantificado através 
da contagem de placas virais geradas a partir da reactivação do vírus 
presente em células B isoladas deste órgão. Observou-se assim um 
aumento da produção de vírus em ratinhos não transgénicos infectados 
com o vírus mutante deficiente em M2 numa fase final da infeção mas não 
numa fase inicial.
Este fenótipo não foi revertido em ratinhos M2 transgénicos infectados 
com vírus mutante ou infectados com vírus não modificado. Nestes 
últimos, a observação de altos títulos de reativação numa fase tardia da 
latência é consistente com a já demonstrada importância da proteína M2 
como um immunodeterminante da imunidade celular protetora, assim 
como o seu impacto no estabelecimento da persistência.
Finalmente, uma considerável redução do número de células B em 
apoptose foi observada em ratinhos não transgénicos infectados com 
vírus MHV-68. Isto está de acordo com o que foi observado anteriormente 
com ratinhos transgénicos imunizados com hemácias de carneiro bem 
como com dados in vitro utilizando uma linha celular linfócitos B imaturos, 
WEHI-231 (Madureira et al., 2005).
Com base nos resultados obtidos com o nosso modelo, sugerimos que M2 
favorece a reativação e consequente transmissão do vírus ao aumentar 
a sensibilidade das células B infectadas em latência para a ativação 
induzida pelo recetor de imunoglobulinas (BCR) através da interação 
com VAV. Além disso, estes dados indicam que a ORF M2 pode funcionar 
como promotor da sobrevivência de células B ativadas.
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Abstract
Impact of viral immunomodulatory proteins at the level of the 
cell and the whole animal
Up to fifty percentage of the genome of large DNA viruses have 
evolved to manipulate the function of important cell biological and 
immunological responses and so give the virus an advantage 
over the host cell. Such genes are potential sources of novel 
health care pharmaceuticals for manipulation of immune responses 
in health and diseases. This thesis focuses in exploring the function 
of two different viral immune modulators, the African Swine 
Fever Virus (AFSV) ORF I329L and the Murine Gamma herpes  Virus 
(MHV-68), ORF M2 genes. Here, We demonstrate that ORF I329L and 
ORF M2 manipulate host innate and adaptive immunity, respectively. 
The ASFV is the only member of a new virus family, the Asfarviridae with a 
tropism for macrophages and which in the wild life hosts the Bushpig and 
Warthog, and it causes an unapparent persistent infection. In contrast, 
infection of domestic pigs with ASFV results in a fatal haemorrhagic 
disease with massive lymphoid apoptosis, and so may be regarded as a 
“recently emerged veterinary disease”. Importantly, the ASFV also infects 
an invertebrate vector, the soft-tick. The survival of ASFV in both 
vertebrates and invertebrates suggests that this virus has evolved 
“immune evasion” strategies for both of these hosts. This, and the fact 
that in the vertebrate host, the virus uniquely infects the central cell of the 
innate immune response, the macrophage, suggests the possibility of TLR 
signaling antagonists in the ASFV genome. 
Thus, the first part of the thesis presents a successful search for an ASFV 
host evasion gene that inhibits an important component of the innate 
immune response controlled by the Toll-Like Receptors (TLRs). The 
work commenced with a bioinformatics search of the ASFV genome 
and, with only marginal sequence homology by basic informatic enquiry 
yielded ORF I329L as a candidate. The ORF I329L is predicted to be 
transmembrane glycoprotein, and this was confirmed by biochemical and 
cell biological investigations. Using luciferase reporter assays, I329L was 
then demonstrated to inhibit TLR3 stimulated activation of NFκB and IFN-β 
by a MyD88 independent mechanism consistent with the targeting of the 
intracellular signaling intermediate TRIF. Additional cellular targets of the 
gene other than TRIF are not ruled out, as many virus host evasion genes 
are multifunctional. Finally, and significantly, introduction of the gene into 
the cells resulted in an inhibition of RANTES secretion in response to 
stimulation with the viral dsRNA analogue poly I:C. In conclusion, ASFV 
ORF I329L is a novel virus host evasion gene evolved to diminish the host 
cell responses, controlled by TLR3.
The MHV-68 virus is a member of the ubiquitous and successful herpes virus 
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group and establishes persistence in murine B-lymphocytes. The MHV-68 
behaves similarly to EBV and KSHV infections in humans, producing 
an acute mononucleosis-like illness and a pool of latently infected B 
cells. Much of what has been learned about the immune response to 
gamma-herpes virus infection with MHV-68 has come from evaluating its 
pathogenesis in different genetically modified mice lacking various 
components of the adaptive immune system. The construction of 
transgenic mice, on the other hand, is a powerful strategy to study 
mechanisms of immunity in vivo, and the use of specific promoters to 
restrict cellular expression to a certain cell type is an additional refinement, 
which may overcome the undesirable effects of whole body transgenesis. 
Thus, the B-cell restricted expression of the MHV-68 ORF M2 in the 
transgenic mice provides a novel approach to explore the mechanism and 
possible exploitation of this gene. Also it has the merit of being relevant in 
the context of an MHV-68 infection, providing a system to study the impact 
in vivo of a single virus protein with cell restricted transgenic expression 
during acute and latent phases of virus infection.
The M2 gene of MHV-68 was selected for B-cell restricted transgenic 
expression as it is thought to be involved in the establishment, 
maintenance and reactivation of latency in B cells. Moreover, M2 interacts 
with Vav signalling system, suggesting that M2 may modulate B-cell 
receptor-mediated signalling events through Vav to manipulate the 
activation, proliferation and/or survival of B cells. Analysing surface marker 
expression of these  M2-transgenic mice, it was observed that the 
M2 transgene was without impact on the development of B cells, 
as there were no differences in B-cell subsets in the bone marrow or in 
the spleen. Transgenic mice immunized with the T dependent antigen 
(DNP-KLH) have statistically higher levels of both IgM and IgG2a antibodies 
than normal mice. Particularly significant was the observation that upon 
immunization with sheep red blood cells, there was a significant decrease 
in B cell apoptosis in the M2-transgenic. 
The response of M2 transgenic mice to infection with the MHV-68 
was also explored. Transgenic and wild-type mice were infected with 
wild-type and M2 deletion mutant viruses, and then the numbers of 
reactivation-competent virus plaques in the spleen were measured as 
an indication of the number of latently infected B cells. The yield of virus 
recovered in normal mice infected with the M2 deficient virus increased 
at the late, but not at earlier phase of infection. This feature was not 
observed in the M2 transgenic mouse, where the response to wild-type and 
M2 knockout viruses was similar. The observation of higher reactivation 
centres in the late phase of latency in transgenic mice infected with 
wild-type viruses is consistent with the proven importance of M2 as a 
determinant of protective cellular immunity, and thus with an impact on the 
establishment of persistence.
Finally, considerably less B cell apoptosis was observed in MHV-68 
infected M2 transgenic mice than in MHV-68 infected normal mice, thereby 
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confirming our observation on sheep red blood cell immunized mice and 
the previous work of Madureira et al. in M2 transfected WEHI-231 B cell 
lines. Based on these results we suggest that M2, through its interaction 
with Vav, increases the sensitivity of the latently infected B cells to activation 
via the immunoglobulin receptor (BCR), and thus might favour reactivation 
and consequent virus transmission. In addition, these experiments suggest 
that M2 might function to promote the survival of activated B cells.
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Viruses & host’s immune system
Viruses
“Marginalized”, viruses do not belong to the five kingdoms of life; they are 
much smaller and much less complex than cells; they usually show up 
with little baggage, often wearing just a thin protein coat wrapped around 
a small cluster of genes (“bad news wrapped in protein”, according 
to Peter Medawar). They do not exhibit autopoiesis, as they do not 
have the self-maintenance metabolic reactions of living systems. They 
live as obligate parasites and are only able to reproduce within living 
cells. However despite their apparent molecular simplicity, viruses 
have evolved sophisticated strategies to survive and propagate within 
their hosts. Viruses act like hijackers invading the host cell and taking 
over it in order to synthesize their proteins and replicate. When viruses 
infect, we must rely on our immune system, one of the most complex 
and remarkable achievements in the evolution of living systems.
Viral infection control
Microorganisms exist in a highly dynamic state of equilibrium 
(homeostasis) with their hosts, in which both immune and non-immune 
pathways contribute to control. Pathogen survival, in virus infections 
results in viral clearance and/or asymptomatic homeostasis. 
In this light, an infection can be viewed as a highly complex interaction 
that takes place between two partners: the host and the pathogen. 
The host vs. pathogen interaction has provided the driving force 
for the reciprocal evolution of the immune system and the many 
pathogen strategies for host evasion.
In the immune-competent individual, primary control of an acute 
infection is provided by both innate and adaptive immune 
responses (Figure 1). On the other hand, the immune system 
microenvironment is not completely sterilized and in many 
cases pathogens have adapted by using general and specific 
strategies to counteract the host immune attack. Thus the 
mammalian immune system has evolved several mechanisms to destroy 
viruses and virus-infected cells and, at the same time, stimulated the 
evolution of virus’ countermeasures to neutralize or evade this host 
attack. 
1.1
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Figure 1. Homeostatic control of infection (Ghazal et al., 2000a). 
Primary control is exerted by immune responses and dependency on host factors 
provides a secondary level of hierarchical control at the cellular level.
Microorganisms exist in a highly dynamic state of equilibrium 
(homeostasis) with their hosts, in which both immune and non-immune 
pathways contribute to control. Pathogen survival, in virus infections 
results in viral clearance and/or asymptomatic homeostasis. In this light, 
an infection can be viewed as a highly complex interaction that takes 
place between two partners: the host and the pathogen. The host vs. 
pathogen interaction has provided the driving force for the reciprocal 
evolution of the immune system and the many pathogen strategies for 
host evasion.
The virus achieves a dynamic balance with the host immune response 
that ensures survival of both pathogen and host. Their study 
cannot merely reveal how viral mechanisms survive and cause disease, 
but also new aspects of immune responses. Therefore, the immune 
system is not completely efficient in clearing a virus during a primary 
infection. The residual population of virus may eventually be eliminated 
or, as is common for a number of viruses, adopt one of two viral survival 
strategies: The establishment of persistence or latency. 
In addition to the innate and adaptive immune responses, a secondary 
level of control is employed by non-immune pathways that are associated 
with immunity and is connected to the obligate dependency of the virus 
on its host. This secondary stage of control plays an essential role in 
modulating infections at the cellular level. Essentially, three categories 
of regulatory response pathways provide the secondary level of control 
in the infected cell: the cell cycle, apoptosis, and the intra- and 
extracellular signalling pathways, all of which reflect changes in the 
intracellular milieu of the cell (Ghazal et al., 2000b). Viral pathogenesis 
is varied, with each progression being characterized by distinct clinical 
manifestations and outcomes. These include: a) acute infection; b) latent 
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infection; c) persistent infection and d) slow virus infection. Acute viral 
infections are characterized by a comparatively rapid incubation time, 
production of large amounts of infectious particles, and resolution either 
by complete viral clearance or death of the host. In the human 
respiratory tract for example, viruses can produce a spectrum of acute 
infections, ranging from the common cold and acute bronchiolitis to 
pneumonia (influenza virus). 
In contrast, latent and persistent infections result from failure of the 
host to completely clear the virus after acute infection, suggesting 
that the virus has evolved a mechanism for immune evasion. In latent 
infections, infectious virus “disappear” after the acute phase, but can 
reappear at a later time. This involves incomplete expression of viral 
genes during periods of latency or quiescence and production of fully 
assembled, replicating viral particles during episodes of reactivation 
or recurrence. Common stimuli of reactivation include an acquired 
immunodeficiency (i.e., organ transplant recipients on immuno 
suppressive therapy) or stress. 
Many DNA viruses produce latent infections. Varicella zoster virus 
exhibits the prototypical latent infection. Persistent infection is 
characterized by continuous viral replication (and therefore, persistence 
of infectious virus), but usually at a lower level than is observed 
during acute infection. This type of infection is also well described 
for  RNA viruses such as measles and lymphocytic choriomeningitis. 
Chronic infection differs from latent viral infections in that 
viral proteins, which might stimulate host immune and 
inflammatory responses, are produced as a result of complete 
viral replication. Slow virus infections, such as rapidly progressive 
dementias caused by prions (proteinaceous infectious 
particles), have only been described to affect the central nervous 
system (Alcami & Koszinowski, 2000) .
The protection from a vast range of potential pathogens encountered 
during the lifetime of an individual is achieved through the highly 
coordinated action of the innate and adaptive arms of the immune 
system. The innate branch of the immune system 
provides a rapid, and relatively nonspecific, initial response 
to pathogens. In contrast, the adaptive branch is required 
for presentation of the four classic features of an immune 
response, namely specificity, memory, diversity, and self-non-self 
discrimination. 
The development of the adaptive arm of the immune system is 
dependent on the tightly regulated activation of B and T lymphocytes 
in response to antigenic stimulation. When a vertebrate animal is 
infected by a pathogen, the immediate response is a non-clonal 
innate response. Meanwhile an adaptive immune response is induced. 
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Notably, the innate immune system also has a key role in the activation 
and modulation of the adaptive immune system as merely the recogni-
tion of an antigen by a lymphocyte is not sufficient to initiate an immune 
response and, in fact, can induce suppression of T cells. 
A common practice to efficiently induce adaptive responses is 
co-injection of  complete Freund’s adjuvant. This is a mixture 
of killed mycobacteria in oil, which was appropriately described 
by Janeway (1989) as “the immunologist’s dirty little secret.” 
Adjuvants are thought to trigger the innate immune system, 
which subsequently provides co-stimulatory signals required 
to stimulate the adaptive immune system (Fearon, 1997; 
Janeway, 1989). The context of an antigen (e.g. its localization, 
the presence of conserved pathogen-specific structures, and any 
tissue damage) is a determinant factor controlling the direction of 
an acquired immune response. Janeway suggested that the innate 
signals allow the vertebrate immune system to distinguish 
between infectious non-self and non infectious self molecules 
(Janeway, 1992).
An illustrative example of the importance of the context of antigens in 
the induction of adaptive responses was given by an experiment where 
viral proteins were converted into self-antigens by inserting their genes 
into the germ line of mice and they failed to provoke autoimmunity. 
The adaptive immune system did not “tolerate” the viral antigens, but 
refrained from responding because the antigens were presented in a non-
inflammatory context. Only when the mice were subsequently infected 
 with the live virus (Ohashi et al., 1991; Oldstone et al., 1991) initiation 
of adaptive immunity resulted from an antigen-specific release of 
nonspecific effectors mechanisms (Janeway, 1989). Specific binding 
between antibody and antigen, for example, triggers the complement 
cascade and attracts phagocytic cells and killer cells. Similarly, specific 
antigen recognition by T cells can lead to the release of nonspecific 
cytotoxic molecules. Thus, the vertebrate immune system combines 
the evolutionary wisdom of the innate immune system with the large 
diversity of the adaptive system. 
The need for innate signals in the induction of adaptive responses, 
however, would allow pathogens to evade the adaptive immune 
response by manipulating the innate response. The flexibility supplied 
by the random generation of lymphocytes is thus vulnerable through its 
requirement for innate signals (Janeway, 1992; Medzhitov et al., 1997). 
This dependence of the adaptive immune system on evolutionarily 
conserved innate signals raises an evolutionary problem. It is often 
argued that the adaptive immune system evolved to cope with rapidly 
coevolving pathogens. The clonal distribution of randomly rearranged 
lymphocyte receptors provides a high flexibility of possible responses, 
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perhaps enabling the adaptive immune system to adapt more quickly to 
coevolving pathogens than the innate immune system can. However, 
if an adaptive immune response depends strictly on the innate im-
mune system, then pathogen evasion of an innate response implies 
 the possible subsequent evasion of an adaptive immune response. 
Viruses have indeed been shown to interfere with the innate 
immune system by producing proteins (e.g. soluble cytokine 
receptors or proteins that regulate antigen presentation) that 
put the immune system “on the wrong track”. Some years ago, 
a commentary in Science (Barinaga, 1992) announced that 
viruses engage in “Star Wars” strategies against the immune 
system. Some of the viral invaders make receptors (“viroceptors”) 
that mimic normal cellular receptors and so can sequester and 
inactivate molecules critical to the function of adaptive immunity 
(Goodman, 2004).
Since then, numerous other viral subterfuges for evading or 
subverting host defence mechanisms have been described and viruses 
are now known to employ an extraordinary spectrum of 
proteins to target immune molecules of the host cells 
(Alcami & Koszinowski, 2000; Engel & Angulo, 2012; Finlay 
& McFadden, 2006; Vossen et al., 2002). One particularly 
effective host defence for the infected cell is to self-destruct 
by programmed cell death, and in fact, cell death is triggered by 
infection with a wide variety of viruses. Many viruses use specific proteins 
to suppress apoptosis in order to extend the life of their cellular host 
and thus provide the necessary time for their replication (Aubert & 
Jerome, 2003). 
The innate arm of the immune system
The innate immune system is the first line of host defence against 
pathogens and is largely mediated by phagocytes including 
macrophages and dendritic cells (DC). The innate immune 
system is not completely unspecific, as it was initially thought, 
since it does discriminate between self and a variety of pathogens. 
To do this, the innate immune system uses a limited number 
of germ line-encoded pattern-recognition receptors (PRRs).
The principal mechanisms of innate immunity are natural 
antibodies, complement mediated mechanisms, inflammation and the 
induction of apoptosis, chemokines and cytokines. 
The immediate response to viral infection relies on PRRs, most 
prominently the Toll-like receptors (TLRs) and the RNA helicases RIG-I 
and MDA-5, as well as double stranded RNA-dependent protein 
kinase (PKR) and the DNA receptor, DAI. These PRRs recognize 
1.3
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pathogen-associated molecular patterns (PAMPs) such as viral proteins 
and nucleic acids. The engagement of these receptors then initiates 
intracellular signalling cascades which ultimately cause the activation 
of transcription factors and the expression of type I interferons 
and pro-inflammatory cytokines (Vossen et al., 2002). This innate 
response establishes an anti-viral state in the infected cell and its 
neighbours and alerts immune cells to the danger. In order to establish a 
productive infection, viruses need to overcome this initial anti-viral 
response. 
For the early control of virus infections, in particular acute infections, 
the interferon response is of paramount importance for most viruses 
and is a particular focus of this thesis. Viruses have evolved several 
molecular strategies to act over different levels on the signalling 
pathway to downregulate the IFN system. The exact strategy used by a 
virus will presumably depend on the biology of the infection and will be 
a major factor that will influence the pathogenesis of that virus infection 
(Randall & Goodbourn, 2008). Often viral antagonists are multifunctional 
proteins that interact with multiple host components, in this manner 
increasing the efficiency of their host evasion and also allowing the 
virus to influence diverse biological processes in infected cells. 
The size of viral genomes contrasts with the number of mammalian 
genes dedicated to host defence mechanisms, providing an additional 
selective pressure for the evolution of such viral multifunctional 
proteins (Haller et al., 2006; Vossen et al., 2002).
The Toll-like receptors (TLRs) family
Toll was initially described as a type-I transmembrane receptor with 
an important role in defence against fungi and Gram-positive bacteria 
in Drosophila melanogaster. The extracellular domain of Toll contains 
leucine-rich repeats (LRR), whereas the intracellular tail of the receptor 
shares striking homology with the intracellular domain of interleukin-1 
(IL-1) receptor type I, which is designated the Toll–IL-1R (TIR) domain 
(Figure 2). The initial data suggested that Toll is an important component 
of the antimicrobial defence of Drosophila, and the suspicion that 
mammalian homologues might have similar functions has proved to 
be well founded. To date, 13 mammalian TLRs have been identified, 
and they all share similarities in their extracellular and intracellular 
domains. The molecular basis of their intracellular signalling depends 
on the conserved part of their TIR domain (Brikos & O’Neill, 2008; Kang 
& Lee, 2011; Watters et al., 2007).
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Figure 2. Schematic structure of an human TLR (Vercammen et al., 2008).
TLRs are activated in response to a large spectrum of conserved 
structures called pathogen associated molecular patterns (PAMPs), 
ranging from bacterial and viral components to fungal and protozoan 
molecules, for example, bacterial lipoproteins, lipoteichoic acid and 
zymosan are recognized by TLR2; double-stranded RNA by TLR3; 
lipopolysaccharide (LPS) and heat-shock proteins by TLR4; flagellin 
by TLR5; single-stranded RNA by TLR7 and TLR8; and CpG motifs of 
bacterial DNA by TLR9. A vast number of ligands have been identified 
that are specifically recognized by different TLRs. A multitude of 
studies have reported additional microbial ligands for TLRs, as 
summarized in many reviews (Demengeot et al., 2006; Gay & Gangloff, 
2007; Kang & Lee, 2011; Uematsu & Akira, 2006). The ability not only to 
respond appropriately but also to self-regulate host response to invading 
pathogens is vital to the capacity to mount an appropriate primary 
immune response. After recognition, a cascade of intracellular 
signalling events is activated which culminates in the induction of pro-
inflammatory cytokines.
Dimerization as a requirement for signaling by TLRs
The binding of agonistic PAMP ligands induces dimerization of the 
ectodomains of the various TLRs, forming strikingly similar structures 
(“m”-shaped complexes). The dimerization of the extracellular domains 
results in the intracellular TIR domains, and this initiates signalling by 
recruiting intracellular adaptor dimerization of proteins (Jin & Lee, 
1.3.2
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2008). In addition, heterodimerization is reported to be responsible for 
differential recognition of PAMPs, and this is apparent in the distinction 
of di- and tri-acylated lipopeptides by TLR2–TLR1 and TLR2–TLR6 
heterodimers, respectively.
There are five adapters identified so far, named a) Myeloid 
differentiation primary response protein 88 (MyD88), b) MyD88-adapter 
like (Mal) or TIR domain-containing adapter (TIRAP), c) TIR domain- 
containing adapter inducing interferon-beta (TRIF) or TIR domain- 
containing adapter molecule-1 (TICAM-1), d) TRIF-related adapter 
molecule (TRAM) or TICAM-2, and e) sterile alpha and 
HEAT-Armadillo motifs (SARM) (Kenny & O’Neill, 2008;). The first four 
play a fundamental role in TLR-signalling, defining which pathways will 
be activated, depending on which of these adapters will be recruited 
by each TLR. Among these adapter proteins MyD88 and TRIF are now 
considered as the signalling ones and hence the TLR pathways can 
be categorized as MyD88-dependent and TRIF-dependent (O’Neill & 
Bowie, 2007).
Signaling Pathways 
TLRs initiate shared and distinct signalling pathways (Figure 3) by 
recruiting different combinations of TIR domain-containing adaptor 
molecules: MyD88 is used by all TLRs except TLR3; TIRAP is used by 
TLR2 and TLR4; TRIF is used by TLR3 and TLR4; and TRAM is used 
only by TLR4 .
1.3.3
Figure 3. TLR signalling pathways (Keogh & Parker, 2011). 
Upon activation by ligands, TLRs recruit TIR adapter proteins MyD88, Mal, TRAM 
and TRIF, which leads to recruitment of IRAKs and ultimately the induction of NFkB-
dependent genes, including TNFα, IL-12, IL-6 and IL-8. TLR3 and TLR4 also signal 
via TRAM and TRIF leading to IRF3-dependent gene expression. In addition, IRF7 is 
activated downstream of TLR7, TLR8 and TLR9, which leads to IRF7-dependent gene 
expression, including IFN-β and IFN-inducible genes.
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Interestingly, TLR4 induces two distinct signalling pathways controlled 
by the TIRAP-MyD88 and TRAM-TRIF pairs of adaptor proteins, 
which elicit the production of pro-inflammatory cytokines and type I 
interferon, respectively. TLR4 activated these two signalling pathways 
sequentially in a process organized around endocytosis of the TLR4 
complex. TLR4 first induces TIRAP-MyD88 signalling at the plasma 
membrane and is then endocytosed and then activates TRAM-TRIF 
signalling from early intracellular endosomes (Kagan et al., 2008). The-
se signalling pathways activate the transcription factors nuclear factor 
NFκB and activator protein-1 (AP-1), which is common to all.
The TLR3 signaling pathway regulation
The signalling pathways of TLR3 are initiated by the sole recruitment of 
TRIF among TIR adaptors, which then activates the TRIF-dependent 
pathway, leading to the subsequent production of inflammatory 
cytokines and type-I IFNs, and to the up-regulation of co-stimulatory 
molecules (Figure 4). TRIF is critical in mediating TLR3 signalling and 
is emphasized by the fact that it is targeted for immune evasion by 
some viral proteins (Figure 5) (Vercammen et al., 2008).
1.3.4
Figure 4. TLR3 signalling pathways (Vercammen et al., 2008). 
Binding of dsRNA to the TLR3-CD14 complex induces the activation of several 
intracellular signalling pathways. The activation of NFkB and IRF3 is achieved by two 
different signalling branches originating from the TLR3 adaptor molecule .
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TLR3 signalling is potentially harmful or even fatal for the host cell. 
Sustained TLR3 activation is associated with the overproduction of 
pro-inflammatory cytokines and can result in systemic inflammatory 
response syndrome. 
In addition, excessive TLR3 expression or triggering is associated 
with several inflammatory diseases, such as inflammation-associated 
myopathies, lupus nephritis, West Nile virus-driven central nervous 
system inflammation, and viral or autoimmune liver disease. 
It is therefore not surprising that mammalian cells have also 
evolved several mechanisms for controlling TLR3-mediated 
responses. For example, Endogenous negative regulators interact 
with TRIF, such as the protein inhibitor of activated signal 
transducers and the activators of transcription (PIASy), 
TNF receptor-associated factor 1 (TRAF1) and the TIR motif-containing 
protein (SARM), A20 protein, and TNF receptor-associated 
factor 4 (TRAF4). However, these proteins inhibit NFkB as 
well as IRF3 activation. PIASy is a member of the SUMO- 
ligase family that also interacts with IRF3 and IRF7. Although this 
protein inhibits TRIF-induced NFkB and IRF3 activation, it has no 
effect on TRIF-induced apoptosis (Zhang et al., 2004). TRAF1 is an 
inducible protein that binds to the TIR domain of TRIF and is cleaved by a 
TRIF-activated caspase. Because caspase inhibition or the 
expression of a noncleavable TRAF1 mutant abolishes the inhibitory 
effect of TRAF1, it has been suggested that TRIF-induced cleavage 
of TRAF1 is essential for the inhibition of TRIF signalling (Su et al., 
2006). The TIR-containing protein SARM also associates with the TIR 
domain of TRIF and is a broad inhibitor of TRIF-induced cytokine and 
chemokine production (Carty et al., 2006).
A20 is a deubiquitinating enzyme that is induced by several stimuli, 
including dsRNA and Sendai virus infection. A20 has been shown 
to co-precipitate with TRIF and to inhibit TLR3-mediated NFkB and 
IRF3 activation. However, its deubiquitinating activity does not seem 
to be required for the inhibition of TRIF signalling (Wang et al., 2004). 
Additionally, A20 has been shown to deubiquitinate RIP1, TRAF6, 
and IKK in the TNF and TLR4 signalling pathway to NFkB, suggesting 
that these signalling proteins might also be targeted in the TLR3 
signalling pathway to NFkB. Furthermore, A20 also co-precipitates with 
TBK1 and IKKε and inhibits IRF3 phosphorylation and dimerization 
following the engagement of TLR3 (Saitoh et al., 2005). Finally, TRAF4 
is another inducible protein that also physically interacts with TRIF and 
TRAF6 and counteracts their function (Takeshita et al., 2005)
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Figure 5. Endogenous and viral inhibitors of TLR3-mediated NFkB or IRF3 
activation (Vercammen et al., 2008). 
Most known inhibitors interfere with the function of TRIF, either by interacting 
with TRIF (PIASy, TRAF1, SARM, A20, TRAF4, and the vaccinia virus protein 
A46R) or by degrading TRIF (hepatitis C virus protease NS3/4A). Other inhibitors 
interact with TRAF6 (TRAF4, A20, and vaccinia virus protein A52R), RIP1 (RIP3), 
TBK1/IKKε (A20, SIKE, and SHP-2), or IRF3 (PIASy). 
In contrast to the above-described inhibitors that inhibit both NFkB and 
IRF3 activation, suppressor of IKKε (SIKE) interferes uniquely with 
TLR3-triggered IRF3 activation. Under physiological conditions, SIKE 
is associated with TBK1 and dissociates upon TLR3 stimulation. The 
over expression of SIKE disrupts the interactions of IKKε or TBK1 with 
TRIF and IRF3, without affecting the interactions of TRIF with TRAF6 
and RIP1. Consistently, the overexpression of SIKE inhibits virus- and 
TLR3-triggered IRF3 but not NFkB activation (Huang et al., 2005). 
Due to the need for phospho-tyrosine residues in the TIR domain of 
TLR3, one might expect that an alternative way of interfering with TLR3 
signalling is dephosphorylation by a tyrosine phosphatase. In this 
context, SH2-containing protein tyrosine phosphatase 2 (SHP-2) 
was recently reported to inhibit TLR3-activated IFN-β production. 
However, this seems to occur by a phosphatase activity-independent 
mechanism, in which SHP-2 interacts with the kinase domain of TBK1 
to inhibit its activity (An et al., 2006).
Although it is surprising how many different endogenous or viral 
proteins and mechanisms have evolve to negatively regulate 
1
32 33
TLR3 signalling (Figure 5), this complexity also underscores 
the importance of the process. The diversity of NFkB and 
IRF inhibitory proteins may  have evolved to establish a 
redundant system in which one negative-feedback regulator can 
compensate for the loss or failure of others. Moreover, specific 
regulatory proteins might change the balance between NFkB and IRF3 
activation. Most likely, the role of specific negative regulatory proteins 
also depends on the cell type or the cell context. 
Innate antiviral responses 
Each TLR has common effects, such as inflammatory cytokine and 
chemokine induction or upregulation of costimulatory molecule 
expression, but also has its specific function. They activate interferon 
regulatory factor 3 (IRF3) and/or IRF7, leading to the production of 
type I IFNs such as IFNα and IFNβ (Colonna, 2007). Activation of the 
IRFs is crucial for the induction of type I IFNs, and although NFkB also 
contributes to IFN induction, it is mainly required for the induction of 
pro-inflammatory cytokines. Type I IFNs can induce an antiviral state in 
most cells and, in addition, have diverse functions in the development 
of adaptive immunity (Barnes et al., 2002; Haller et al., 2006). 
IRF together with NFkB family of transcription factors are the two key 
transcription factors that are activated during an antiviral immune 
response. TLR3- and TLR4-induced IRF activation is mediated by 
TRIF, whereas MyD88 is sufficient for IRF activation induced by TLR7, 
8 and 9 (Colonna, 2007). TLR signalling to NFkB proceeds mainly via 
MyD88, the IRAKs and TRAF-6. 
The signalling pathway emanating from RIG-I is less well defined, 
but it involves a mitochondrial adaptor molecule called IPS-1 (IFN-β 
promoter stimulator) also called MAVS (mitochondrial antiviral 
signalling), Cardif [CARD (caspase recruitment domain) adaptor 
inducing IFNβ] or VISA (virus induced signalling activator) for 
activation of both NFkB and IRF-3. Even though their upstream 
signalling pathways are distinct the signalling pathways elicited by 
the different classes of PRRs, converge at the level of the IKK [IκB 
(inhibitory kB) kinase] complex (containing IKK-α, IKK-β and IKK-γ) for 
activation of IRF-3 and IRF-7.
Role of TLRs in macrophages
Toll-Like Receptors are very important for a rapid activation of 
the innate immune system, especially for the efficient function of 
macrophages. The latter are very important because they are the 
scavengers of the immune system, producers of immunomodulatory 
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molecules and, for this thesis, because they are the main target cells 
of African Swine Fever Virus (ASFV). Due to their heterogeneity, 
macrophages have the ability to reside in many different tissues 
of the body. Their function is to ‘reside’ in those tissues and 
remove apoptotic and necrotic cells, as well as any invading pathogens. 
To do this, macrophages express surface receptors that 
bind to apoptotic cells and invading pathogens, leading 
to their internalization in a process known as phagocytosis. 
In addition, it is crucially important that, in response to 
pathogens, macrophages are able to mount an appropriate 
immune response to further aid in the fight against infection. 
The macrophage contribution to the immune response can 
be divided into an immediate innate response through the 
detection and engulfment of invading pathogens and the secretion of 
immunomodulatory molecules, and into acquired immune response 
through antigenic presentation, thus initiating T cell responses 
(Banerjee & Gerondakis, 2007).
The major receptors for detection of invading pathogens are the 
well-known Toll-like receptors (TLRs). These are expressed in a 
cell-specific way, varying greatly from cell-to-cell. Unlike other 
cells that express only some TLRs, macrophages express most of 
the known TLRs. The fact that most of the TLRs are expressed by 
macrophages stresses the importance of these receptors for the 
function of these cells. Not only are they essential for the immediate 
detection of invading pathogens, thereby initiating an inflammatory 
response, but also they are important for each of the stages of 
phagocytosis, ranging from engulfment of invading pathogens, to 
antigen processing and presentation of antigenic peptides. In addition, 
TLR signalling is also required for the up-regulation of cytokines, MHC 
molecules and co-stimulatory molecules that are needed to mount an 
appropriate adaptive T cell response. 
Furthermore, to some extent TLR expression is specie specific, 
differing among species. For example, porcine alveolar macrophages 
express TLR3 (Chaung et al., 2010; Liu et al., 2009; Sang et al., 
2008), whereas bovine alveolar macrophages evidently do not 
(Werling et al., 2006). Moreover, differences exist between and within 
species in regards to TLR3 regulation. For example, TLR3 expression is 
induced by LPS in murine macrophages, but not in human macrophages 
(Alexopoulou et al., 2001). In murine macrophages TLR3 upregulation 
involves autocrine/paracrine IFN-β, whereas in human macrophages 
the IFN-β induced upregulation of TLR3 is blocked by pre-treatment 
with LPS (Heinz et al., 2003). Mice fail to express TLR10, however they 
express additional TLRs such as TLR11, TLR12 and TLR13 which are 
absent in humans (Beutler, 2004).
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Phagocytosis by macrophages is essential for the removal of 
apoptotic and necrotic cells, as well as for the ingestion and processing of 
invading pathogens. These results in the death of the pathogen and 
the presentation of antigen peptides derived from pathogenic proteins 
and incorporated into MHC class II of the Antigen Presenting Cell 
(APC). The MHCII-peptide complex is recognized by CD4+ T cells, 
resulting in the activation of the adaptive immune responses. As 
Phagocytosis of pathogens often goes together with inflammatory 
responses and the inflammatory response is driven by TLRs, it was 
suggested that phagocytosis and TLR activation could 
be functionally linked (Underhill & Gantner, 2004). 
Evidence that TLRs play a role in phagocytosis come from a study 
that show that TLR-1, TLR-6 and TLR-2 were recruited to phagosomes 
containing bacterial components in all stages of phagocytosis, but also 
to phagosomes containing IgG-opsonized erythrocytes that do not 
display any microbial components. This suggests that TLRs are 
recruited to phagosomes, where they interact with pathogen PAMPs, 
leading an inflammatory response (Ozinsky et al., 2000). Stimulation of 
mammalian cells transfected with porcine TLR3 and TLR7-constructs 
with their respective agonists, poly (I:C) and imiquimod (R837), and 
adenovirus provoked activation of interferon regulatory factors (IRFs) 
providing molecular and functional information about the role of TLR3 
and TLR7 in mediating immune protection against porcine viral diseases 
(Sang et al., 2008). 
Mechanisms to manipulate PPRs
Viruses have also evolved a range of mechanisms to interfere with the 
signalling pathways elicited in response to their detection by the innate 
immune system. Some viral proteins specifically target certain PRRs 
or their downstream signalling pathways, while others have a broader 
range of action and interfere with NFkB and/or IRF activation more 
generally. 
Three major TLR-mediated escape mechanisms have been 
identified to-date: a) TLR2-mediated immunosuppression, due to 
either premature or biased anti-inflammatory effects; b) TLR-mediated 
induction of viral replication; c) Prevention of TLR recognition, which 
inhibition of the IFN response due to stimulation of TLR3 being of 
particular relevance in virus infections.
a) TLR2-mediated immunosuppression, due to either premature or 
biased anti-inflammatory effects:
In contrast of TLR4, TLR2 signals are strong mediators of 
anti-inflammatory effects and are needed during the recovery 
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phase of infection for the reversal of the inflammatory process. 
Immunosuppression induced by TLR2 is  due  to either an exaggeration 
or a premature activation of the normal anti-inflammatory effects of 
TLR stimulation. The first study that investigated the differential effects 
of TLR2 and TLR4 stimulation on dendritic cells, reported the failure of 
TLR2 ligands to induce the release of IL-12 and interferon (IFN-γ), thus 
favouring a Th2-type response (Hirschfeld et al., 2001). As mentioned 
above, microorganisms have developed strategies to either block or 
avoid their recognition by TLRs and hence the subsequent activation 
of innate defences. For example, Treponema inhibits cell activation 
induced by several TLRs (TLR3, TLR4 and TLR9) by blocking the 
function of LPS-binding protein and CD14 (Re & Strominger, 2001).
b) TLR-mediated induction of viral replication:
 A different strategy for escaping TLR recognition is used by the fungus 
Aspergillus fumigates. It evades immune recognition by germinating 
hyphae that are not recognized by TLR4 recognition, but are 
recognized by the TLR2, thus shifting the balance towards a 
permissive IL-10 and Th2-type profile (Netea et al., 2003). Several 
bacterial pathogens have also modified the structure of particular 
PAMPs to avoid recognition by TLR4 or TLR5; pathogens, such 
as Porphyromonas gingivalis or Leptospira, have LPS structures 
(normally recognized by TLR4) that only interact with TLR2 
(Hirschfeld et al., 2001; Werts et al., 2001), whereas flagellin of 
Helicobacter pylori is not properly recognized by TLR5, permitting 
the survival of the bacteria without loss of virulence (Gewirtz et al., 
2004).
A particular form of immune evasion is represented by stimulation of 
viral replication through TLR activation and is demonstrated 
specifically by retroviruses. In this respect, signalling through TLR2, 
TLR4 and TLR9 significantly enhances human immunodeficiency 
virus (HIV)-1 replication in either mast cells (Sundstrom et al., 
2004) or transgenic mice. During coinfection with mycobacteria 
and HIV-1,  HIV-1 expression is potentiated by mycobacteria 
through TLR2 stimulation (Báfica et al., 2003). Another retrovirus, the 
Mouse Mammary Tumour Virus (MMTV), persists indefinitely in 
C3H/HeN mice, but not in the TLR4-defective C3H/HeJ mice. The 
immune escape of MMTV by persistent infection is mediated by TLR4-
triggered production of the immunosuppressive cytokine IL-10 (Jude 
et al., 2003). 
c) Prevention of TLR recognition, which inhibition of the IFN 
response due to stimulation of TLR3 being of particular relevance in 
virus infections. 
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Recently, viral proteins have been described which prevent RNA 
detection through RIG-I and MDA-5: the Paramyxovirus V proteins, 
which bind to MDA-5, and Influenza Virus NS1, which binds to RIG-I. 
Other proteins such as Ebola virus VP35 bind to the dsRNA and 
thereby prevent detection by RIG-I and also PKR. Hepatitis C virus 
expresses the protease NS3/4a, which cleaves TRIF and the RLH 
(RIG-like helicase) adaptor IPS-1 and thereby specifically targets and 
evades TLR3- and TLR4- as well as RLH-signalling. 
All these examples suggest that microorganisms manipulate specific 
PRR-mediated signals to escape from the host defence, either 
by down-modulation of leukocyte function, or amplification of viral 
replication. Definitely virus mechanisms for manipulation of TLR 
mediated responses provide a route towards better antiviral strategies 
and vaccines. 
Other examples for viral proteins that target specific PRR signalling 
pathways are the VACV (Vaccinia virus) TLR antagonists A52 
and A46. The poxvirus protein A52R blocks activation 
of the pivotal transcription factor NFkB, which is induced 
by multiple TLRs (including TLR3) through association with 
IRAK2 and TRAF6 (Tumour Necrosis Factor Receptor-Associated 
Factor-6), two key proteins of the TLR intracellular signalling 
cascade, and interferes with the induction of pro-inflammatory 
cytokines (Harte et al., 2003; Maloney et al., 2005). A46 contains 
a TIR (Toll/IL-1 receptor) domain, interacts with the host TIR adaptors 
and thereby disrupts TLR signalling to NFkB and IRF-3 (Stack et al., 
2005). Apart from A46 and A52, VACV encodes a whole range of 
immunomodulatory proteins, including several NFkB inhibitors, 
such as N1L K1 (Shisler & Jin, 2004) and M2 (Gedey et al., 2006) 
(Figure 6).
All these examples suggest that microorganisms manipulate specific 
PRR-mediated signals to escape from the host defence, either 
by down-modulation of leukocyte function, or amplification of viral 
replication. Definitely virus mechanisms for manipulation of TLR 
mediated responses provide a route towards better antiviral strategies 
and vaccines.
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Figure 6. Viral evasion and subversion of Toll-like receptor signalling (Bowie & 
Unterholzner, 2008).
Following activation; recruit the adaptor proteins MyD88, TRIF, MAL and TRAM, as 
indicated. These then triggers signalling cascades involving IRAK and TRAF proteins, 
which finally converge at the activation of the IKK family members and TBK1. 
The vaccinia virus protein A46R sequesters all these adaptor proteins, whereas the 
hepatitis C virus protein NS5A selectively binds MyD88 and the HCV NS3–4A protease 
 cleaves TRIF. Human T-cell leukaemia virus type 1 protein p30 acts even further 
upstream by reducing the expression of TLR4. VACV A52R binds to and inhibits 
IRAK2, thereby affecting several TLR pathways that lead to NFkB activation .
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African Swine Fever Virus (ASFV) 
African Swine Fever Virus (ASFV) is able to survive in a vertebrate 
(pig) and an invertebrate (tick), which suggests that this virus may 
have evolved efficient “immune evasion” strategies in both of these 
two hosts. This, and the fact that in the pig the virus uniquely infects 
the central cell of the innate immune response, the macrophage, raises 
the possibility of Toll-like receptor (TLRs) signalling antagonists in the 
ASFV genome. Interfering with innate immune response is a common 
strategy in viruses for host evasion and escape of recognition by the 
immune system; thus avoiding being eliminated from the organism (De 
Oliveira et al., 2011).
The principal event of pathogen recognition is the interaction of 
their PAMP’s with host PRR’s triggering the first steps of immune 
response. Various intracellular signalling pathways can operate between 
recognition of the pathogen and the ultimate cellular response.
The replication of ASFV in macrophages provides an opportunity for 
the virus to interfere with both the innate and de adaptive response 
to the infection by manipulating macrophage function.  Different 
classes of ASFV encoded proteins which interfere with host defences 
have been identified (Chapman et al., 2008; Dixon et al., 2004). And 
many more are thought to inhibit this and others immune pathways.  
Pathogenicity and epidemiology
The ASFV causes an acute haemorrhagic fever with high mortality 
rates in domestic pigs, and unapparent infection with transient, low 
viremic titers, persistent infections in its natural hosts, warthogs, bush 
pigs and soft ticks of the species Ornithodoros.  The pathogenesis 
of ASFV in ticks (O. porcinus porcinus) is characterized by a low 
infectious dose, lifelong infection, efficient transmission to both pigs 
and ticks, and low mortality until after the first oviposition. Thus 
ticks probably constitute the most important natural vector of ASFV, 
although both the mammalian and tick hosts are probably required for 
the maintenance of ASFV in the sylvatic cycle (Kleiboeker & Scoles, 
2001).
The disease is a problem for pig farming worldwide and leads to 
economic losses in affected countries. The main targets for virus 
replication are cells of monocyte/macrophage lineage and those 
expressing cell surface markers characteristic of intermediate/late 
stages of differentiation are permissive for virus replication (McCullough 
et al., 1999). In the early stages of infection virus replication is seen 
primarily in macrophages and this is most likely the primary event 
leading to the haemorrhagic and lymphoid apoptotic pathology 
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(Oura et al., 1998). In common with other viral haemorrhagic fevers, 
ASFV is characterized by damage to vascular endothelial 
cells and this contributes to vascular permeability. This is thought to 
be caused by factors released from virus-infected macrophages, 
although direct infection of endothelial  cells may be involved. As 
infection of endothelial cells in vitro by ASFV leads to induction of 
apoptosis which could contribute to the destruction of vascular 
endothelial cells in infected pigs (Vallée et al., 2001).
Virus transmission
Montgomery in Kenya first identified the disease in the 1920s 
following spread from infected wildlife. Subsequently it was established 
that ASFV infection has been present over a very long period in 
Eastern and Southern Africa in warthogs (Phacochoerus 
aethiopicus), bush pigs (Potamochoerus porcus) and a species 
of soft tick (Ornithodoros porcinus). These wildlife hosts can be 
persistently infected over long time periods without showing disease 
signs. Ticks become infected by feeding on warthogs and young warthogs 
develop a sufficiently high viraemia to infect ticks. Virus can be 
transmitted between ticks transadially, transovarially and transexually 
from male to female. Infected ticks transmit virus to warthogs on which 
they feed. Direct transmission between warthogs is thought to be 
infrequent and thus the tick vector plays an important role in the sylvatic cycle 
(Kleiboeker & Scoles, 2001). 
The virus is very well adapted to its hosts, probably 
reflecting a long-term evolution and adaption in this transmission 
cycle. Once introduced into the domestic pig population, the 
virus can be transmitted directly between pigs without the 
requirement of the tick vector, although the tick may provide an 
important reservoir of virus if it present in pig houses. Spread of ASFV 
to most sub-Saharan African countries has occurred and it was also 
introduced to Portugal in 1957 and 1960. The disease remained 
endemic in Spain and Portugal until the mid-1990s. In southern 
Spain and Portugal the tick species Ornithodoros erraticus acted as a 
vector for the virus contributing to the difficulties in disease eradication. 
ASFV is thought to have spread to other European countries and to 
Brazil and the Caribbean from Spain and Portugal. Except for Sardinia 
outside Africa ASFV has now been eradicated (Costard et al., 2009). 
However recently, ASFV has entered countries of the old Soviet Union 
and is considered to be out of control (Chapman et al., 2011)
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Virus Structure, Entry, Replication Cycle and Assembly
ASFV is a large, enveloped, icosahedral double-stranded DNA virus 
and is the only recognized member of the Asfarviridae family (Dixon et 
al., 2012). The virus shares similarities in its genome organization with 
other large DNA virus families, which replicate at least partially in the 
cytoplasm. These virus families may share a common ancestor. This 
virus superfamily, named the nucleo-cytoplasmic large DNA virus family 
(NCLDV), also includes the Poxviridae, Iridoviridae, Phycodnaviridae 
and Mimiviridae (Lyer et al., 2006). Also the replication strategy of 
ASFV is similar to the Poxviridae (Rodríguez & Salas, 2012).
Virus encoded proteins
The ASFV genome encodes about 150 proteins, including structural 
proteins, enzymes and factors required for replication and transcription 
of the virus genome. There are in addition, many other proteins 
which have evolved for manipulation of host cell biology and immune 
response and which have a role in facilitating virus survival, 
persistence and transmission.  
ASFV proteins involved in host immune evasion
Since ASFV shares a similar replication strategy with poxviruses, it has 
been predicted that the number of proteins involved in virus replication 
is similar in the two viruses. A core of 90 genes is conserved between 
different genera of the Chordopoxvirinae subfamily, suggesting that 
this represents the minimal number of genes required for replication 
(Upton et al., 2003).Thus, 70 to 85 ASFV ORFs may encode proteins 
that are not essential for replication. Many of the remaining plays 
an important role in host manipulation. These include a number of 
proteins, which help the virus to evade host defences and persist in the 
host. By interfering with macrophage function, the virus could diminish 
both the initial innate response to infection as well as the later acquired 
immune response. The identified ASFV virus proteins with known 
roles, up to date, in evading host defences can manipulated the system 
into several ways (Dixon et al., 2012) 1) ASFV proteins that interfere 
with activation of transcription factors of genes encoding immunomo-
dulatory proteins; 2) ASFV adhesion proteins, which can modulate in-
teractions of infected cells or extracellular virions with the extracellular 
environment; 3) ASFV proteins that inhibit apoptosis and can thus pro-
long survival of infected cells and facilitate virus replication; 4) ASFV 
Proteins that inhibit type I interferon induction and responses or use 
TLR-based escape mechanisms.
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1.4.3
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1.5 The adaptive arm of the immune system
The key players in the adaptive immune response are T and 
B-lymphocytes. The T lymphocytes that mature in the thymus are 
activated through a system known as antigen presentation. In this 
process, the antigen-presenting cell (APC) activates the T or B cell 
by presenting a peptide derived from a protein antigen. Antigen 
presentation is achieved via two different molecules: major 
histocompatibility complex (MHC) class-I molecules and MHC class-II 
molecules. MHC class-I molecules are used by all of the body’s cells 
to display proteins from inside the cell, which have been degraded to 
peptides and then incorporated into the MHC-I molecule. This type of 
antigen presentation is principally used to signal cytotoxic T cells of 
the immune system to kill infected cells. In contrast, MHC II molecules 
are used by the antigen presenting cells of the immune system to 
display proteins brought in from the extracellular environment and 
causes the activation and proliferation of naive helper T cells. Specialized 
antigen presenting cells, particularly dendritic cells, are instrumental in 
presentation using MHC-II molecules.
All T cells have a TCR, composed of two different polypeptide chains 
that recognize a specific antigen. While approximately 5% of circulating 
T cells contain a γδ receptor and do not express either CD4 or CD8 
molecules, the vast majority of mature T cells, contains a αβ-TCR 
and express CD4 or CD8 on their cell surface (Marrack et al., 1983). 
These cells recognize a small peptide antigen presented by an MHC 
molecule on the surface of an infected cell (CD8+ T cells) or activated 
immune cell (CD4+ T cells). Within the two classes of αβ T cells, helper 
T cells express the CD4 molecule and recognize exogenous antigen 
presented on an MHC-II molecule, and cytotoxic T cells express the 
CD8 molecule and recognize endogenous antigen presented on an 
MHC-I molecule. 
The CD4 and CD8 molecules act as co-receptors and signalling 
molecules, assisting in antigen recognition and guiding the cell which 
actions to take in response to activation. Following antigen recognition, 
the cell’s T cell receptors cluster together, or cross-link, to allow the 
cell to reach the signalling threshold necessary to activate the cell. 
This cross-linking often occurs through signalling aggregates in the 
cell surface called lipid rafts, which bring together TCRs and other 
associated signalling molecules in order to generate and amplify a 
signal. A T cell activated through its cross-linked TCRs will proliferate 
and up regulate growth factor receptors on its surface. This activation 
also requires additional co-stimulatory molecules, such as B7 on an 
antigen-presenting cell (Janes et al., 1999).
CD4+ T helper cells help to activate B cells and other T cells by 
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secreting cytokines. A naïve helper T cell (Th0) when encounter 
antigens in secondary lymphoid organs usually secretes only IL-2, but 
upon activation, it will generally differentiate depending on the signals 
it receives from environment they are capable of differentiating into 
inflammatory Th1 cells, helper Th2 cells or pathogenic Th17 cells, which are 
distinguished by the cytokines they produce. Th1 cell usually secretes 
cytokines such as IL-1, IFN-γ, and TNF, activate macrophages and 
participate in the generation of cytotoxic lymphocytes, resulting in a 
cell-mediated immune response, Th2 cell secretes IL-4, IL-5, IL-6 
and IL-10, while Th17 cell secretes IL-17 and IL-22, pro-inflammatory 
cytokines that have been linked to the pathogenesis of autoimmune 
diseases and to immune responses to bacterial and fungal infections 
(Fang et al., 2010). Therefore, the immune response is directed to the 
type of response that is required to deal with the pathogen encountered 
cellular-mediated responses for intracellular pathogens or antibody 
responses for extracellular pathogens. Equally important, each 
subpopulation can exert inhibitory influences on the other.  IFN-γ 
produced by Th1 cells inhibits proliferation of Th2 cells and 
differentiation of Th17 cells and IL-10 produced by Th2 cells inhibits 
production of IFN-γ by Th1 cells. In addition, IL-4 inhibits production 
of Th1 cells and differentiation of Th17 cells (Schmidt-Weber et al., 
2007).
The CD8+ T cells, or cytotoxic lymphocytes (CTLs) stop the spread 
of the infection by killing infected cells. Activation of CTLs requires 
antigen presentation via MHC-I molecule, as well as signals from helper 
T cells. Upon activation, and subsequent proliferation, the CD8+ T cells 
circulate in the bloodstream and recognize the appropriate infected cell 
by its display of pathogen peptide-MHC-I complexes. Recognition is 
then followed by killing of the infected cell through its perforin, which 
creates holes in the cell membrane, or FasL, which binds to a receptor 
on the cell surface, thus inducing programmed cell death (apoptosis) 
in infected cells. While the vast majority of effector cells disappear 
from the circulation following pathogen clearance (“activation induced 
cell death”), there remains a heterogeneous population of circulating 
or in peripheral tissues long-lived CD8+ memory T cells capable of 
mounting rapid recall responses on antigen reencounter (Zhang & 
Bevan, 2011).
All T cells are derived losfrom hematopoietic stem cells (HSCs) that 
reside in the bone marrow and migrate to the thymus. Most of the 
T cells generated in the thymus are short-lived, because they fail 
stringent rigorous selection criteria, which ensure that only cells 
bearing useful antigen receptors mature for export to the peripheral 
lymphoid tissues where they regulate immune responses. To survive, 
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immature thymocytes must express T-cell receptors (TCRs) capable 
of binding to molecules of the major histocompatibility complex (MHC) 
on thymic epithelial cells (positive selection). However, those with 
receptors which bind with high affinity to self-antigens presented by 
MHC molecules are induced to die by apoptosis (negative selection), 
thereby ensuring immunological tolerance (Strasser et al., 1994) .
Unlike T cells, in mammals B cells stays in the bone marrow and do 
not migrate to another location to complete their maturation. The B cell 
contains a B cell receptor (BCR), which like the TCR is derived from 
the rearrangement of gene segments, is composed of two different 
proteins. In the case of the BCR, the proteins are the heavy chain (Hc) 
and light chain (Lc), which associate to form the bivalent four chain 
(Hc)2 (Lc)2 molecule. 
The antigen specificity of BCR is identical to the antibodies, which 
will be secreted by its plasma cell descendants upon antigenic 
activation and differentiation. The surface Ig receptor has essentially no 
intracellular domain and so its signal transduction is through 
Hc-associated proteins Igα and Igβ. Like many receptors, crosslink 
of the BCR is the first step in the generation of a signal sufficient 
to begin a signalling cascade within the cell. B cells also contain 
complement receptors, which cross-linking with the BCR, resulting in an 
amplification of the signal (Harwood & Batista, 2010). Different of 
T cells, which can only recognize appropriately presented peptide 
antigens, B cells are able to recognize native antigen molecules 
binding to their BCRs. The B cell, however, require a secondary signal, 
which can be delivered through several pathways. The most common 
second signal is provided by the T cell and requires the interaction 
of a CD40L molecule on the surface of a T helper cell with the CD40 
receptor on B cells. Some B cells can undergo T cell independent 
polyclonal activation. The independent provides a subset of B 
cells that recognize molecules on the surface of invaders not 
normally recognized by T cells, such as bacterial polysaccharides 
and lipids. 
Whatever the stimulus, oncea B cell is activated further proliferation 
ensures but differentiate to secrete antibodies requires a cytokine 
signal.  Upon activation, a B cell may alternatively to become a 
memory cell. Plasma cells, also called antibody-secreting cell secrete 
antibodies at a rate of 10.000 immunoglobulins per second for several 
days and then die (Slifka et al., 1998). In contrast to plasma cells, 
memory cells retain their membrane-bound B cell receptors and 
continue to survive for longer periods of time, thus providing its 
classical secondary, or “memory” response, which is fundamental to 
vaccines. The secondary response to an antigen is faster, stronger, 
and has a higher affinity than the primary response. Memory B cells 
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are typically formed in immune responses that require T cell help.
Although T cells are important to the immune response, they do not 
constitute a major component of the experiments performed in this 
thesis and, in contrast to B cells, they will not be discussed in further 
detail. The next section will describe, in greater detail, the process of 
B cell maturation. 
 
B-Cell development and Differentiation
The differentiation pathway from stem cell to mature B lymphocyte 
can be divided into several stages characterized by proliferation, 
differentiation and apoptosis. This process starts with hematopoietic 
stem cells (HSCs) in the liver during fetal development and in the bone 
marrow (BM) after birth.
Figure 7. Antigen-independent development of B cells (Shapiro-Shelef  & Calame, 
2005).  
B cells develop from pluripotent stem cells in the bone marrow, where full commitment 
to the B-cell lineage requires the transcription factor paired box protein 5 (PAX5). Naive 
B cells that exit the bone marrow continue to undergo maturation in the spleen to form 
long-lived naive follicular B cells and, to a lesser extent, naïve marginal-zone B cells.
1.5.1
In each sequential developmental stage, specific genetic programs are 
completed in specific environments. In general, cells either pass to the 
next step of differentiation or are eliminated by apoptosis. 
In each sequential developmental stage, specific genetic programs 
Thus, in the early phases of differentiation in the bone marrow, 
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toproductively rearrange the H and L chain genes and the consequent 
signalling function of the BCR are essential requirements  . The presence 
of the BCR is also indispensable for the survival of mature B cells in the 
periphery .The different stages of B-cell development can be identified 
by the presence of specific cell surface markers (Figure 7). The earliest 
operationally B-lineage associated surface marker is a member of 
the common leukocyte antigen family CD45, and is usually referred 
as B220. It should be noted, however, that while some surface 
markers are lost after a stem cell becomes a precursor of a B cell, others, 
such as CD19, are gained. The development stage after a lymphoid 
progenitor is committed to become a B cell is the pro-B cell, which 
expresses the molecules B220 and CD43 on its surface. Following this, 
the pro-B cell differentiates into a pre-B cell, which expresses B220 on 
its surface, but does not express CD43, the pre-B cell then develops 
into an immature B cell, which has the surface markers B220 and IgM 
(Shapiro-Shelef & Calame, 2005). While all of the stages preceding 
the immature B cell stage are marked by a rearrangement of B cell 
receptor genes, the immature B cell possesses fully rearranged heavy/
light chain genes, which are expressed on the cell surface. Immature B 
cells further develop into mature naive B cells, which retain B220, IgM 
but not express IgD. Mature naive B cells are similar to effector B cells, 
but as they have not yet encountered antigen, they do not possess all 
of the characteristics of either plasma or memory cells. It is important to 
note that upon maturation, mature naïve B cells leave the bone marrow 
and enter the periphery, where they will be activated if they encounter 
an antigen for which they have specificity (Cambier et al., 2007). 
Upon activation, a B cell becomes a lymphoblast looses IgD and 
differentiates either into a plasma cell or a memory cell. Throughout 
the maturation process, diversity is generated between B cells as the 
B cell receptor molecule undergoes a series of changes due to the 
necessary integration of DNA sequences coding for their 
Variable J, D and constant region (Figure 8).
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When immature B cells are ready to exit the Bone Marrow (BM), they 
express on their surface CD19, intermediate levels of B220 and very 
low to high levels of IgM, the first Ig chain to be expressed. They do not 
express CD21, CD23 and only a small fraction expresses low levels of 
IgD (Carsetti et al., 1995). The IgMhigh cells, enter the spleen through 
the terminal branches of central arterioles (Allman et al., 1993; Lortan 
et al., 1987). Only the B cells that express high levels of IgM and that 
have a functional BCR, leave the BM and enter the peripheral lymphoid 
system for subsequent development and differentiation into mature B 
cells (Rolink et al., 2004). It is known that signalling through the BCR is 
essential for transition from the immature to mature B cells population 
to occur (Chung et al., 2003). In fact, signalling through the BCR is 
essential in the development and survival of all B cells (Pillai et al., 
2004). 
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1.5.2 B-Cell immune function in host defence
By secreting antigen-specific immunoglobulin antibody, the B cell 
plays an essential role in host defence. Resting B cells reside in the 
circulation and migrate to the spleen and lymph nodes. Activation 
of the B-cell receptor by antigen, in conjunction with appropriate 
co-stimulation causes, the resting B cell to proliferate and differentiate 
into a plasma cell, which makes and secretes large amounts of 
immunoglobulin antibody. In addition to the antigen receptor, B cells 
exhibit a large number of additional cell surface receptors, which are 
activated by T-cell surface molecules, cytokines, bacterial endotoxin, 
and other ligands. 
The key general steps in signalling pathways downstream of these 
receptors that regulate steps in development of the mature B cell and 
modulate responses to antigen are the following: First, antibodies can 
neutralize pathogens such as viruses and intracellular bacteria by 
binding to the cell surface and making the pathogen unable to enter 
the body’s cells. Neutralization is also helpful in preventing bacterial 
toxins from entering cells. Second, antibody molecules can mark a 
pathogen for destruction by phagocytosis, a phenomenon called 
opsonisation. Third, antibodies can activate the complement protein 
system, causing the complement proteins to bind to the pathogen 
with the resultant opsonisation of the pathogen. Because the antibody 
response takes time to form, it is typically more critical during a 
secondary response than a primary response. While other 
mechanisms of immunity may be more effective in clearing 
the pathogen during a primary response, antibodies 
from differentiated memory B cells are extremely effective 
in stopping an infection upon the second introduction of a 
pathogen. Finally, B-cells are able to present specific 
antigens peptides to cognate CD4+ T cells with extremely 
high efficiency so that they obtain help for the 
production of high-affinity antibodies. The high-affinity 
BCR enables B cells to efficiently capture specific antigens 
present even at extremely low but immunologically relevant 
concentrations, far below those required for presentation 
by antigen-non specific B cells as well as DCs (Lanzavecchia, 
1987; Pape et al., 2007). Nonspecific antigens derived 
from endogenous self-peptide and pinocytosed proteins are 
also presented by B cells, but the outcome of presentation of 
non-specific antigen is T cell tolerance. Consequently, B cells can 
either activate or inactivate T cell, depending on the nature of the 
antigen. In the presence of dendritic cells or activated macrophages, 
the role of B cells in presenting nonspecific antigens is negligible. 
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Several studies have suggested a role for B cell in the induction of 
regulatory T cells (Mann et al., 2007). 
 Molecular mechanisms underlying the B cell activation 
B cell activation is followed by high affinity maturation in germinal 
centres (GCs), leading to the production of both plasma B cells 
capable of producing high-affinity antibodies and long-lived memory 
B cells (Rajewsky, 1996).Thus, the end of the adaptive immune 
response for the individual is the neutralization and elimination of antigen, 
accompanied by the acquisition of long-lasting protection from 
secondary challenge with the same pathogen.  
B cell activation is initiated in response to specific antigen binding 
to the B cell receptor (BCR). The BCR is a complex comprised of 
membrane immunoglobulin (Ig) heavy and light chains, in association 
with the Igβ heterodimer (Reth, 1989). Engagement of BCR by antigen 
allows tyrosine phosphorylation of the intracellular Igβ immunoreceptor 
tyrosine activation motifs (ITAMs) by Src-family kinases, such as Lyn, 
leading in turn to the activation of Syk (Dal Porto et al., 2004a). This 
activation initiates the coordinated assembly of the signalosome, 
composed of a variety of intracellular signalling molecules, such as 
Vav, Bruton’s tyrosine kinase (Btk), (Dal Porto et al., 2004b; Kurosaki, 
1999) as well as adaptor proteins, such as B cell linker (Blnk) 
(Goitsuka et al., 1998). 
The collective accumulation and activity of signalling 
molecules within the signalosome triggers a variety of cellular 
processes, including regulation of gene expression, reorgani-
zation of the cytoskeleton, and BCR mediated internalization 
of antigen complexes. Antigen internalized through the BCR 
is subsequently processed inside specific endosomal compartments 
and presented in complex with MHC II to recruit specific T cell help 
(Lanzavecchia, 1985).
Hence, B cell activation is dependent on the organization of a range 
of molecules, requiring the synchronization of both intracellular 
signalling pathways and intercellular communication. Classic 
biochemical techniques have been used to gain valuable insight into the 
interactions of individual macromolecules, in response to B cell 
stimulation with model ligands, such as high affinity antibodies or 
soluble antigens. 
1.5.3
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The immunological synapse & B-Cell spreading
BCR signalling and cytoskeleton reorganization mediate B cell 
dendrite formation “spreading”, increasing the possibility of cell 
interactions and facilitating the formation of greater numbers of BCR 
clusters and thus contributing to cell activation. The immunological 
synapse, originally reported for CD4+ T cells (Grakoui et al., 1999), 
is recognized as a common feature of antigen recognition by specific 
immune receptors (Batista et al., 2001; Stinchcombe et al., 2001).
The immunological synapse forms as a result of an extraordinary 
and coordinated reorganization of molecules in the membrane and 
cytoskeleton. The mature immunological synapse is characterized 
by an increase of immunoreceptor-antigen complexes in a central 
supramolecular activation cluster (cSMAC), surrounded by a ring of 
integrins forming the peripheral supramolecular activation cluster 
(pSMAC). 
The immunological synapse plays an essential role in B cell activation. 
After recognition of membrane-bound antigen, the BCR signalosome 
is assembled by the highly coordinated and sequential recruitment 
of initiating kinases, such as Lyn and Syk; intracellular signalling 
molecules, such as Vav, PI3K, PLC2 and Btk; and adaptors, such as 
Blnk and CD19 (Harwood & Batista, 2010)
During B cell spreading, the contact area increases, allowing for the 
amplification of the generation of signalling BCR micro clusters and 
thus enhancing B cell activation. After spreading, a slower contraction 
occurs, which thought to be involved in the amplification of signalling 
BCR and formation of BCR micro clusters within the cSMAC, so that 
antigen can be internalized into endosomes for later antigen presentation 
to T helper cells. 
The rapid spreading response, mediated by the extension of lamellipodial 
projections, allows B cells to engage more antigen as they progress 
over the antigen-containing surface and in that manner propagate 
signalling through the BCR. The degree of the spreading and contraction 
response is dependent again on the nature of the stimulating 
antigen, such that a higher antigen avidity stimulates spreading and B cell 
activation consequently (Fleire et al., 2006). The resulting, more 
prolonged contraction phase then allows for the collection of more 
antigen into the central aggregate, which is subsequently internalized 
and presented to T cells, thus contributing to B cell activation 
(Lanzavecchia, 1985). 
A number of intracellular signalling molecules involved in effecting the 
spreading response have been identified (Weber et al., 2008). The 
absolute dependence of spreading on Src family kinases was seen 
by the abrogation of spreading in Lyn deficient B cells. After the 
1.5.4
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sequential recruitment and activation of Src and Syk kinases to BCR 
micro clusters, the cooperative action of PLC2 and Vav within these 
micro-signalosomes was also found to be critical for effective 
propagation of signalling to enable B cell spreading. A similar 
stabilization of signalling micro clusters through cooperation of their 
component parts had been previously noted in T cells (Bunnell et al., 
2001) and may favour a greater sensitivity discrimination between 
antigen and self-nonself. The correct spatiotemporal localization of 
these molecules through the activity of adaptor proteins such as Blnk is 
very important for the proper functioning of PLC2 and Vav in mediating 
B cell spreading (Weber et al., 2008). 
Considerable changes in B cell morphology during spreading and 
contraction. The identification of a key role for Vav in the propagation 
of the spreading response offers some insight into mechanisms 
underlying the regulation of cytoskeleton reorganisations. As such, 
Vav has been demonstrated to be involved in the deactivation of the 
ezrin-radixin-moesin (ERM) protein ezrin (Faure et al., 2004), and, 
in addition, Vav can function as a guanine nucleotide exchange 
factor (GEF) for the cytoskeleton-modifying RhoGTPases (Jaffe 
& Hall, 2005). In line with this, it has been demonstrated that the 
Vav-dependent activation of Rac1 is required for BCR-mediated 
spreading in mature B cells (Brezski & Monroe, 2007). The activity 
of the small GTPase Rap, regulated by Vav, has been shown to 
perform a critical role in the activation of B cells through the regulation of 
spreading and immunological synapse formation (Arana et al., 
2008; Lin et al., 2008). The resulting spreading response provides a 
mechanism for the propagation of BCR-mediated signalling and the 
facilitation of B cell activation. 
The importance of Follicular Dendritic cells (FDCs) in the presentation 
of antigen to B cells has been well established. Some studies based 
in dynamic visualization of GC B cells after administration of antigen 
suggested that B cells may not occupy a fixed position on the 
surface of FDCs (Allen et al., 2007; Schwickert et al., 2007). However, 
Hauser et al. were able to identify a population of relatively stationary B 
cells, after antigenic stimulation, forming close associations with FDCs. 
Then, B cells can encounter antigen through a variety of different 
mechanisms in vivo (Harwood & Batista, 2008).
The mechanism for each particular antigen is dependent both on the 
properties of the antigen itself and its route of entry into the body. 
The studies observe that B cells within the GC adopt an unusual, 
heterogeneous morphology with many elongated processes. In 
the light of these investigations, it has been proposed that even 
migrating B cells may be capable of sequestering antigen through their 
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extended processes as they crawl across the surface of FDCs (Allen 
et al., 2007). This antigen could subsequently be presented to T helper 
cells, suggesting a possible mechanism whereby the highest affinity B 
cell clone would be the most able to compete effectively for specific T 
cell help.
Germinal Center
Germinal centres develop in the B cell follicles of secondary 
lymphoid tissues during T cell-dependent (TD) antibody responses. The 
B cells that give rise to germinal centres are initially activated outside 
follicles in the T cell-rich zones through T cell help. The germinal 
centres formed are oligoclonal and results from massive clonal expansion 
(MacLennan, 1994). During this step, a site-directed hypermutation 
mechanism is activated that acts on their immunoglobulin-variable 
(Ig-v)-region genes. At the end of the period of exponential growth 
of B blasts, the classical structure of germinal centres emerges. The 
B blasts become centroblasts in the dark zone of the germinal centres, 
which develops at that limit of the FDC-network close to the T 
zones. The centroblasts are still in rapid cell cycle but maintain a stable 
sized population as their progeny move to the heart of the FDC-net-
work where they exit cell cycle as centrocytes (Allen et al., 2007; Sh-
lomchik & Weisel, 2012).  Centrocytes seem to be selected for their 
ability to interact with antigen bound to FDCs. There is a high death 
rate among centrocytes in vivo, and when these cells are isolated in 
vitro, they undergo apoptosis within hours of culture. The long-term 
survival is achieved by signalling through their surface CD40. After 
activation through CD40, centrocytes increase their surface Ig and acquire 
characteristics of memory cells and recognition of antigen presented by 
FDC and its presentation to T cells, which can be induced at the point of 
cognate interaction. Centrocytes positively selected through interaction 
with antigen on FDC receive further signals, which induce the cells to 
differentiate to become either plasma cells and express CD40 ligand 
or memory B cells. The affinity maturation of antibodies that occurs 
during immune responses to protein antigens involves site-directed 
hypermutation of immunoglobulin variable-region genes that is activa-
ted in germinal centres (MacLennan, 1994; Victora & Nussenzweig, 
2012) (Figure 9).
1.5.5
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Germinal centres persist for about 3 weeks following immunization, but 
after this, memory B blasts continue to proliferate in follicles throughout 
the months of T cell-dependent antibody responses. These cells are 
probably the source of memory cells. 
Immature and mature B-cell subpopulations in the spleen
Most of the successfully generated immature splenic B cell population 
will reach maturity, and data from several authors indicates that at this 
stage of transition from immature to mature B cells, negative selection 
will no longer take place (Coutinho et al., 1995; Rolink et al., 1998)
All immature splenic B cells can be subdivided according to their 
surface expression of IgM, IgD, CD21, CD23 and CD1d, and the 
current classification of B cell subpopulations is based on the 
differential expression of these markers. Immature splenic B cells 
express CD93, which distinguishes from the mature cells that do not 
express this marker (Figure 7) (Rolink et al., 1998)  
The immature subpopulations of B cells in the spleen can be divided 
into the newly formed (NF) or Transitional 1 (T1) cells. The T1 
cells are characterized by high and low expression of IgM and IgD, 
respectively, and by the absence of CD21 and CD23. In the more mature 
Transitional 2 (T2) population, expression of IgM, IgD, CD21 and 
CD23 is high. Also, the T2 subpopulation shows lower levels of CD93, 
compared to the T1 population (Cambier et al., 2007; Dal Porto et al., 
2004b; Rolink et al., 2004). The Transitional 3 (T3) subpopulation is 
characterized by the surface expression of high levels of IgD, CD1d, 
Figure 9. Mature germinal centres are divided into dark and light zones 
(Küppers, 2003). 
The proliferating blasts, centroblasts, occupy the dark zone and give rise 
to centrocytes that are not in cell cycle and fill the light zone. The light 
zone contains a rich network of follicular dendritic cells (FDC) that have the 
capacity to take up antigen and hold this on their surface.
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CD21 and CD23, and intermediate levels of IgM (Figure 7) (Rolink 
et al., 2004; Shapiro-Shelef & Calame, 2005). In mice, the ratio 
between the T1:T2:T3 subpopulation is 1:1:1 and is not altered with 
the age of the animal, but as the mice get older, there is a decline in the 
proportional contribution of immature B cells to the pool of total splenic 
B cells (Rolink et al., 2004).
As the immature B cells enter the lymphoid follicles of the peripheral 
lymphoid system, they acquire the more mature follicular phenotype 
(FO). These cells express high levels of IgD and CD23, intermediate 
levels of CD21, low levels of IgM, and progressively lower levels of 
CD93 and CD24 (Rolink et al., 1998, 2004). This follicular population 
is the main cell type in the pool of naive B cells in the spleen, with 
relatively short half-life of around, 2-3 months (Pillai et al., 2004). 
Some FO B cells will migrate to the marginal sinuses in the spleen and 
differentiate into marginal (MZ) zone B cells. These are larger than FO 
B cells, have characteristically and distinctively crinkled membranes 
(Oliver et al., 1999) and are mostly located between two concentric 
layers of macrophages (Pillai et al., 2005). Marginal zone B cells are 
IgMhighIgDlowCD21highCD1dhighCD23-, and do not differentiate to plasma 
cells in response to specific antigen receptor ligation. They are, however, 
quickly activated, expressing high levels of CD80 (B7-1) and CD86 
(B7-2), and stimulation with lipopolysaccharide (LPS), anti-CD40 
and IL-4 may result in their differentiation into plasma cells within 
a matter of hours (Oliver et al., 1999). Their proliferation in response to 
LPS is much more vigorous than that of FO B cells and they will fail to 
develop in the absence of CD19 (Pillai et al., 2005).
It is accepted that FO B cells are important for the T-dependent 
germinal centre-based responses, while MZ B cells seem to contribute 
to T-independent responses to blood-borne pathogens, even though 
they may also contribute to T-dependent responses, because, since 
they express high levels of CD80 and CD86, they might present 
blood-borne pathogens to naïve T cells (Pillai et al., 2004).
B1 cells: development and selection 
The peritoneal cavity of mice is enriched for B-1 B cells, a lymphocyte 
subset that differs phenotypically, functionally, and developmentally 
from the conventional B-2 B cells. This long-lived, self-renewing 
subset of cells is predominantly abundant in young individuals and, 
in the mouse, is present mainly in the peritoneal cavity, with small 
numbers also detectable in the spleen and lymph nodes of adult mice 
(Pillai et al. 2004). They are especially involved in T-independent 
responses to antigens present in the intestinal mucosa.  In 
normal mice, B-1 B cells produce a significant proportion of natural IgM 
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autoantibodies in the serum, and display an enriched expression of 
self-reactive BCRs (Hardy, 2006; Pillai et al., 2004). 
These B-1 cells are IgMhiIgD-CD23-CD11b+ and can be further 
subdivided in the B-1a and B-1b, with the distinguishing characteristic 
of CD5 surface expression by B-1a but not B-1b subpopulations 
(Hardy et al., 1996; Herzenberg et al., 1986)  (Hardy and Hayakawa 
1986; Herzenberg et al. 1986; Hardy and Hayakawa 1992). The B-1a 
cells develop from HSCs derived from the foetal liver (Hayakawa et al. 
1985; Hardy and Hayakawa 1992), while B-1b originate from HSCs 
from both foetal liver and BM (Hardy & Hayakawa, 1994; Kantor et al., 
1992).  Proliferation of both B-1 B and B-1a B cells generation requires 
BCR signalling. In fact, all the components of the Btk/PLC-/PKC- 
pathway are necessary for the generation of B1 B cells, but it seems 
that B1b B cells can sometimes be generated in bacterially infected 
Xid mice (Pillai et al., 2004). Work from several groups has 
demonstrated that B1-b cells are critically and more strongly dependent 
than B2 B cells on normal BCR signalling for their development and/or 
maintenance (Hardy, 2006).
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T  cell dependent and T cell independent activation
 
In order for B cells to carry out their effector functions they must first 
be activated by encountering the pathogen for which they are specific. 
Antigen recognition is not the only necessary event for activation, 
however. In most cases, B cells must also receive a signal from T 
cells, and in other cases, they must receive a special kind of signal 
from the pathogen. These two types of responses are termed thymus- 
dependent (TD) and thymus-independent (TI) humoral responses 
(Figure 10). While the TD response is more typical, TI responses 
are also important for defence of against bacterial pathogens. In the 
thymus-dependent response, an antibody response by B cells requires 
help from T cells, which recognize the same antigen. 
Figure 10. B cell activation by T cell-dependent and T cell-independent antigens 
(Ollila & Vihinen, 2005).
A large number of similar antigens can directly initiate B cell activation (TI, top 
and TD, right). T cell-dependent antigens are degraded  into  small peptides and 
presented to T cells by MHC molecules. T cell receptors recognize the antigen 
and B cells become activated. Many other cell surface proteins are also 
important for this event. Several signalling pathways are activated after BCR 
stimulation as well as the kinases and adaptor proteins involved
This critical interaction of a B cell and T cell specific for the same 
antigen is termed linked recognition. The B cell and T cell do not need 
recognize the same epitope on the antigen; they must only recognize 
epitopes on the same antigen molecule. In order for a B cell to be fully 
activated, it must receive help from an activated T helper (Th) cell. A 
T-helper cell can be activated by any antigen-presenting cell (dendritic, 
macrophage or B cells) displaying its cognate antigen presented in the 
context of MHC class-II molecule. Upon recognizing an antigen, a B 
cell will travel to the border between the T cell zone and B cell zone of 
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the lymph node, where activation occurs if it encounters a T cell with 
specificity for an antigenic peptide presented by class I MHC. CD40 
on the B cell also binds to its ligand, CD40L (also called CD154), on 
the T cell. The activation also involves the interaction with cytokines 
such as IL-4 and IL-5. Activated B cells then begins to proliferate and 
differentiates, forming a germinal centre. From the germinal centre, 
cells are released that become plasma cells, travelling through the 
periphery to the bone marrow and spleen to secrete antibody 
molecules. In the model of a TD humoral response, helper T cells are 
necessary to create an effective antibody response to a pathogen 
Although the thymus-dependent response is the typical mechanism 
of humoral response, in some cases B cells do not require the help 
of T cells in order to become activated. These thymus independent 
antibody responses are directed to responses and are divided into 
those against antigens that are also mitogen such as LPS, CpG, or 
poly-IC, (TI-I response) and those against antigens that have no 
intrinsic mitogenic activity and composed of highly repetitive 
structures, such as bacteria capsular polysaccharides, Dextran or 
Ficoll (TI-II response) (Obukhanych & Nussenzweig, 2006) . 
TI-II antigens are typically repetitive polysaccharides of bacterial 
surfaces, which activate B cells through an extensive BCR- 
crosslinking. B cells respond to TI-II antigens in the absence of MHC 
class II-restricted T-cell help by a mechanism that depends on the 
expression of a functional Bruton’s tyrosine kinase (Btk). These 
responses are lost or absent in neonates and in hosts with congenital 
or reduced defects in the expression of a functional Bruton’s tyrosine 
kinase and distinguish them from the T-cell-independent type 1 (TI-I) 
antigens (Mosier et al., 1977).
The TI-II response is critically dependent on the formation of a small 
number of antigen receptor clusters that induces a local membrane 
association of multiple activated Btk molecules, which results in 
long-term mobilization of intracellular ionized calcium. This persistent 
calcium fluxes efficiently recruit transcription factors and induce 
T-cell-independent B-cell activation and proliferation. There are studies 
suggesting that while this first signal of multivalent membrane Ig 
cross-linking can induce B-cell proliferation, TLRs could recognize 
molecular motifs on the surface of pathogens and provide the TI-2- 
activated B cell with a second signal (Coutinho et al., 1974; Vos et al., 
2000).
For this type of antigen at concentrations that are too low, there is 
insufficient cross-linking of the BCR to activate the B cell and at high 
concentrations, the cell enters in apoptosis. While TI antigens are 
efficient at activating B cells, and may do so more quickly than TD 
antigens because of the lack of requirement for T cells, they are largely 
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inefficient at generating B cell memory. Their principal function is to 
provide a rapid primary response to microbial infections (Defrance et 
al., 2011).
Murine Herpes Virus (MHV-68)
Pathogenicity of MHV-68
Gammaherpesviruses are lymphotropic viruses which establish 
lifelong infections in their hosts and are associated with cellular 
transformation and the development of malignancies, particularly 
in immunosuppressed individuals (Nash et al., 2001). The MHV-68 
virion exhibits morphological similarity to the virion organization of other 
gammaherpesviruses. The viral genome encodes canonical capsid, 
tegument, and glycoprotein homologues found in gammaherpesviruses 
(Virgin et al., 1997). 
The overall similarities of MHV-68 to other gammaherpesviruses 
in terms of genomic organization, pathological symptoms and the 
establishment of both lytic and latent infection make it a valuable 
animal model for human herpes viruses. Closely related to EBV and 
KSHV (Clambey et al., 2002) this small-animal model can give clues to 
the versions of human gammaherpesviruses.
By analogy with others animal gammaherpesviruses MHV-68 may 
naturally be transmitted by a mucosal route of infection where the 
respiratory tract is likely to be a primary target. Although the 
experimental infection via the intra-peritoneal route does not 
represent the physiological situation, this approach has merit for 
evaluating the pathogenesis of replication-defective mutant viruses. 
At this time, the natural route of transmission is unknown and there 
are some documented cases of MHV transmission between animals 
infected when a mother ate her infected pups (Blaskovic et al., 1984), or 
transmission via milk of infected mothers (Raslova et al., 2001). 
 
Immunity against MHV-68
Following intranasal inoculation of mice with MHV-68, a productive in-
fection occurs in the lung. This is cleared around day 10-post infection 
(p.i.), principally by CD8+ T cells. At about this time, the virus spreads 
to the spleen, where it becomes latent mostly in B lymphocytes, 
macrophages and dendritic cells, but later predominantly in B 
lymphocytes (Dutia et al., 1999; Simas & Efstathiou, 1998). The 
establishment of the latent state is first characterized by a transient 
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expansion of infected germinal centre (GC) B cells in splenic follicles, 
followed by long-term latent infection, probably in memory B cells. As 
has been proposed for Epstein Barr virus (EBV), the infection of GC 
B cells by MHV-68 may constitute a strategy to expand the latently 
infected cell pool and gain access to long-lived memory B cells (Nash 
et al., 2001).
Gamma-herpes virus proteins involved in host immune 
evasion
Herpes viruses have double-stranded DNA genomes of 100 to 250kbp, 
consisting of up to 225 open reading frames (ORFs). These large 
and complex genomes can code for a huge repertoire of gene 
functions evolved for manipulation of host cell biology and immune 
responses. Although the complete sequence of the genome of many 
herpes viruses has been determined, the precise function for many 
of the viral genes, both in vitro, and in particular in vivo, has not been 
elucidated (Nash et al., 2001).
In summary, gamma-herpes viruses behave like many other 
persistent viruses. They exploit naive host to replicate extensively in an 
exaggerated primary infection and establish a sizeable pool of latent 
genomes. Latency then provides a relatively stable, immunologically 
silent mode of persistence. Reactivation from latency allows virions 
to be shed and transmitted to new hosts, where the cycle begins 
again. Gamma-herpes viruses achieve a long-term infectivity order of 
magnitude higher than pathogens such as HIV and hepatitis C 
virus. This high efficiency of exit from the persistently infected host has 
made them ubiquitous pathogens. Host immunity generally prevents 
disease, but not viral transmission, most probably because immune 
evasion keeps low level reactivation below the threshold of immune 
recognition (Stevenson & Efstathiou, 2005). The same immune 
evasion makes EBV among the first pathogens to cause disease when 
there is immune suppression.
B cells are very important for systemic viral dissemination and probably 
for transit back to mucosal surfaces, where there is reactivation and 
viral shedding. B cells may also traffic virus to and from 
non-lymphoid sites of latency such as vascular endothelium 
(Weck et al., 1997). ORF72 and ORF74 contribute to efficient ex vivo 
reactivation, but whether they are also important for 
in vivo reactivation remains unproven. Gp150 is required 
for efficient viral release from infected cells and is therefore 
likely to be required for virion shedding. MHV-68 also encode, 
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mK3 protein, that downregulate MHC-I (Stevenson et al., 2000) 
and a viral bcl-2 homolog, a viral cyclin, and a chemokine-binding 
protein, M3 (Van Berkel et al., 1999; van Dyk et al., 1999; Gangappa 
et al., 2002).
The left end of the unique region of the MHV-68 genome has 
attracted considerable interest due to the presence of four open 
reading frames (ORFs) (M1, M2, M3, and M4) and eight viral tRNA-like 
genes (vtRNAs), none of which have a homologue in viral or eukaryotic 
proteins, suggesting that these genes may perform a unique function 
for the virus as they share positional homology to latency-associated 
genes in other gammaherpesviruses.
To understand the mechanisms by which gammaherpesviruses 
maintain a latent infection while evading destruction by the host 
immune response, research has focused on genes transcribed during 
latency. 
M2 ORF has attracted particular interest because its expression is 
restricted to latent infection in vitro and in vivo, with a peak of expression 
the spleen around day 14 p.i. M2 is expressed predominantly, if not 
solely, within B cells and not in splenic macrophages and dendritic 
cells that also harbour latent virus (Macrae et al., 2003). Moreover 
previous reports based in results in B-cell-deficient mice point out the 
possibility that M2 expression in the spleen was not exclusive to B 
cells as M2 was detected in peritoneal exudates cells (PECs) following 
intraperitoneal inoculation of µMT knockout mice which fail to develop 
mature B cells (Virgin et al., 1999), indicating that macrophages could 
also be a reservoir for latent MHV-68 (Weck et al., 1999). Although 
these reports would seem to be inconsistent with the hypothesis that 
M2 expression is B-cell-restricted, an alternative explanation is that 
µMT mice do indeed generate B cells, through an µM-independent 
pathway that specifically generates immunoglobulin A (Macpherson et 
al., 2001).
Analysis of the sub localization of M2 protein in A20 B cell line 
demonstrated a cytoplasmic and plasma membrane associated 
localization (Macrae et al., 2003). Its localization suggests a possible 
role in cell signalling, also suggested by several studies in vivo. 
M2-deficient MHV-68, which is deficient in latency amplification, has 
more latency than wild-type virus late in infection, predominantly in 
germinal centre B cells (Simas et al., 2004).
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Function of the M2 protein
The M2 open reading frame (ORF) is located in a cluster of unique 
genes at the left end of the MHV-68 genome and shares positional 
homology with latency and transformation-associated genes present 
in other characterized gammaherpesviruses (Virgin & Speck, 1999). 
The M2 gene was shown to be transcribed in latently infected tissue 
in vitro and to encode a latency-associated antigen in the MHV-68 
latently infected murine B-lymphoma cell line S11 (Husain et al., 1999). 
The gene encoding this protein is located near the 5’ end of the MHV-68 
genome. Initial analysis of the M2 transcript revealed a spliced 
transcript composed of two exons, i.e., a noncoding 110-nucleotide 
(nt) 5’ exon and a 1,235-nt 3’ exon that contains the M2 ORF, and a 
656-nt 3’ untranslated region (Husain et al., 1999). Analysis of 
M2 gene transcription in latently infected mice identified a novel 
transcript arising from the region of the M2 gene, which contains a 
short ORF (M2b). The analysis of viruses lacking an intact M2b failed 
to identify a role for this putative gene product in MHV-68 infection 
(DeZalia & Speck, 2008). However, the organization of candidate cis 
elements identified upstream of the distal promoter was consistent 
with the hypothesis that this promoter may be differentially utilized 
suggesting the possibility that distinct transcription regulation of the M2 
gene may be involved in the role of the M2 protein in establishment of 
latency versus its role in reactivation from latency (DeZalia & Speck, 
2008).
An examination of its primary sequence indicates the presence of 
multiple proline-rich regions (PRRs) and potential phosphorylation 
sites. Although M2 is a unique protein with no known homologues 
in viruses, mice, or humans, inspection of the amino acid sequence 
reveals many hallmarks of a bona fide signalling molecule, including 
9 PXXP motifs and a central positively charged region, leading to the 
hypothesis that M2 may manipulate signal transduction pathways. 
Biochemical analysis suggested that M2 is capable of interacting with 
a number of SH3 domain-containing proteins, including Vav1, Vav-2, 
and Vav-3; Fyn; the tyrosine kinases TXK and Tec; Nck2; Grb2; 
endophilins II and III; Ras GTPase-activating protein 1; and 
Rho GTPase-activating protein 4 (Madureira et al., 2005; Rodrigues 
et al., 2006). In fact, specific key SH3 binding motifs 
and tyrosine phosphorylation motifs contribute significantly to 
the establishment of latency and reactivation in vitro 
(Herskowitz et al., 2008). Furthermore, it was demonstrated in B-cell 
lines by others that three PXXP motifs located in the c-terminal 
half of M2 are required to bind Vav1 and induce phosphorylation 
of Vav1 leading to downstream Rac1 stimulation (Madureira et al., 2005; 
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Rodrigues et al., 2006). Additionally, M2 activates the Vav1/Rac1 
pathway through a trimolecular complex with Vav1 and Fyn, 
leading to enhanced Vav1 phosphorylation (Pires de Miranda 
et al., 2008; Rodrigues et al., 2006). Vav proteins are enzymes 
that promote GDP/GTP exchange on Rho/Rac proteins in a 
phosphorylation-dependent manner, thereby favouring the ra-
pid transition of those GTPases from their inactive (GDP-bound) 
to active (GTP-bound) states during signal transduction. The 
activation of Rho/Rac proteins promotes extensive changes 
in intracellular pathways related to cytoskeletal change, mitogenesis, 
and cell survival (Rodrigues et al., 2006).
Others in vitro studies have demonstrated that the M2 protein has a 
cell-type-dependent localization and effectively inhibits interferon- 
mediated signal transduction by downregulation of STAT1/2 expression 
(Liang et al., 2004) and inhibits apoptosis induced by DNA damage 
via interaction with the DDB1/COP9/cullin repair complex and the 
ATM DNA damage signal transducer respectively (Liang et al., 2006) 
similar to the impact of Kaposi’s sarcoma-associated herpesvirus 
(KSHV) infection (Shin et al., 2006). However, these findings were not 
confirmed by in vivo experiments using MHV-68 M2 deletion mutant 
viruses. 
M2 expression in primary B cells leads to interleukin-10-dependent 
B-cell proliferation and secretion of IL-10, IL-2, MIP-1a, and IL-6 
(Siegel et al., 2008). Primary B cells expressing M2 differentiate into a 
pre-plasma memory B-cell phenotype, an intermediate differentiation 
state between plasma and memory B cells (Siegel et al., 2008). 
M2 gene in the virus-host interaction
In order to establish the role of M2 gene in the virus-host interaction 
various studies were done using different M2-deficient MHV-68 
strains to evaluate their pathogenesis. The first mutant made by 
Jacoby et al., 2002 was made by introduction of a stop codon and an 
elevation of the level of genome-positive cells in the spleen after 
peritoneal infection was also observed. M2 was differentially 
required for acute replication in vivo. While mutation of M2 did not affect 
acute phase of virus replication in the lungs of mice following intranasal 
inoculation, acute-phase virus replication in the spleen was decreased 
compared to that of the wild-type and marker rescue viruses following 
intraperitoneal inoculation. 
Upon intranasal inoculation, M2 mutant viruses exhibited a significant 
decrease in the establishment of latency in the spleen on day 16-post 
infection, as measured by the frequency of viral genome-positive cells. 
In addition, M2 mutant viral genome-positive cells reactivated from 
1.6.5
1
63
latency inefficiently compared to wild-type and marker rescue 
viruses. By day 42 after intranasal inoculations, the frequencies of M2 
mutant and wild-type viral genome-positive cells were nearly 
equivalent, and little reactivation was detected from either 
population. In sharp contrast to the results obtained following intra 
nasal inoculation, after intraperitoneal inoculation, no 
significant defect was observed in the establishment or 
reactivation from latency with the M2 mutant viruses indicated 
that the requirements for the establishment of latency are 
affected by the route of infection (Clambey et al., 2002).
The second mutant performed by Macrae et al., 2003 was made 
by a frameshift mutation in the M2 open reading frame that caused 
premature termination of translation of M2 after amino acid residue 90. 
The M2 mutant showed no defect in productive replication in vivo or 
in lungs after infection of mice. Likewise, the characteristic transient 
increase in spleen cell number, Vbeta4 T-cell-receptor-positive CD8+ 
T cell mononucleosis, and establishment of latency were unaffected. 
However, the M2 mutant virus was defective in its ability to cause the 
transient sharp rise in latently infected cells normally seen in the spleen 
after infection of mice. This study also reported that the expression 
of M2 is restricted to B cells in the spleen and that M2 encodes a 
30-kDa protein localizing predominantly in the cytoplasm and plasma 
membrane of B cells.
Given that M2 was required for the expansion of latently infected cells 
within the spleen during acute infection, it was somewhat surprising 
that mutation of M2 did not negatively affect the establishment of 
long-term latency. This is supported by similar observations ob-
tained with other M2 mutants (Jacoby et al., 2002) and with MHV-76 
(Macrae et al., 2001). However, other experiments with 
M2 deficient MHV-68 viruses demonstrated that the absence 
of M2 results in reduced levels of splenic latency at short 
times after infection. This deficit was correlated with a decreased 
number of infected follicles rather than inability to expand the 
latent load in GC B cells. In spite of this, a lack of M2 was 
associated with increased long-term levels of latency in germinal 
centre B cells. This phenotype has been correlated with a 
deficit of latency establishment in memory B cells 
(Simas et al., 2004). Additionally, infection with an 
M2 null MHV-68 (M2.Stop) leads to a significant 
decrease in serum IL-10 levels at day 16-post infection, 
correlating with an increase in the frequency of MHV-68-specific 
CD8 T cells (Siegel et al., 2008). Mechanism that is consistent 
with previous analyses of MHV-68 mutants that have suggested a role 
for the M2 protein in MHV-68 pathogenesis promoting the expansion and 
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differentiation of MHV-68 latently infected B cells (perhaps facilitating 
the establishment of virus latency in memory B cells). 
It was also reported that the 193-amino-acid M2 protein contains 
an immunodominant CD8+ T-cell epitope, suggesting that immune 
recognition of M2-expressing cells is critical for the resolution of 
splenomegaly and, perhaps, the maintenance of the host-virus 
equilibrium that underlies viral persistence (Husain et al., 1999).
MHV-68 reactivation
Chronic gamma-herpesvirus infection is a dynamic process involving 
latent infection, reactivation from latency, and low-level persistent 
replication. The gamma-herpes viruses maintain latent infection as 
a result of an complex balance between host factors that suppress 
infection and viral factors that facilitate evasion of the immune 
response. Immune effectors limit reactivation and subsequent 
replication events, and the adaptive immune response ultimately 
restricts infection to a level compatible with life-long infection 
(Tibbets et al., 2006). Both innate and adaptive immune responses 
play an active role in limiting virus infection. The absence of type I 
interferon (IFN) results in a lethal MHV-68 infection, emphasizing 
the central role of these cytokines at the early stages 
of infection. In contrast, type II IFN is not essential for the 
recovery from infection in the lung,but a failure of 
type II IFN receptor signalling results in the atrophy of lymphoid tissue 
associated with virus persistence (Barton et al., 2011). 
CD8+ T cells play a major role in recovery from the primary 
infection, and also in regulating latently infected cells 
expressing the M2 gene product. CD4+ T cells have a key role in 
surveillance against virus recurrences in the lung, in part mediated 
through the collaboration on the generation of neutralizing antibodies. 
In the absence of CD4+ T cells, virus-specific CD8+ T cells are 
able to control the primary infection in the respiratory tract, 
yet surprisingly the memory CD8+ T cells generated are 
unable to inhibit virus recurrences in the lung (Nash et al., 
2001).This could be explained in part by the observations that 
these viruses can downregulate MHC-I expression and 
also restrict inflammatory cell responses by producing a 
chemokine-binding protein (M3 gene product) (Smith et al., 2007).
The maintenance of chronic MHV-68 infection, at least in some 
latency reservoirs, appears to be dependent on the capacity 
of the virus to reactivate from latency in vitro. However, the signals 
that lead to MHV-68 reactivation in vivo are not well characterized. 
Stimulation of latently infected B cells appears to be a critical component 
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to the reactivation of gamma-herpes viruses. This hypothesis has been 
supported by the inhibition of EBV lytic replication of anti-Ig stimulated 
cells using the immunosuppressive drugs cyclosporine A and FK506 
(Durandy, 2001). It was reported that the reactivation of MHV-68 
from latently infected splenic B cells at late times post-infection can 
similarly be triggered by either anti-Ig/anti-CD40 or LPS stimulation 
(Moser et al., 2005). This studies draw attention to the idea that there 
were common intracellular signalling pathways that, in general, lead 
to gammaherpesvirus reactivation from latently infected B cells. Later, 
it was described that stimulation of latently infected B cell lines with 
ligands for TLRs 3, 4, 5, and 9 enhanced MHV-68 reactivation; the 
ex-vivo stimulation of latently infected primary splenocytes, recovered 
from infected mice, with poly (I:C), LPS, flagellin, or CpG DNA led to 
early B-cell activation, B-cell proliferation, and a significant increase in 
the frequency of latently infected cells reactivating the virus (Gargano 
et al., 2009). And, interestingly, in vivo TLR stimulation also induced 
B-cell activation and MHV-68 reactivation, resulting in higher levels of 
virus replication in the lungs which correlated with an increase in MHV-68 
specific CD8+ T-cell responses, demonstrating that TLR stimulation 
can drive MHV-68 reactivation from latency and suggests that periodic 
pathogen exposure may contribute to the homeostatic maintenance 
of chronic gammaherpesvirus infection through stimulating virus 
reactivation and reseeding latency reservoirs (Gargano et al., 2009).
Scope and outline of this Thesis
The advent of the genomic era has brought a huge amount of viral 
genome information. Biological databases have flourished in last years 
and the development of tools capable of analysing this information has 
provided a valuable tool for rational approaches to the study of the 
function of viral genes. At the same time, the progressive advances 
in the molecular biology have permitted the design of innovative 
approaches to dissect the precise roles of viral proteins. Thus, during 
the past decades, the identification of the key molecular properties 
and signalling pathways of viral genes have contributed much to our 
understanding of the pathogenesis of many viruses. 
The work of this thesis focuses on an analysis of two virus host evasion 
genes in two very different circumstances, the in vitro and the in vivo, 
with the shared understand their contribution to the complex dialogue 
between the pathogen and host. 
The first gene, ORF I329L, from African Swine Fever (ASFV) was 
identified and characterized following the hypothesis that this virus, 
as a pathogen of both ticks and pigs, would have evolved genes to 
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manipulate the innate immune response, as it is a common denominator 
between vertebrate and invertebrate animals. It was selected on the 
basis of a very marginal sequence homology with Toll-like receptors, 
the subsequent confirmed by functional studies on the impact of the 
virus gene in vitro.
The second gene, M2 of MHV-68, was selected because of its known 
association with the establishment of latency in B cells, and the 
strategy, accordingly, was to generate B-cell restricted transgenic 
expression of M2 and then to restricted transgenic expression of M2 
and then to assess the impact of the transgene on the ontogeny and 
function of B-cells in vivo, the latter in response to function of B-cells in 
vivo, the latter in response to conventional antigens and infections with 
wild-type and M2 deficient MHV-68 viruses. 
The work developed to achieve these goals is presented in this disser-
tation in three chapters: 
Chapter 2 - A novel TLR3 inhibitor encoded by African Swine Fever 
Virus (ASFV) 
Chapter 3 - The impact of B cell restricted transgenic expression of a 
Mouse Herpes Virus (MHV-68) host evasion gene 
Chapter 4 - Evaluation of the M2 role in the MHV-68 Pathogenesis 
through an innovative approach.
1
67
References
Alcami, A. & Koszinowski, U. H. (2000). 
Viral mechanisms of immune evasion. Trends in 
microbiology 8, 410–8.
Alexopoulou, L., Holt, A. C., Medzhitov, R. 
& Flavell, R. A. (2001). Recognition of double-
stranded RNA and activation of NF-kappaB by 
Toll-like receptor 3. Nature 413, 732–8.
Allen, C. D. C., Okada, T. & Cyster, J. G. (2007). 
Germinal-center organization and cellular dy-
namics. Immunity 27, 190–202.
Allman, D. M., Ferguson, S. E., Lentz, V. M. & 
Cancro, M. P. (1993). Peripheral B cell matura-
tion. II. Heat-stable antigen(hi) splenic B cells 
are an immature developmental intermediate in 
the production of long-lived marrow-derived B 
cells. Journal of immunology (Baltimore, Md : 
1950) 151, 4431–44.
An, H., Zhao, W., Hou, J., Zhang, Y., Xie, Y., 
Zheng, Y., Xu, H., Qian, C., Zhou, J., & other 
authors. (2006). SHP-2 phosphatase nega-
tively regulates the TRIF adaptor protein-de-
pendent type I interferon and proinflammatory 
cytokine production. Immunity 25, 919–28.
Arana, E., Vehlow, A., Harwood, N. E., 
Vigorito, E., Henderson, R., Turner, M., 
Tybulewicz, V. L. J. & Batista, F. D. (2008). 
Activation of the small GTPase Rac2 via the 
B cell receptor regulates B cell adhesion and 
immunological-synapse formation. Immunity 
28, 88–99.
Aubert, M. & Jerome, K. R. (2003). Apoptosis 
prevention as a mechanism of immune 
evasion. International reviews of immunology 
22, 361–71.
Banerjee, A. & Gerondakis, S. (2007). 
Coordinating TLR-activated signaling 
pathways in cells of the immune system. 
Immunology and cell biology 85, 420–4. 
Barinaga, M. (1992). Viruses launch their 
own “star wars”. Science (New York, NY) 258, 
1730–1.
Barnes, B., Lubyova, B. & Pitha, P. M. (2002). 
On the role of IRF in host defense. Journal of 
interferon & cytokine research : the official journal 
of the International Society for Interferon and 
Cytokine Research 22, 59–71.
Barton, E., Mandal, P. & Speck, S. H. (2011). 
Pathogenesis and host control of gamma 
herpesviruses: lessons from the mouse. 
Annual review of immunology 29, 351–97. Annual 
Reviews.
Batista, F. D., Iber, D. & Neuberger, M. S. 
(2001). B cells acquire antigen from target cells 
after synapse formation. Nature 411, 489–94.
Van Berkel, V., Preiter, K., Virgin, H. W. & 
Speck, S. H. (1999). Identification and initial 
characterization of the murine gammaherpes-
virus 68 gene M3, encoding an abundantly se-
creted protein. Journal of virology 73, 4524–9.
Beutler, B. (2004). Inferences, questions and 
possibilities in Toll-like receptor signalling. 
Nature 430, 257–63.
Blaskovic, D., Staneková, D. & Rajcáni, J. 
(1984). Experimental pathogenesis of murine 
herpesvirus in newborn mice. Acta virologica 
28, 225–31.
Bowie, A. G. & Unterholzner, L. (2008). Viral 
evasion and subversion of pattern-recognition 
receptor signalling. Nature reviews Immunology 
8, 911–22.
Brezski, R. J. & Monroe, J. G. (2007). B cell 
1
68 69
antigen receptor-induced Rac1 activation and 
Rac1-dependent spreading are impaired in 
transitional immature B cells due to levels of 
membrane cholesterol. Journal of immunology 
(Baltimore, Md : 1950) 179, 4464–72.
Brikos, C. & O’Neill, L. A. J. (2008). Signalling 
of toll-like receptors. Handbook of experimental 
pharmacology 21–50.
Bunnell, S. C., Kapoor, V., Trible, R. P., Zhang, 
W. & Samelson, L. E. (2001). Dynamic actin 
polymerization drives T cell receptor-induced 
spreading: a role for the signal transduction 
 adaptor LAT. Immunity 14, 315–29.
Báfica, A., Scanga, C. A., Schito, M. L., Hie-
ny, S. & Sher, A. (2003). Cutting edge: in vivo 
induction of integrated HIV-1 expression by 
mycobacteria is critically dependent on Toll-like 
receptor 2. Journal of immunology (Baltimore, 
Md : 1950) 171, 1123–7.
Cambier, J. C., Gauld, S. B., Merrell, K. T. & 
Vilen, B. J. (2007). B-cell anergy: from trans-
genic models to naturally occurring anergic B 
cells? Nature reviews Immunology 7, 633–43.
Carsetti, R., Köhler, G. & Lamers, M. C. 
(1995). Transitional B cells are the target of 
negative selection in the B cell compartment. 
The Journal of experimental medicine 181, 
2129–40.
Carty, M., Goodbody, R., Schröder, M., 
Stack, J., Moynagh, P. N. & Bowie, A. G. 
(2006). The human adaptor SARM negatively 
regulates adaptor protein TRIF-dependent Toll-
like receptor signaling. Nature immunology 7, 
1074–81.
Chapman, D. a G., Tcherepanov, V., Upton, 
C. & Dixon, L. K. (2008). Comparison of the 
genome sequences of non-pathogenic and 
pathogenic African swine fever virus isolates. 
The Journal of general virology 89, 397–408.
Chapman, D. A. G., Darby, A. C., Da Silva, 
M., Upton, C., Radford, A. D. & Dixon, L. 
K. (2011). Genomic analysis of highly virulent 
Georgia 2007/1 isolate of African swine fever 
virus. Emerging infectious diseases 17, 599–
605.
Chaung, H.-C., Chen, C.-W., Hsieh, B.-L. & 
Chung, W.-B. (2010). Toll-Like Receptor ex-
pressions in porcine alveolar macrophages and 
Dendritic Cells in responding to poly IC stimu-
lation and porcine reproductive and respiratory 
syndrome virus (PRRSV) infection. Compara-
tive immunology, microbiology and infectious 
diseases 33, 197–213.
Chen, J. & Alt, F. W. (1993). Gene rearrange-
ment and B-cell development. Current opinion 
in immunology 5, 194–200.
Chung, J. B., Silverman, M. & Monroe, J. G. 
(2003). Transitional B cells: step by step to-
wards immune competence. Trends in immu-
nology 24, 343–9.
Clambey, E. T., Virgin, H. W. & Speck, S. 
H. (2002). Characterization of a spontaneous 
9.5-kilobase-deletion mutant of murine gamma-
herpesvirus 68 reveals tissue-specific genetic 
requirements for latency. Journal of virology 76, 
6532–44.
Colonna, M. (2007). TLR pathways and IFN-
regulatory factors: to each its own. European 
journal of immunology 37, 306–9.
Costard, S., Wieland, B., De Glanville, W., 
Jori, F., Rowlands, R., Vosloo, W., Roger, F., 
Pfeiffer, D. U. & Dixon, L. K. (2009). African 
swine fever: how can global spread be prevent-
ed? Philosophical transactions of the Royal So-
1
69
ciety of London Series B, Biological sciences 
364, 2683–96.
Coutinho, A., Gronowicz, E., Bullock, 
W. W. & Möller, G. (1974). Mechanism of 
thymus-independent immunocyte trigger-
ing. Mitogenic activation of B cells results 
in specific immune responses. The Jour-
nal of experimental medicine 139, 74–92. 
Coutinho, A., Kazatchkine, M. D. & 
Avrameas, S. (1995). Natural autoantibodies. 
Current opinion in immunology 7, 812–8.
Dal Porto, J. M., Burke, K. & Cambier, J. C. 
(2004a). Regulation of BCR signal transduction 
in B-1 cells requires the expression of the Src 
family kinase Lck. Immunity 21, 443–53.
Dal Porto, J. M., Gauld, S. B., Merrell, K. T., 
Mills, D., Pugh-Bernard, A. E. & Cambier, J. 
(2004b). B cell antigen receptor signaling 101. 
Molecular immunology 41, 599–613.
Defrance, T., Taillardet, M. & Genestier, L. 
(2011). T cell-independent B cell memory. Cur-
rent opinion in immunology 23, 330–6.
Demengeot, J., Zelenay, S., Moraes-Fontes, 
M. F., Caramalho, I. & Coutinho, A. (2006). 
Regulatory T cells in microbial infection. Spring-
er seminars in immunopathology 28, 41–50.
DeZalia, M. & Speck, S. H. (2008). Identifica-
tion of closely spaced but distinct transcription 
initiation sites for the murine gammaherpesvi-
rus 68 latency-associated M2 gene. Journal of 
virology 82, 7411–21.
Dixon, L. K., Abrams, C. C., Bowick, G., 
Goatley, L. C., Kay-Jackson, P. C., Chapman, 
D., Liverani, E., Nix, R., Silk, R. & Zhang, F. 
(2004). African swine fever virus proteins in-
volved in evading host defence systems. Veter-
inary immunology and immunopathology 100, 
117–34.
Dixon, L. K., Chapman, D. D. G., Netherton, 
C. L. & Upton, C. (2012). African swine fever 
virus replication and genomics. Virus research 
1–12. Elsevier B.V.
Durandy, A. (2001). Anti-B cell and anti-cy-
tokine therapy for the treatment of post-trans-
plant lymphoproliferative disorder: past, pre-
sent, and future. Transplant infectious disease : 
an official journal of the Transplantation Society 
3, 104–7.
Dutia, B. M., Stewart, J. P., Clayton, R. A., 
Dyson, H. & Nash, A. A. (1999). Kinetic and 
phenotypic changes in murine lymphocytes 
infected with murine gammaherpesvirus-68 in 
vivo. The Journal of general virology 80 ( Pt 10, 
2729–2736. Soc General Microbiol.
Van Dyk, L. F., Hess, J. L., Katz, J. D., Jaco-
by, M., Speck, S. H. & Virgin HW, I. V. (1999). 
The murine gammaherpesvirus 68 v-cyclin 
gene is an oncogene that promotes cell cycle 
progression in primary lymphocytes. Journal of 
virology 73, 5110–22.
Engel, P. & Angulo, A. (2012). Viral immu-
nomodulatory proteins: usurping host genes as 
a survival strategy. Advances in experimental 
medicine and biology 738, 256–76.
Fang, Y., Yu, S., Ellis, J. S., Sharav, T. & 
Braley-Mullen, H. (2010). Comparison of sen-
sitivity of Th1, Th2, and Th17 cells to Fas-me-
diated apoptosis. Journal of leukocyte biology 
87, 1019–28.
Faure, S., Salazar-Fontana, L. I., Semichon, 
M., Tybulewicz, V. L. J., Bismuth, G., Traut-
mann, A., Germain, R. N. & Delon, J. (2004). 
ERM proteins regulate cytoskeleton relaxation 
1
70 71
promoting T cell-APC conjugation. Nature im-
munology 5, 272–9.
Fearon, D. T. (1997). Seeking wisdom in innate 
immunity. Nature 388, 323–4.
Finlay, B. B. & McFadden, G. (2006). Anti-im-
munology: evasion of the host immune system by 
bacterial and viral pathogens. Cell 124, 767–82. 
Fleire, S. J., Goldman, J. P., Carrasco, Y. R., 
Weber, M., Bray, D. & Batista, F. D. (2006). B 
cell ligand discrimination through a spreading 
and contraction response. Science (New York, 
NY) 312, 738–41.
Gangappa, S., Van Dyk, L. F., Jewett, T. J., 
Speck, S. H. & Virgin, H. W. (2002). Identifi-
cation of the in vivo role of a viral bcl-2. The 
Journal of experimental medicine 195, 931–40.
Gargano, L. M., Forrest, J. C. & Speck, S. H. 
(2009). Signaling through Toll-like receptors in-
duces murine gammaherpesvirus 68 reactiva-
tion in vivo. Journal of virology 83, 1474–82.
Gay, N. J. & Gangloff, M. (2007). Structure 
and function of Toll receptors and their ligands. 
Annual review of biochemistry 76, 141–65.
Gedey, R., Jin, X.-L., Hinthong, O. & Shisler, 
J. L. (2006). Poxviral regulation of the host NF-
kappaB response: the vaccinia virus M2L pro-
tein inhibits induction of NF-kappaB activation 
via an ERK2 pathway in virus-infected human 
embryonic kidney cells. Journal of virology 80, 
8676–85.
Ghazal, P., García-Ramírez, J., González-
Armas, J. C., Kurz, S. & Angulo, A. (2000a). 
Principles of homeostasis in governing virus 
activation and latency. Immunologic research 
21, 219–23.
Ghazal, P., González Armas, J. C., García-
Ramírez, J. J., Kurz, S. & Angulo, A. (2000b). 
Viruses: hostages to the cell. Virology 275, 
233–7.
Goitsuka, R., Fujimura, Y., Mamada, H., Um-
eda, A., Morimura, T., Uetsuka, K., Doi, K., 
Tsuji, S. & Kitamura, D. (1998). BASH, a novel 
signaling molecule preferentially expressed in 
B cells of the bursa of Fabricius. Journal of im-
munology (Baltimore, Md : 1950) 161, 5804–8.
Goodman, L. (2004). Viral star wars. The Jour-
nal of clinical investigation 113, 649.
Grakoui, A., Bromley, S. K., Sumen, C., Da-
vis, M. M., Shaw, A. S., Allen, P. M. & Dustin, 
M. L. (1999). The immunological synapse: a 
molecular machine controlling T cell activation. 
Science (New York, NY) 285, 221–7.
Haller, O., Kochs, G. & Weber, F. (2006). The 
interferon response circuit: induction and sup-
pression by pathogenic viruses. Virology 344, 
119–30.
Hardy, R. R. & Hayakawa, K. (1994). CD5 B 
cells, a fetal B cell lineage. Advances in immu-
nology 55, 297–339.
Hardy, R. R., Li, Y. S. & Hayakawa, K. (1996). 
Distinctive developmental origins and specifici-
ties of the CD5+ B-cell subset. Seminars in im-
munology 8, 37–44.
Hardy, R. R. (2006). B-1 B cell development. 
Journal of immunology (Baltimore, Md : 1950) 
177, 2749–54.
Harte, M. T., Haga, I. R., Maloney, G., Gray, P., 
Reading, P. C., Bartlett, N. W., Smith, G. L., 
Bowie, A. & O’Neill, L. A. J. (2003). The poxvi-
rus protein A52R targets Toll-like receptor sign-
aling complexes to suppress host defense. The 
Journal of experimental medicine 197, 343–51.
1
71
Harwood, N. E. & Batista, F. D. (2008). New 
insights into the early molecular events under-
lying B cell activation. Immunity 28, 609–19.
Harwood, N. E. & Batista, F. D. (2010). Early 
events in B cell activation. Annual review of im-
munology 28, 185–210.
 
Hauser, A. E., Shlomchik, M. J. & Haberman, 
A. M. (2007). In vivo imaging studies shed light 
on germinal-centre development. Nature re-
views Immunology 7, 499–504.
Heinz, S., Haehnel, V., Karaghiosoff, M., 
Schwarzfischer, L., Müller, M., Krause, 
S. W. & Rehli, M. (2003). Species-specific 
regulation of Toll-like receptor 3 genes in men 
and mice. The Journal of biological chemistry 
278, 21502–9.
Herskowitz, J. H., Siegel, A. M., Jacoby, M. A. 
& Speck, S. H. (2008). Systematic mutagenesis 
of the murine gammaherpesvirus 68 M2 
protein identifies domains important for chronic 
infection. Journal of virology 82, 3295–310.
Herzenberg, L. A., Stall, A. M., Lalor, P. A., 
Sidman, C., Moore, W. A. & Parks, D. R. 
(1986). The Ly-1 B cell lineage. Immunological 
reviews 93, 81–102.
Hirschfeld, M., Weis, J. J., Toshchakov, V., 
Salkowski, C. A., Cody, M. J., Ward, D. C., 
Qureshi, N., Michalek, S. M. & Vogel, S. N. 
(2001). Signaling by toll-like receptor 2 and 4 
agonists results in differential gene expression 
in murine macrophages. Infection and immunity 
69, 1477–82.
Huang, J., Liu, T., Xu, L.-G., Chen, D., Zhai, 
Z. & Shu, H.-B. (2005). SIKE is an IKK epsi-
lon/TBK1-associated suppressor of TLR3- and 
virus-triggered IRF-3 activation pathways. The 
EMBO journal 24, 4018–28.
Husain, S. M., Usherwood, E. J., Dyson, H., 
Coleclough, C., Coppola, M. a, Woodland, 
D. L., Blackman, M. a, Stewart, J. P. & Sam-
ple, J. T. (1999). Murine gammaherpesvirus 
M2 gene is latency-associated and its protein a 
target for CD8(+) T lymphocytes. Proceedings 
of the National Academy of Sciences of the 
United States of America 96, 7508–13.
Lyer, L. M., Balaji, S., Koonin, E. V & Aravind, 
L. (2006). Evolutionary genomics of nucleo-
cytoplasmic large DNA viruses. Virus research 
117, 156–84.
Jacoby, M. A., Virgin, H. W. & Speck, S. H. 
(2002). Disruption of the M2 gene of murine 
gammaherpesvirus 68 alters splenic latency 
following intranasal, but not intraperitoneal, 
inoculation. Journal of virology 76, 1790–801.
Jaffe, A. B. & Hall, A. (2005). Rho GTPases: 
biochemistry and biology. Annual review of cell 
and developmental biology 21, 247–69.
Janes, P. W., Ley, S. C. & Magee, A. I. 
(1999). Aggregation of lipid rafts accompanies 
signaling via the T cell antigen receptor. The 
Journal of cell biology 147, 447–61.
Janeway, C. A. (1989). Approaching the 
asymptote? Evolution and revolution in 
immunology. Cold Spring Harbor symposia on 
quantitative biology 54 Pt 1, 1–13.
Janeway, C. A. (1992). The immune system 
evolved to discriminate infectious nonself from 
noninfectious self. Immunology today 13, 11–6.
Jin, M. S. & Lee, J.-O. (2008). Structures 
of the toll-like receptor family and its ligand 
complexes. Immunity 29, 182–91.
Jude, B. A., Pobezinskaya, Y., Bishop, J., 
Parke, S., Medzhitov, R. M., Chervonsky, A. 
1
72 73
V & Golovkina, T. V. (2003). Subversion of the 
innate immune system by a retrovirus. Nature 
immunology 4, 573–8.
Kagan, J. C., Su, T., Horng, T., Chow, A., 
Akira, S. & Medzhitov, R. (2008). TRAM cou-
ples endocytosis of Toll-like receptor 4 to the 
induction of interferon-beta. Nature immunol-
ogy 9, 361–8.
Kang, J. Y. & Lee, J.-O. (2011). Structural biol-
ogy of the Toll-like receptor family. Annual re-
view of biochemistry 80, 917–41.
Kantor, A. B., Stall, A. M., Adams, S. & Her-
zenberg, L. A. (1992). Differential develop-
ment of progenitor activity for three B-cell line-
ages. Proceedings of the National Academy of 
Sciences of the United States of America 89, 
3320–4.
Kenny, E. F. & O’Neill, L. A. J. (2008). Sig-
nalling adaptors used by Toll-like receptors: an 
update. Cytokine 43, 342–9.
Keogh, B. & Parker, A. E. (2011). Toll-like 
receptors as targets for immune disorders. 
Trends in pharmacological sciences 32, 435–
42. Elsevier Ltd.
Kleiboeker, S. B. & Scoles, G. A. (2001). 
Pathogenesis of African swine fever virus in 
Ornithodoros ticks. Animal health research re-
views / Conference of Research Workers in 
Animal Diseases 2, 121–8.
Kurosaki, T. (1999). Genetic analysis of B cell 
antigen receptor signaling. Annual review of im-
munology 17, 555–92.
Küppers, R. (2003). B cells under influence: 
transformation of B cells by Epstein-Barr virus. 
Nature reviews Immunology 3, 801–12.
Lam, K. P., Kühn, R. & Rajewsky, K. (1997). 
In vivo ablation of surface immunoglobulin on 
mature B cells by inducible gene targeting re-
sults in rapid cell death. Cell 90, 1073–83.
Lanzavecchia, A. (1985). Antigen-specific inter-
action between T and B cells. Nature 314, 537–9. 
Lanzavecchia, A. (1987). Antigen uptake and 
accumulation in antigen-specific B cells. Immu-
nological reviews 99, 39–51.
Liang, X., Shin, Y. C., Means, R. E. & Jung, 
J. U. (2004). Inhibition of interferon-mediated 
antiviral activity by murine gammaherpesvirus 
68 latency-associated M2 protein. Journal of 
virology 78, 12416–27.
Liang, X., Pickering, M. T., Cho, N.-H., Chang, 
H., Volkert, M. R., Kowalik, T. F. & Jung, J. 
U. (2006). Deregulation of DNA damage signal 
transduction by herpesvirus latency-associated 
M2. Journal of virology 80, 5862–74.
Lin, K. B. L., Freeman, S. A., Zabetian, S., 
Brugger, H., Weber, M., Lei, V., Dang-Law-
son, M., Tse, K. W. K., Santamaria, R., & oth-
er authors. (2008). The rap GTPases regulate 
B cell morphology, immune-synapse formation, 
and signaling by particulate B cell receptor li-
gands. Immunity 28, 75–87.
Liu, C.-H., Chaung, H.-C., Chang, H.-L., 
Peng, Y.-T. & Chung, W.-B. (2009). Expres-
sion of Toll-like receptor mRNA and cytokines 
in pigs infected with porcine reproductive and 
respiratory syndrome virus. Veterinary microbi-
ology 136, 266–76.
Loder, F., Mutschler, B., Ray, R. J., Paige, 
C. J., Sideras, P., Torres, R., Lamers, M. C. 
& Carsetti, R. (1999). B cell development in 
the spleen takes place in discrete steps and 
is determined by the quality of B cell receptor-
derived signals. The Journal of experimental 
1
73
medicine 190, 75–89.
Lortan, J. E., Roobottom, C. A., Oldfield, S. & 
MacLennan, I. C. (1987). Newly produced virgin 
B cells migrate to secondary lymphoid organs 
but their capacity to enter follicles is restricted. 
European journal of immunology 17, 1311–6. 
MacLennan, I. C. (1994). Germinal centers. 
Annual review of immunology 12, 117–39.
Macpherson, A. J., Lamarre, A., McCoy, K., 
Harriman, G. R., Odermatt, B., Dougan, G., 
Hengartner, H. & Zinkernagel, R. M. (2001). 
IgA production without mu or delta chain ex-
pression in developing B cells. Nature immu-
nology 2, 625–31.
Macrae, A. I., Dutia, B. M., Milligan, S., 
Brownstein, D. G., Allen, D. J., Mistrikova, 
J., Davison, A. J., Nash, A. A. & Stewart, J. 
P. (2001). Analysis of a novel strain of murine 
gammaherpesvirus reveals a genomic locus 
important for acute pathogenesis. Journal of 
virology 75, 5315–27.
Macrae, A. I., Usherwood, E. J., Husain, S. 
M., Flaño, E., Kim, I.-J., Woodland, D. L., 
Nash, A. A., Blackman, M. A., Sample, J. T. 
& Stewart, J. P. (2003). Murid herpesvirus 4 
strain 68 M2 protein is a B-cell-associated an-
tigen important for latency but not lymphocyto-
sis. Journal of virology 77, 9700–9.
Madureira, P. a, Matos, P., Soeiro, I., Dixon, 
L. K., Simas, J. P. & Lam, E. W.-F. (2005). 
Murine gamma-herpesvirus 68 latency protein 
M2 binds to Vav signaling proteins and inhib-
its B-cell receptor-induced cell cycle arrest and 
apoptosis in WEHI-231 B cells. The Journal of 
biological chemistry 280, 37310–8.
Maloney, G., Schroder, M., Bowie, A. G. & 
Schröder, M. (2005). Vaccinia virus protein 
A52R activates p38 mitogen-activated protein 
kinase and potentiates lipopolysaccharide-in-
duced interleukin-10. JBiolChem 280, 30838–
30844.
Mann, M. K., Maresz, K., Shriver, L. P., Tan, 
Y. & Dittel, B. N. (2007). B cell regulation of 
CD4+CD25+ T regulatory cells and IL-10 via B7 
is essential for recovery from experimental au-
toimmune encephalomyelitis. Journal of immu-
nology (Baltimore, Md : 1950) 178, 3447–56. 
Marrack, P., Hannum, C., Harris, M., Haskins, 
K., Kubo, R., Pigeon, M., Shimonkevitz, R., 
White, J. & Kappler, J. (1983). Antigen-specif-
ic, major histocompatibility complex-restricted 
T cell receptors. Immunological reviews 76, 
131–45.
McCullough, K. C., Basta, S., Knötig, S., Ger-
ber, H., Schaffner, R., Kim, Y. B., Saalmüller, 
A. & Summerfield, A. (1999). Intermediate 
stages in monocyte-macrophage differentiation 
modulate phenotype and susceptibility to virus 
infection. Immunology 98, 203–12.
Medzhitov, R., Preston-Hurlburt, P. & 
Janeway, C. A. (1997). A human homologue of 
the Drosophila Toll protein signals activation of 
adaptive immunity. Nature 388, 394–7.
Moser, J. M., Upton, J. W., Allen, R. D., Wil-
son, C. B. & Speck, S. H. (2005). Role of B-
cell proliferation in the establishment of gam-
maherpesvirus latency. Journal of virology 79, 
9480–91.
Mosier, D. E., Zaldivar, N. M., Goldings, 
E., Mond, J., Scher, I. & Paul, W. E. (1977). 
Formation of antibody in the newborn mouse: 
study of T-cell-independent antibody response. 
The Journal of infectious diseases 136 Suppl, 
S14–9.
Nash, A. A., Dutia, B. M., Stewart, J. P. & 
1
74 75
Davison, A. J. (2001). Natural history of mu-
rine gamma-herpesvirus infection. Philosophical 
transactions of the Royal Society of London Se-
ries B, Biological sciences 356, 569–79.
Netea, M. G., Warris, A., Van der Meer, J. W. 
M., Fenton, M. J., Verver-Janssen, T. J. G., 
Jacobs, L. E. H., Andresen, T., Verweij, P. E. 
& Kullberg, B. J. (2003). Aspergillus fumigatus 
evades immune recognition during germination 
through loss of toll-like receptor-4-mediated sig-
nal transduction. The Journal of infectious dis-
eases 188, 320–6.
Obukhanych, T. V & Nussenzweig, M. C. 
(2006). T-independent type II immune responses 
generate memory B cells. The Journal of experi-
mental medicine 203, 305–10.
Ohashi, P. S., Oehen, S., Buerki, K., Pircher, 
H., Ohashi, C. T., Odermatt, B., Malissen, B., 
Zinkernagel, R. M. & Hengartner, H. (1991). 
Ablation of “tolerance” and induction of diabetes 
by virus infection in viral antigen transgenic mice. 
Cell 65, 305–17.
Oldstone, M. B., Nerenberg, M., Southern, P., 
Price, J. & Lewicki, H. (1991). Virus infection 
triggers insulin-dependent diabetes mellitus in a 
transgenic model: role of anti-self (virus) immune 
response. Cell 65, 319–31.
De Oliveira, V. L., Almeida, S. C. P., Soares, 
H. R., Crespo, A., Marshall-Clarke, S. & Park-
house, R. M. E. (2011). A novel TLR3 inhibitor 
encoded by African swine fever virus (ASFV). Ar-
chives of virology 156, 597–609.
Oliver, A. M., Martin, F. & Kearney, J. F. (1999). 
IgMhighCD21high lymphocytes enriched in the 
splenic marginal zone generate effector cells 
more rapidly than the bulk of follicular B cells. 
Journal of immunology (Baltimore, Md : 1950) 
162, 7198–207.
Ollila, J. & Vihinen, M. (2005). B cells. The in-
ternational journal of biochemistry & cell biology 
37, 518–23.
Oura, C. A., Powell, P. P. & Parkhouse, R. M. 
(1998). African swine fever: a disease character-
ized by apoptosis. The Journal of general virology 
79 ( Pt 6), 1427–38.
Ozinsky, A., Underhill, D. M., Fontenot, J. 
D., Hajjar, A. M., Smith, K. D., Wilson, C. B., 
Schroeder, L. & Aderem, A. (2000). The reper-
toire for pattern recognition of pathogens by the 
innate immune system is defined by coopera-
tion between toll-like receptors. Proceedings of 
the National Academy of Sciences of the United 
States of America 97, 13766–71.
O’Neill, L. A. J. & Bowie, A. G. (2007). The fam-
ily of five: TIR-domain-containing adaptors in 
Toll-like receptor signalling. NatRevImmunol 7, 
353–364.
Pape, K. A., Catron, D. M., Itano, A. A. & Jen-
kins, M. K. (2007). The humoral immune re-
sponse is initiated in lymph nodes by B cells that 
acquire soluble antigen directly in the follicles. Im-
munity 26, 491–502.
Pillai, S., Cariappa, A. & Moran, S. T. (2004). 
Positive selection and lineage commitment during 
peripheral B-lymphocyte development. Immuno-
logical reviews 197, 206–18.
Pillai, S., Cariappa, A. & Moran, S. T. (2005). 
Marginal zone B cells. Annual review of immunol-
ogy 23, 161–96.
Pires de Miranda, M., Alenquer, M., Marques, 
S., Rodrigues, L., Lopes, F., Bustelo, X. R. & 
Simas, J. P. (2008). The Gammaherpesvirus m2 
protein manipulates the Fyn/Vav pathway through 
a multidocking mechanism of assembly. PloS one 
3, e1654.
1
75
Rajewsky, K. (1996). Clonal selection and 
learning in the antibody system. Nature 381, 
751–8.
Randall, R. E. & Goodbourn, S. (2008). Inter-
ferons and viruses: an interplay between induc-
tion, signalling, antiviral responses and virus 
countermeasures. The Journal of general virol-
ogy 89, 1–47.
Raslova, H., Berebbi, M., Rajcani, J., Sara-
sin, A., Matis, J. & Kudelova, M. (2001). Sus-
ceptibility of mouse mammary glands to murine 
gammaherpesvirus 72 (MHV-72) infection: evi-
dence of MHV-72 transmission via breast milk. 
Microbial pathogenesis 31, 47–58.
Re, F. & Strominger, J. L. (2001). Toll-like re-
ceptor 2 (TLR2) and TLR4 differentially activate 
human dendritic cells. The Journal of biological 
chemistry 276, 37692–9.
Reth, M. (1989). Antigen receptor tail clue. Na-
ture 338, 383–4.
Rodrigues, L., Pires de Miranda, M., Caloca, 
M. J., Bustelo, X. R. & Simas, J. P. (2006). 
Activation of Vav by the gammaherpesvirus M2 
protein contributes to the establishment of viral 
latency in B lymphocytes. Journal of virology 
80, 6123–35.
Rodríguez, J. M. & Salas, M. L. (2012). African 
swine fever virus transcription. Virus research. 
Elsevier B.V.
Rolink, A. G., Andersson, J. & Melchers, F. 
(1998). Characterization of immature B cells by 
a novel monoclonal antibody, by turnover and 
by mitogen reactivity. European journal of im-
munology 28, 3738–48.
Rolink, A. G., Andersson, J. & Melchers, F. 
(2004). Molecular mechanisms guiding late 
stages of B-cell development. Immunological 
reviews 197, 41–50.
Rowlands, R. J., Michaud, V., Heath, L., 
Hutchings, G., Oura, C., Vosloo, W., Dwarka, 
R., Onashvili, T., Albina, E. & Dixon, L. K. 
(2008). African swine fever virus isolate, Geor-
gia, 2007. Emerging infectious diseases 14, 
1870–4.
Saitoh, T., Yamamoto, M., Miyagishi, M., 
Taira, K., Nakanishi, M., Fujita, T., Akira, S., 
Yamamoto, N. & Yamaoka, S. (2005). A20 is 
a negative regulator of IFN regulatory factor 3 
signaling. Journal of immunology (Baltimore, 
Md : 1950) 174, 1507–12.
Sang, Y., Yang, J., Ross, C. R., Rowland, R. 
R. R. & Blecha, F. (2008). Molecular identifica-
tion and functional expression of porcine Toll-
like receptor (TLR) 3 and TLR7. Veterinary im-
munology and immunopathology 125, 162–7.
Schmidt-Weber, C. B., Akdis, M. & Akdis, C. 
A. (2007). TH17 cells in the big picture of im-
munology. The Journal of allergy and clinical 
immunology 120, 247–54.
Schwickert, T. A., Lindquist, R. L., Shakhar, 
G., Livshits, G., Skokos, D., Kosco-Vilbois, 
M. H., Dustin, M. L. & Nussenzweig, M. C. 
(2007). In vivo imaging of germinal centres re-
veals a dynamic open structure. Nature 446, 
83–7
.
Shapiro-Shelef, M. & Calame, K. (2005). 
Regulation of plasma-cell development. Nature 
reviews Immunology 5, 230–42.
Shin, Y. C., Nakamura, H., Liang, X., Feng, P., 
Chang, H., Kowalik, T. F. & Jung, J. U. (2006). 
Inhibition of the ATM/p53 signal transduction 
pathway by Kaposi’s sarcoma-associated her-
1
76 77
pesvirus interferon regulatory factor 1. Journal of 
virology 80, 2257–66.
Shisler, J. L. & Jin, X.-L. (2004). The vaccinia 
virus K1L gene product inhibits host NF-kappaB 
activation by preventing IkappaBalpha degrada-
tion. Journal of virology 78, 3553–60.
Shlomchik, M. J. & Weisel, F. (2012). Germinal 
center selection and the development of memory 
B and plasma cells. Immunological reviews 247, 
52–63.
Siegel, A. M., Herskowitz, J. H. & Speck, S. 
H. (2008). The MHV-68 M2 protein drives IL-10 
dependent B cell proliferation and differentiation. 
PLoS pathogens 4, e1000039.
Simas, J. P. & Efstathiou, S. (1998). Murine 
gammaherpesvirus 68: a model for the study of 
gammaherpesvirus pathogenesis. Trends in Mi-
crobiology 6, 276–282.
Simas, J. P., Marques, S., Bridgeman, A., Ef-
stathiou, S. & Adler, H. (2004). The M2 gene 
product of murine gammaherpesvirus 68 is re-
quired for efficient colonization of splenic follicles 
but is not necessary for expansion of latently 
infected germinal centre B cells. The Journal of 
general virology 85, 2789–97.
Slifka, M. K., Antia, R., Whitmire, J. K. & 
Ahmed, R. (1998). Humoral immunity due to 
long-lived plasma cells. Immunity 8, 363–72.
Smith, K. A., Efstathiou, S. & Cooke, A. (2007). 
Murine gammaherpesvirus-68 infection alters 
self-antigen presentation and type 1 diabetes 
onset in NOD mice. Journal of immunology 
(Baltimore, Md : 1950) 179, 7325–33. 
Stack, J., Haga, I. R., Schroder, M., Bartlett, N. 
W., Maloney, G., Reading, P. C., Fitzgerald, K. 
A., Smith, G. L., Bowie, A. G. & Schröder, M. 
(2005). Vaccinia virus protein A46R targets mul-
tiple Toll-like-interleukin-1 receptor adaptors and 
contributes to virulence. JExpMed 201, 1007–
1018.
Stevenson, P. G., Efstathiou, S., Doherty, P. C. 
& Lehner, P. J. (2000). Inhibition of MHC class 
I-restricted antigen presentation by gamma 2-her-
pesviruses. Proceedings of the National Acade-
my of Sciences of the United States of America 
97, 8455–60.
Stevenson, P. G. & Efstathiou, S. (2005). Im-
mune mechanisms in murine gammaherpes-
virus-68 infection. Viral immunology 18, 445–56.
Stinchcombe, J. C., Bossi, G., Booth, S. & 
Griffiths, G. M. (2001). The immunological syn-
apse of CTL contains a secretory domain and 
membrane bridges. Immunity 15, 751–61.
Strasser, A., Harris, A. W., Von Boehmer, H. 
& Cory, S. (1994). Positive and negative selec-
tion of T cells in T-cell receptor transgenic mice 
expressing a bcl-2 transgene. Proceedings of 
the National Academy of Sciences of the United 
States of America 91, 1376–80.
Su, X., Li, S., Meng, M., Qian, W., Xie, W., Chen, 
D., Zhai, Z. & Shu, H.-B. (2006). TNF receptor-
associated factor-1 (TRAF1) negatively regulates 
Toll/IL-1 receptor domain-containing adaptor 
inducing IFN-beta (TRIF)-mediated signaling. 
European journal of immunology 36, 199–206.
Sundstrom, J. B., Little, D. M., Villinger, F., 
Ellis, J. E. & Ansari, A. A. (2004). Signaling 
through Toll-like receptors triggers HIV-1 replica-
tion in latently infected mast cells. Journal of im-
munology (Baltimore, Md : 1950) 172, 4391–401.
Takeda, K. & Akira, S. (2007). Toll-like receptors. 
Current protocols in immunology / edited by John 
E Coligan . [et al. Chapter 14, Unit 14.12.
1
77
Takeshita, F., Ishii, K. J., Kobiyama, K., Ko-
jima, Y., Coban, C., Sasaki, S., Ishii, N., Klin-
man, D. M., Okuda, K., & other authors. (2005). 
TRAF4 acts as a silencer in TLR-mediated signal-
ing through the association with TRAF6 and TRIF. 
European journal of immunology 35, 2477–85.
Tibbetts, S. A., Suarez, F., Steed, A. L., Sim-
mons, J. A. & Virgin, H. W. (2006). A gamma-
herpesvirus deficient in replication establishes 
chronic infection in vivo and is impervious to 
restriction by adaptive immune cells. Virology 
353, 210–9.
Uematsu, S. & Akira, S. (2006). The role of Toll-
like receptors in immune disorders. Expert opin-
ion on biological therapy 6, 203–14.
Underhill, D. M. & Gantner, B. (2004). Integra-
tion of Toll-like receptor and phagocytic signaling 
for tailored immunity. Microbes and infection / In-
stitut Pasteur 6, 1368–73.
Upton, C., Slack, S., Hunter, A. L., Ehlers, A. & 
Roper, R. L. (2003). Poxvirus orthologous clus-
ters: toward defining the minimum essential pox-
virus genome. Journal of virology 77, 7590–600.
Vallée, I., Tait, S. W. & Powell, P. P. (2001). 
African swine fever virus infection of porcine aor-
tic endothelial cells leads to inhibition of inflamma-
tory responses, activation of the thrombotic state, 
and apoptosis. Journal of virology 75, 10372–82.
Vercammen, E., Staal, J. & Beyaert, R. (2008). 
Sensing of viral infection and activation of innate 
immunity by toll-like receptor 3. ClinMicrobiolRev 
21, 13–25.
Victora, G. D. & Nussenzweig, M. C. (2012). 
Germinal centers. Annual review of immunology 
30, 429–57.
Virgin, H. W. & Speck, S. H. (1999). Unraveling 
immunity to gamma-herpesviruses: a new model 
for understanding the role of immunity in chronic 
virus infection. Current opinion in immunology 11, 
371–9.
Virgin, H. W., Latreille, P., Wamsley, P., 
Hallsworth, K., Weck, K. E., Dal Canto, A. J. 
& Speck, S. H. (1997). Complete sequence and 
genomic analysis of murine gammaherpesvirus 
68. Journal of virology 71, 5894–904.
Virgin, H. W., Presti, R. M., Li, X. Y., Liu, C. & 
Speck, S. H. (1999). Three distinct regions of the 
murine gammaherpesvirus 68 genome are tran-
scriptionally active in latently infected mice. Jour-
nal of virology 73, 2321–32.
Vos, Q., Lees, A., Wu, Z. Q., Snapper, C. M. & 
Mond, J. J. (2000). B-cell activation by T-cell-
independent type 2 antigens as an integral part 
of the humoral immune response to pathogenic 
microorganisms. Immunological reviews 176, 
154–70.
Vossen, M. T. M., Westerhout, E. M., 
Söderberg-Nauclér, C. & Wiertz, E. J. H. J. 
(2002). Viral immune evasion: a masterpiece of 
evolution. Immunogenetics 54, 527–42.
Wang, Y.-Y., Li, L., Han, K.-J., Zhai, Z. & Shu, 
H.-B. (2004). A20 is a potent inhibitor of TLR3- 
and Sendai virus-induced activation of NF-kap-
paB and ISRE and IFN-beta promoter. FEBS let-
ters 576, 86–90.
Watters, T. M., Kenny, E. F. & O’Neill, L. A. J. 
(2007). Structure, function and regulation of the 
Toll/IL-1 receptor adaptor proteins. Immunology 
and cell biology 85, 411–9.
Weber, M., Treanor, B., Depoil, D., Shinohara, 
H., Harwood, N. E., Hikida, M., Kurosaki, T. & 
Batista, F. D. (2008). Phospholipase C-gamma2 
and Vav cooperate within signaling microclus-
ters to propagate B cell spreading in response to 
membrane-bound antigen. The Journal of experi-
1
78 79
mental medicine 205, 853–68.
Weck, K. E., Dal Canto, A. J., Gould, J. D., 
O’Guin, A. K., Roth, K. A., Saffitz, J. E., 
Speck, S. H. & Virgin, H. W. (1997). Murine 
gamma-herpesvirus 68 causes severe large-
vessel arteritis in mice lacking interferon-gam-
ma responsiveness: a new model for virus-
induced vascular disease. Nature medicine 3, 
1346–53.
Weck, K. E., Kim, S. S., Virgin HW, I. V & 
Speck, S. H. (1999). B cells regulate murine 
gammaherpesvirus 68 latency. Journal of virol-
ogy 73, 4651–61.
Werling, D., Piercy, J. & Coffey, T. J. (2006).  
Expression of TOLL-like receptors (TLR) by 
bovine antigen-presenting cells-potential role 
in pathogen discrimination? Veterinary immu-
nology and immunopathology 112, 2–11.
Werts, C., Tapping, R. I., Mathison, J. C., 
Chuang, T. H., Kravchenko, V., Saint Girons, 
I., Haake, D. A., Godowski, P. J., Hayashi, F., 
& other authors. (2001). Leptospiral lipopoly-
saccharide activates cells through a TLR2-
dependent mechanism. Nature immunology 2, 
346–52.
Zhang, J., Xu, L.-G., Han, K.-J., Wei, X. & 
Shu, H.-B. (2004). PIASy represses TRIF-in-
duced ISRE and NF-kappaB activation but not 
apoptosis. FEBS letters 570, 97–101.
Zhang, N. & Bevan, M. J. (2011). CD8(+) T 
cells: foot soldiers of the immune system. Im-
munity 35, 161–8.
79

 
A Novel TLR3 Inhibitor Encoded by African Swine 
Fever Virus (ASFV)02
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Abstract
African swine fever virus (ASFV) encodes proteins that manipulate 
important host antiviral mechanisms. Bioinformatic analysis of the ASFV 
genome revealed ORF I329L, a gene without any previous functional 
characterization as a possible inhibitor of TLR signaling. We demonstrate 
that ORF I329L encodes a highly glycosylated protein expressed 
in the cell membrane and on its surface. I329L also inhibited 
dsRNA-stimulated activation of NFkB and IRF3, two key players in 
innate immunity. Consistent with this, expression of I329L protein also 
inhibited the activation of interferon-β and CCL5. Finally, overexpression 
of TRIF reversed I329L-mediated inhibition of both NFkB and IRF3 
activation. Our results suggest that TRIF, a key MyD88-inde-
pendent adaptor molecule, is a possible target of this viral host 
immunomodulation gene. The demonstration of an ASFV host evasion 
molecule inhibiting TLR responses is consistent with the ability 
of this virus to infect vertebrate and invertebrate hosts, both of which 
deploy innate immunity controlled by conserved TLR systems.
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Introduction
African swine fever virus (ASFV) is a lethal haemorrhagic pathogen 
of domestic pigs. In its natural mammalian hosts, the Warthog and 
Bushpig, however, the virus is persistent, non-pathogenic and 
transmitted by an invertebrate vector, the soft tick. The virus may 
therefore be considered as a veterinary model for recently 
emerged haemorrhagic infections. AFSV is an enveloped DNA 
virus with icosahedral morphology that is now classified as the only 
member of a new virus family, Asfarviridae (Dixon et al., 2004). It 
exhibits a characteristic genomic structure, large numbers of novel 
genes and a cytoplasmic replication strategy, and, in contrast to all 
other DNA viruses, this arbovirus infects both vertebrate (swine) and 
invertebrate (tick) hosts. The ability of the virus to infect macrophages 
and to persist in its natural hosts, and in domestic pigs, which 
recover from infection with less virulent isolates, shows that the virus has 
effective mechanisms to evade host defense systems, in particular, 
innate immunity. It is estimated that half to two-thirds of the approximately 
150 genes encoded by ASFV do not have known viral or cellular 
homologs (Chapman et al., 2008). Most of the structural proteins and 
enzymes have been identified, but many of these non-homologous 
genes have no homology to known proteins or enzymes. 
Therefore, we hypothesize that some of these genes have evolved for, 
or may be involved in, host evasion. Such genes provide a source of 
potentially valuable tools for understanding virus pathogenesis and for 
identifying novel aspects of the vertebrate immune system. The fact 
that ASFV has adapted to infect both mammalian macrophages and 
an invertebrate tick host suggests that this virus may have evolved 
immune evasion genes focused on innate immunity, more specifically, 
for manipulation of the Toll-like receptor (TLR) signalling system, which is 
conserved in both mammals and arthropods. Moreover, there is abundant 
expression of TLRs in macrophages, where they play a critical 
role in the detection of viral infections, leading to the inflammatory 
response and induction of an interferon (IFN)-mediated anti-viral state 
in infected and neighbouring cells (Kawai & Akira, 2007). Under some 
circumstances, however, uncontrolled activation of macrophages leads 
to undesirable pathological consequences.
To date there are at least 13 distinct mammalian TLRs, all sharing 
similarities in their extracellular and intracellular domains, in 
particular, the conserved intracellular Toll/IL-1 receptor (TIR) domain 
(Brikos & O’Neill, 2008; Watters et al., 2007). Dimerization of TLRs 
induced by interaction with the corresponding ligands initiates the 
intracellular signalling cascade, followed by recruitment of intracellular 
adaptor proteins to their dimerized intracellular domains (Jin & Lee, 
2
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2008). Among the adaptor proteins, myeloid differentiation primary 
response gene (MyD88) and TIR-domain-containing adaptor- inducing 
interferon-β (TRIF) are critical for signalling, and hence, TLR signalling 
falls into the MyD88-dependent and TRIF-dependent pathways 
(O’Neill & Bowie, 2007; Yamamoto et al., 2002), both terminating in 
activation of the transcription factors nuclear factor kB (NFkB) and activator 
protein-1 (AP-1). Binding to each TLR induces common effects, such 
as induction of inflammatory cytokines and chemokines and more 
specific and restricted activities, such as the induction of interferon-β 
(IFN-β). In turn, IFN-β amplifies the IFN response and the development 
of antiviral activity, thus contributing to an important defense against 
viral infections (Kaisho & Akira, 2006). The transcription factors 
interferon regulatory factor-3 (IRF-3) and interferon regulatory factor-7 
(IRF-7) are master regulators of type I IFN activation and participate 
in both the TLR-dependent and independent pathways of innate 
immune responses to viral pathogens (Hiscott, 2007). Type I IFNs 
not only induce an antiviral state in most cells but also have diverse 
functions in the development of adaptive immunity. 
The existence of several mechanisms in the immunocompetent 
host to avoid infections by pathogens has provided the selective 
pressure for successful viral pathogens to acquire strategies 
during evolution to evade the host immune responses 
(Alcami & Koszinowski, 2000), in particular for inhibiting and regu-
lating TLR function, with several targeting the MyD88-dependent 
pathway (Bowie & Unterholzner, 2008). Viral infections 
are frequently sensed by TLR3, which detects dsRNA produced 
during replication of both DNA and RNA viruses. MyD88-independent 
signalling through the TLR3 pathway is initiated by the recruitment 
of the adaptor TRIF, leading to the subsequent production 
of inflammatory cytokines and type I IFNs and the up-regulation 
of co-stimulatory molecules. The importance of TLR3 signalling 
is emphasized by the fact that it is a target for immune evasion 
by viruses (Vercammen et al., 2008), for example vaccinia 
virus A52R Malone (Bowie et al., 2000; Harte et al., 2003; 
Maloney et al., 2005) and A46R (Bowie et al., 2000; Stack et al., 2005) 
proteins or hepatitis C virus (HCV) NS3/4A protease (Li et al., 
2005a, b). Downstream of TRIF, Sterile-alpha and Armadillo 
motif containing protein (SARM), another cellular molecule with 
a TIR domain, provides an important regulatory point in the MyD88-
independent pathways (Carty et al., 2006). Viruses may benefit from 
disrupting TLR signalling, and indeed it has been suggested that 
vaccinia virus directly engages TLRs (Yang et al., 2004; Zhu et al., 
2007). Taking into account the complexity of pathogen recognition 
receptor (PRR) signalling in the innate immune response, it is 
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likely that viruses have evolved a whole range of mechanisms target-
ing different PRRs and at different levels of their signalling pathways. 
Thus, the study of virus evasion strategies is not only directly rele-
vant to understanding virus pathogenesis but can also define novel 
aspects of our own immune system. For example, in HCV infection, 
the viral NS3/4, a protease complex targets and cleaves the interferon 
promoter stimulator-1 (IPS-1) adaptor protein to ablate signalling of 
immune defenses controlled by IFN a/b. Similarly, the finding that 
cleavage of IPS-1 by NS3/4 releases it from the mitochondrial membrane 
revealed that the mitochondrial attachment of IPS-1 is functionally 
important (Li et al., 2005b). Here, we report a successful search for 
an ASFV host evasion gene that inhibits an important component of 
the innate immune response controlled by a TLR. A combination of 
bioinformatics, biochemical and reporter gene assays identified the 
ORF I329L, a late-expressed protein (Rodriguez et al., 1992), which 
was characterized as a type I transmembrane protein with homology 
to TRIF in the C-terminal region and shown to be capable of inhibiting 
the TLR3 signalling pathway through an as yet undefined effect on the 
critical intracellular signalling adaptor molecule TRIF.
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Materials and methods 
Bioinformatic analysis
Full-length sequences of non-assigned ASFV ORFs were 
screened for homologies using protein-protein BLAST from the National 
Center for Biotechnology Information (NCBI). Screening for patterns or 
domains was performed using InterProScan 17.0 from the 
European Molecular Biology Laboratory (EMBL) and Prosite 20.33 
databases. The transmembrane region prediction was performed by 
TransMembrane Helix prediction using the Hidden Markov Models 
2.0 (TMHMM) program (Sonnhammer et al., 1998), and 3D-structure 
similarities were analyzed with Protein Homology/analogy Recognition 
Engine (Phyre) (Bennett-Lovsey et al., 2008). Multiple sequence 
alignments were made with ClustalW2 from the European 
Bioinformatics Institute (EBI) website.
Plasmids
Plasmids pcDNA3-HA and pHR-CMV-eGFP were gifts from Dr. L. Dixon 
(Institute for Animal Health, Pirbright, UK) and Dr. Y. Ikeda (University 
College London, London, UK), respectively. The pFlag-TRIF- and 
pCCL5-promoter-containing plasmids were gifts from Dr. Andrew 
G. Bowie (Trinity College, Ireland), pDsRed-Monomer-Golgi and 
pDsRed2-ER vectors were purchased from ClonTech (catalogue 
number 632480 and 632409, respectively). The β-gal- CMV- (β-gal), 
the NFkB- (pPRD2) and IRF3- and IFN-β- promoter-containing 
plasmids were gifts from Dr. S. Goodbourn (St George’s University, 
London).
The plasmids expressing TLR3 and CD4-TLRs chimaeras were 
provided by Dr. R. Medhzitov (Yale University, USA). Cloning of 
I329L, the ASFV ORF I329L (accession number NP_042833) was 
obtained by PCR amplification from DNA of the tissue-culture-adapted 
non-pathogenic ASFV isolate Ba71V (Uniprot database, 
code I329_ASFB7) with primers incorporating restriction 
sites for BamHI upstream and EcoRV downstream of the 
ORF and using the high-fidelity enzyme Pfu DNA polymerase. 
The primers used were 5’caggatccatgc- taagggttttcatattttttg3’, 
5’ctgatatcctttcttcttgaacatgaaacc3’. The amplified product was 
identified with ethidium bromide visualization on an agarose gel 
based on the expected size of the amplicon, and the DNA was 
purified from the excised band. The fragment was then cloned into 
plasmid pcDNA3-HA, fused in frame with an N-terminal influenza 
3.1
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haemagglutinin (HA) peptide tag. The fidelity of the sequence of the 
cloned fragment was confirmed by automated sequencing.
For construction of a recombinant Lentivirus vector (pHR-CMV-
HAI329L-eGFP), the I329L gene was excised from pcDNA3, together 
with the HA tag, and cloned into the vector pHR-CMV-eGFP upstream 
of an internal ribosome entry site (IRES)-driven enhanced green 
fluorescent protein gene (eGFP).
Cells
Human HEK-293T and murine NIH-3T3 cell lines were cultured in 
5% CO2 at 37
oC in Dulbecco’s modified Eagle medium (DMEM) with 
GlutaMAXTM-I and 1000mg/l glucose, supplemented with 10% (v/v) 
heat-inactivated fetal calf serum (FCS) and 100U/ml and 100μg/ml 
penicillin and streptomycin, respectively (all products from Invitrogen). 
The stable cell line 293-hTLR3-HA (HEK- TLR3), purchased from 
InvivoGen®, was maintained under the same conditions and cultured in 
regular DMEM supplemented with 10lg/ml blasticidin (Marshall-Clarke 
et al., 2007).
Lentivirus production
Lentivirus was produced by transient transfection of HEK- 293T cells 
with a weight ratio of 3:1:1 of vector to packaging to envelope plasmids, 
respectively, using FuGENE 6 (Roche) according to the manufacturer’s 
instructions. Control Lentivirus was produced by cotransfection of the 
packaging and envelope plasmid together with the empty pHR-CMV-
eGFP plasmid. For production of recombinant Lentivirus-expressing 
I329L, the plasmid pHR-CMV-HA-I329L-eGFP was used. 
Supernatants containing the Lentivirus were collected at 48h and 72h 
post-transfection and clarified by centrifugation, and the Lentivirus 
was collected by ultracentrifugation (125,000 x g, 3h, 4oC). Virus pellets 
were ressuspended in fresh culture medium, frozen at -80oC and 
titrated by infection of HEK-293T cells with a dilution factor of 4. 
Analysis of lentivirus-infected cells was done by detecting eGFP- 
positive cells by flow cytometry at 48h post infection (p.i.). Lentivirus 
transduction of NIH-3T3 cells with I329L. The NIH-I329L and NIH-
eGFP stable cell lines were produced by lentivirus infection of NIH-3T3 
cells with the recombinant pHR-CMV-HA-I329L-eGFP and empty pHR- 
CMV-eGFP (prepared as described in the section ‘‘Cloning of I329L’’), 
respectively, using a multiplicity of infection (m.o.i.) of 10 in DMEM. 
Analysis of NIH-I329L to determine the percentage of transduced cells 
was done by detecting eGFP-positive cells by flow cytometry at 48 h 
post-infection (p.i.), and this was verified to be greater than 99%.
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3.5 Antibodies
The antibodies used in this study were as follows: rat monoclonal 
high-affinity antibody (clone 3F10) against HA conjugated with 
horseradish peroxidase (HRP) (Roche, 12013819001), rabbit polyclonal 
affinity-purified antibody against HA for immunoprecipitation assays 
(Sigma H6908), rat monoclonal high-affinity antibody (clone 3F10) 
against HA for immunofluorescence assays (Roche, 11867423001), 
donkey affinity-purified anti-rat IgG antibody conjugated with AMCA 
(Jackson Immuno Research, 712-155-150), mouse monoclonal 
antibody (clone B-5-1-2) against α-tubulin (Sigma-Aldrich, T6074) and 
rabbit polyclonal anti-mouse Immunoglobulins conjugated with HRP 
(Dako, P0161).
Immunoblotting
NIH-I329L cells were cultured in 75-cm2 flasks at 37oC, under 
5% CO2, in DMEM with GlutaMAXTM-I and 1000mg/l glucose, 
supplemented with 10% (v/v) heat- inactivated FCS and 100U/ml 
and 100μg/ml penicillin and streptomycin, respectively (all products 
from Invitrogen). Cells were lysed in cold lysis buffer (6M urea, 75mM 
NaCl, 1mM EDTA, 1% (v/v) NP40, 2% (v/v) glycerol, 1mM PMSF, 
1μM DTT, 25 mM HEPES, pH 7.4). After protein quantification by 
the Bradford method using the Bio-Rad Protein Assay reagent, ex-
tracts were boiled (5min, 100oC) with sample buffer (1.7% [w/v] SDS, 
5% [v/v] glycerol, 0.1M DTT, bromophenol blue [0.02 mg/ml], 58mM 
Tris-HCl, pH 6.8). Proteins were then separated by 10-12% 
SDS-PAGE and electroblotted onto polyvinylidene fluoride (PVDF, 
BioRad) membranes and blocked with PBS-5% (w/v) non-fat dried 
milk for 1h at room temperature (RT). The development of the blots to 
reveal recombinant viral proteins was performed with a rat monoclonal 
high affinity antibody against HA conjugated with HRP (Roche) by 
incubating for 1h at RT or overnight at 4oC, and the identified molecules 
were revealed with ECL chemiluminescent reagents (PerBio Science) 
according to the manufacturer’s instructions. Blots were also developed 
with a mouse monoclonal antibody against α-tubulin (Sigma-Aldrich), 
followed by rabbit polyclonal anti-mouse immunoglobulins-HRP (Dako) 
to provide an internal control for protein loading. Immunoprecipitation 
Mouse NIH-I329L and mouse NIH-eGFP cells were collected by 
scraping from 75-cm2 flasks and lysed using cold RIPA buffer (6M 
Urea, 75mM NaCl, 1mM EDTA, 1% (v/v) NP40, 2% (v/v) glycerol, 
1mM PMSF, 5.5μg/ml protease inhibitors (SIGMA) and 1μM DTT, 
25mM HEPES, pH 7.4) (1ml per 7x106 cells). The resulting protein 
extract was centrifuged at 20,000 x g for 10min at 4oC to remove 
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cellular debris. The supernatant of the protein extracts was collected 
and, after determining the concentration of protein, was pre-cleared by 
adding 100μl of protein G beads. After rotating for 1h at 4oC, the be-
ads were removed by centrifugation, and the recombinant I329L was 
recovered from the supernatant by adding protein G beads (100μl) 
and 5μg of rabbit polyclonal affinity-purified anti-HA antibody (Sigma). 
Following rotation for 1.5h at 4oC, the beads were then washed twice 
with lysis buffer without NP-40 and urea, and finally heated at 100oC for 
10min with loading buffer (2% [w/v] SDS, 2% [v/v] β-mercaptoethanol, 
0.1% [w/v] bromophenol blue, 10% [v/v] glycerol, 50mM Tris-HCl, 
pH 6.8) for 10min, and centrifuged for 30sec. The supernatants were 
then loaded onto an SDS-PAGE gel (10%).
Cell-surface biotinylation
Cell-surface biotinylation was done using a kit purchased from Pierce 
(#21335). One 75-cm2 flask with transduced NIH-I329L cells was 
cultured until the cells reached 95% confluence. Then, the cells 
were washed twice with cold PBS and EZ-Link Sulfo-NHS-LC-Biotin 
dissolved in cold PBS (0.5mg/ml) was added to the cells, followed by 
incubation on a rocking platform with gentle agitation (30min, 4oC). 
To stop the reaction, 500μl of a ‘‘quenching’’ solution (supplied by 
the manufacturer without information) was added to each flask. Cells 
were then scraped off, centrifuged, washed with TBS and lysed in 
modified RIPA buffer (1% [v/v] Triton X-100, 0.2% [w/v] Na-deoxycholate, 
150mM NaCl, 1 mM EDTA, 0.2% (w/v) SDS, 1mM PMSF, protease 
inhibitors, 50mM Tris-HCl, pH 7.4). The biotinylated surface 
proteins were recovered from the detergent lysate with streptavidin 
beads (Pierce Kit, #89881) (overnight, 4oC, in an orbital shaker). 
The streptavidin beads were centrifuged, washed 3 times with lysis 
buffer without detergent, and finally suspended in 100μl 1x loading 
buffer (2% [w/v] SDS, 2% [v/v] β-mercaptoethanol, 0.1%[w/v] 
bromophenol blue, 10%[v/v] glycerol, 50 mM Tris-HCl, pH 6.8). 
The samples were heated (10min, 100oC) and centrifuged, and the 
supernatants were loaded onto 10% SDS-PAGE gel. After 
electrophoresis, the proteins were transferred to a PVDF membrane 
(Bio-Rad) and blocked with 5% non-fat dried milk (1h, RT). 
The biotinylated HAI329L protein was revealed with a rat 
monoclonal high-affinity antibody against HA conjugated with HRP 
(Roche), followed by ECL chemiluminescent reagents (PerBio 
Science) according to the manufacturer’s instructions.
3.7
2
91
3.8 Deglycosylation assay 
Lentivirus-transduced NIH-I329L cells were collected, and the 
recombinant I329L was immunoprecipitated as described above. 
Bound I329L was eluted from the anti- HA protein G beads by heating 
(10min, 100oC) in 0.5% (w/v) SDS with 10% (v/v) β-mercaptoethanol. 
For deglycosylation, the eluted sample was treated with peptide-N 
glycosidase F (PNGaseF) (Roche) or endoglycosidase H (Endo H) 
(New England Biolabs) according to the manufacturer’s 
instructions. As controls, the enzymes were omitted. Proteins were then 
precipitated with ethanol at 80% (v/v) (overnight, -20oC). The pellet was 
ressuspended in 20μl of SDS-PAGE loading buffer, heated (10min, 
100oC), and loaded onto an SDS-PAGE gel.
Immunofluorescence to demonstrate co-localization of 
I329L with ER and Golgi 
NIH-I329L cells were seeded onto coverslips (pre-treated with 1% 
[v/v] poly-L-lysine) and incubated overnight at 37oC and 5% CO2. For 
double staining to reveal the endoplasmatic reticulum and the transmedial 
region of the Golgi apparatus, the cells were transfected using 
Lipofectamine 2000 (Invitrogen) with 2μg of a plasmid coding for the 
ER retention sequence KDEL (plasmid pDsRed2-ER, Clontech) or 
coding for a sequence corresponding to the N-terminal 81 amino acids 
of human beta-1, 4-galactosyltransferase (GT) (plasmid pDsRed- 
Monomer-Golgi, Clontech) fused with the fluorescent red protein. After 
transfection for 24h, the cells were fixed with 4% (w/v) paraformaldehyde 
in PBS for 20min at RT and then incubated in a blocking solution (PBS 
containing 0.05% Tween-20 and 5% normal goat serum) (30min, 
RT). The cells were permeabilized using PBS containing 0.1% (v/v) 
Triton X-100. To detect recombinant I329L, a primary rat monoclonal 
high-affinity antibody against HA diluted in blocking solution was used 
(1h, RT), followed by a donkey affinity-purified anti-rat IgG antibody 
conjugated with AMCA (1h, RT). All washes after incubation with 
antibody were performed at RT with PBS containing 0.05% (v/v) 
Tween-20. Cells were mounted in Vectashield (Vector Laboratories) 
and observed under a fluorescence microscope. HA-I329L is shown 
with a green colour for better visual perception. Fluorescent images 
were taken with a Leica DMRA2 microscope equipped with a cooled 
CCD camera (Leica. Corp., Wetzlar, Germany).
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Luciferase reporter assays 
For the CD4-TLR reporter gene assay, HEK-293T cells were cultured 
in 24-well plates at 6x104/well, and 24h later, they were transfected 
using Lipofectamine 2000 (Invitrogen) with three plasmids. One, the 
NFkB-driven luciferase reporter contained only the positive regulatory 
domain, PRD2, of the NFkB binding site of the IFN-β promoter (NFkB) 
(100ng), the second contained β-gal-CMV (β-gal) (25ng), and the third 
chimeric plasmid contained a CD4 extracellular domain co-ligated 
upstream of a TLR1 (CD4-TLR1) or TLR3 (CD4-TLR3) intracellular 
domain (50ng). The effect of the co-transfection of the I329L gene 
cloned into the pcDNA3 plasmid (pcDNA3-I329L) (300ng) provides 
an assay for interference of the viral protein with the TLR signalling 
pathway (Medzhitov et al., 1997). Empty pcDNA3 served as the negative 
control (pcDNA3). After incubating for 48h at 37
oC, the cells were 
lysed in 100μl lysis solution (ABX210LM, Promega Systems) 
according to the manufacturer’s instructions, and samples were 
assayed for both luciferase and β-galactosidase activities. The 
luciferase activity was normalized to the β-galactosidase activity from 
the co-transfected plasmid internal control and expressed as luciferase 
relative to galactosidase activity. Values are expressed as mean 
relative stimulation ± SD (calculated from triplicate determinations). A 
minimum of three independent assays was done for each experiment re-
ported. In similar reporter assays, HEK-TLR3 cells were transfected with 
reporter plasmids for IFN-β, NFkB, CCL5, and the internal control 
β-gal, and expression plasmids pcDNA3-I329L or pcDNA3 (negative 
control), keeping the total amounts of DNA and equimolar ratios con-
stant in all assays by adding the appropriate amount of empty vector. 
After 48h, cells were stimulated with polyinosinic: polycytidylic acid 
(poly (I:C)) or IL1-β (PeproTech) or TNF-α (PeproTech) as indicated 
in the figures for 5 hours. The cells were lysed and assayed for lu-
ciferase as described above. IFN-β reporter assays were also done 
using HEK 293T cells ectopically expressing TRIF. Transfections were 
performed with equal amounts of DNA mixtures comprising 25ng of 
TRIF plasmid vector (TRIF), the I329L plasmid vector (pcDNA3-I329L) 
(0, 100, 200 and 300ng), the IFN-β-reporter plasmids (IFN-β) (100ng) 
and the β-gal internal control plasmid (β-gal)  (25ng). The pcDNA3 ne-
gative control was included in the transfection whenever necessary 
in order to keep the total amounts of DNA and equimolar ratios con-
stant in all assays. After 48h, the cells were stimulated for 6 hours 
with poly (I:C) (25μg/ml) where indicated, before harvesting the cells.
Lysis and luciferase activity were measured and normalized to the 
β-galactosidase activity as described above. Finally, to determine 
the impact of intracellular stimulation with poly (I:C), HEK-293T cells 
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were transfected with 300ng empty vector (pcDNA3) or 300ng I329L 
plasmid vector (pcDNA3-I329L) together with 100ng of IFN-β plasmid 
(IFN-β). After 48h, the cells were stimulated for 6h with intracellularly 
delivered poly (I:C) (0.5μg/ml) using Lipofectamine 2000 (Invitrogen). 
Lysis and luciferase activity were measured and normalized to the 
β-galactosidase activity as described above.
Statistical analysis
Data are expressed as mean ± SD and were analyzed for significance 
using Student’s T test. P-values are as follows: *** P<0.005, ** P<0.01 
and * P<0.05.
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Results
Identification of ASFV ORF I329L as a potential homologue 
of the TLR family 
Bioinformatic analysis of the sequence of pI329L from the tissue- 
culture-adapted non-pathogenic ASFV isolate Ba71V (Uniprot 
database code I329_ASFB7), which grows in a variety of commonly 
used fibroblast cell lines, reveals a type I membrane structure with 
a 17-amino-acid signal peptide (amino acids 1-17), followed by an 
N-terminal extracellular domain (amino acids 18-239), a transmembrane 
domain (amino acids 240-260), and a 69-amino-acid C-terminal 
intracellular domain (amino acids 261-329). 
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Figure 1. Homology with TLR3 in the intercellular domain of ASFV protein I329L. 
The analysis presented here was performed with ClustalW2. 1A. Sequence of 
the intracellular domain of I329L (amino acid residues 260 to 329) indicating the 
predicted BOX1 and BOX2 regions. 1B. Predicted TIR-like domain in the BOX1 domain 
of I329L has sequence homology with known proteins containing the BOX1 TIR domain. 
1C. Predicted TIR-like domain in the BOX2 domain of I329L. 
A I329L intra LRSICKKYSCTKQDKSSHN YIPLIPSY TFSLKKH RHPETAVVEDH TTSANSPIVYIPTTE
B TLR3   - - - - - - - - - - - - - - - - - - FE   AYKDKD - - -  - - - - - - - -  - - - - - - - - - - - - - - - - 
 TRIF   - - - - - -  - - - - -  - - -   QKF_   ARAD - - -  - - - - - - - -  - - - - - - - - - - - - - - -  - - 
 IL1R   - - - - -  - - - -  - - - - -  DGKT   PKTV - - -  - - - - - - - -  - - - - - - - - - - - - - - - - - -
 mIL1R  - - - - -  - - - -  - - - - -  DGKT   PKTLGEGSFS - - -  - - - - - - - -  - - - - - - - - - - - 
 IL-1 Rrp  - - - - -  - - - -  - - - - -  DGKT   LKECRP - - -  - - - - - - - -  - - - - - - - - - - - - - - - 
 mIL-1Rrp  - - - - -  - - - -  - - - - -  DGKT   LKECHPENKE - - -  - - - - - - - -  - - - - - - - - - - -
 mIL1RAcP  - - - - -  - - - -  - - - - -  DGKE   ARN - - - - - -  - - -  - - - - - - - -  - - - - - - - - - - - - 
 SARM   - - - - -  - - - -  - - - - -- - GDT   RRNS - - -  - - -  - - - - - - - -  - - - - - - - - - - - - - - 
 MyD88  - - - - -  - - - -  - - - - -- - PER   CPSD - - - - - - -  - - - - - - - -  - - - - - - - - - - - - - 
 Toll_Dros  - - - - -  - - - -  - - - - -- - DKK   SHKD- - - - - - - -  - - - - - - - -  - - - - - - - - - - - - -  
 IL-13_RACP  - - - - -  - - - -  - - - - -- - KKD   AKWSS - - - - - -  - - -  - - - - - - - -  - - - - - - - - - -
 mIL18_RACP - - - - -  - - - -  - - - - -- - KKE   SNWSS - - - - -  - - - - - - - -  - - - - - - - - - - - - - - 
 TLR4   - - - - -  - - - -  - - - - --  GENI   SSQ - - - - - - -  - - -  - - - - - - - -  - - - - - - - - - - - 
 I329L_intra          LRSICKKYSCTKQDKSSHN   TFSLKKHRHPETAVVEDHTTSANSPIVYIPTTE
C
 
 TL3_binding - - - - - - - - - - - - -  RDFEAGVFELE - - - - - - - - - - - - - - -
 I329L_intra PLIPSYTFSLKKH RHPETAVVEDH TTSANSPIVYIPTTE
                              
BOX1 BOX2
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YNFV I_LH
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YDI YV_SY
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A number of potential glycosylation sites were indicated, at amino acids 
32, 39, 44, 76, 82, 101, 185, and 219. Simple sequence examination 
of the sequence database did not show any gene similar to I329L; 
however, after multiple alignments with several TLR proteins, a weak 
but interesting alignment between I329L and TLR from Drosophila 
melanogaster was revealed. Importantly, the intracellular domain of 
I329L aligned with BOX1 and BOX2 regions of the human TIR-like 
domain of TLR3 (Figure 1A), with a sequence similarity of 35% to TLR3 
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in BOX1 (Figure 1B). Furthermore, the BOX2 of TLR3 also showed 
similarities with the I329L intracellular domain (Figure 1C). 
Finally, the conserved extracellular region with leucine-rich repeats 
(LRRs) is an important motif for interaction between proteins and is 
common to several TLRs. Although the observed similarity was 
admittedly weak, we nonetheless decided to clone and test I329L for its 
impact on poly (I:C)-stimulated innate immunity in reporter assays (see 
below).The cellular distribution of ASFV ORF I329L is consistent with 
ER, Golgi and plasma membrane localization Bioinformatic analysis and 
demonstration of extensive glycosylation suggested that the I329L 
protein was a typical transmembrane protein. This possibility was 
confirmed in I329L-lentivirus-transduced NIH-3T3 cells (NIH-I329L) 
by immunofluorescence and cell-surface labelling. For 
immunofluorescence of I329L, the I329L protein was detected with 
a rat monoclonal high-affinity antibody (clone 3F10) against HA, 
followed by a donkey affinity- purified anti-rat IgG antibody conjugated 
with AMCA. Co-detection of the endoplasmic reticulum (ER) and 
Golgi apparatus was achieved by simultaneously transfecting the 
cells with two marker plasmids: one coding for red-fluorescent protein 
(dsRed) fused with the KDEL sequence in order to target ER (plasmid 
pDsRed2-ER) and the other coding for dsRed fused with an integral 
protein of the Golgi apparatus (plasmid pDsRed-Monomer-Golgi). As 
can be seen, the cellular distribution of I329L corresponds to that of the 
markers for ER and Golgi (Figure 2A and 2B) , indicating that I329L 
passes through the secretory pathway. Finally, since the intracellular 
secretory pathway frequently culminates the incorporation of glycoproteins 
into the cell membrane, viable NIH-I329L-transduced cells were 
surface-biotinylated. Subsequent immunoprecipitation with streptavidin 
and western blotting with anti-HA to detect I329L confirmed the surface 
expression of I329L in the transduced cells (Figure 2D).
ASFV ORF I329L codes for a highly glycosylated protein
Expression of HA-I329L in NIH-3T3 cells was accomplished by 
transduction with HA-I329L recombinant Lentivirus (NIH-I329L). The 
protein immunoprecipitated with anti-HA antibody migrated in SDS-PAGE 
with an apparent molecular weight of *50 kDa, significantly larger than 
the molecular weight predicted from the amino acid sequence alone 
(Figure 2C, lanes b and d), thus raising the possibility of extensive 
glycosylation, as indeed is suggested by bioinformatic predictions. 
Therefore, the recombinant I329L protein was immunoprecipitated 
from NIH-I329L cells and digested with two endoglycosidases, 
PNGase F, which digests high-mannose, hybrid and complex types of 
oligosaccharides, and endoglycosidase H (EndoH), which digests 
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only high-mannose and hybrid types of oligosaccharides. Digestion 
with EndoH and PNGase F yielded recombinant proteins that 
migrated with a molecular mass of *37 kDa (Figure 2C, lande a), and 
*36 kDa (Figure 2C, lane c) , respectively, thus confirming that the 
I329L protein is extensively glycosylated. Furthermore, the molecular 
weight observed for the sample after digestion with PNGase F was 
lower than after digestion with Endo H, suggesting that I329L has a 
small number of glycans of the complex type.
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Figure  2. ASFV protein I329L is higly glycosylated and localizes to cell 
membranes. 
2A. I329L protein distribution is consistent with endoplasmic reticulum 
localization. Lentivirus-transduced NIH-I329L cells were transfected with 
plasmid pDsRed2-ER to localize the protein to the ER (red, left) and then co-stained 
with a rat monoclonal high-affinity antibody against the HA, followed by a donkey 
affinity-purified anti-rat IgG antibody conjugated with AMCA (left, middle). The 
colocalization is evident in the merged image (right panel). 2B. I329L protein 
distribution is consistent with Golgi localization. The NIH-I329L cells were transfected 
with plasmid pDsRed-Monomer-Golgi to localize the protein to the Golgi (red, left) and 
then co-stained with a rat monoclonal high-affinity antibody against the HA, followed 
by a donkey affinity purified anti-rat IgG antibody conjugated with AMCA (left, middle). 
The colocalization is evident in the merged image (right panel). 2C. The I329L protein 
was immunoprecipitated from lysates from the lentivirus-transduced NIH-I329L cell 
line with rabbit anti-HA antibodies bound to protein G beads. The bound protein was 
eluted and digested with EndoH (a) or PNGase (c) and examined by SDS- PAGE. 
Controls samples were treated with only EndoH buffer (b) or only PNGase buffer (d). 
2D) I329L protein is expressed at the cell surface. Biotinylated surface proteins from 
biotynylated NIH-I329L cells were collected with streptavidin beads, loaded onto a 10% 
SDS-PAGE gel and transferred to PVDF membranes, and I329L was revealed with a 
rat monoclonal antibody against HA conjugated with HRP (band in lane NIHI329L on 
the left). Lane NIHeGFP represents NIH-3T3 cells transduced with the empty lentivirus. 
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ASFV ORF I329L inhibits TLR3 signalling
An important sensor of viral infections is TLR3, which detects 
dsRNA and signals through a MyD88-indepen- dent pathway. In order to 
demonstrate that I329L was interfering with TLR3 signalling, we used 
two entirely different experiments. In the first approach, we used a 
CD4-TLR assay focusing on an NFkB-driven luciferase reporter. These 
CD4-TLR constructs comprise the murine CD4 extracellular domain 
co-ligated to the cytoplasmatic domain of a human TLR. The extracellular 
CD4 domain dimerizes spontaneously, resulting in dimerization of 
the intracellular TLR domain and thus constitutive activation of NFkB, 
which is detected using the simultaneously transfected luciferase 
reporter plasmid. Using this system, expression of I329L was found 
to inhibit the induction of the NFkB-dependent reporter gene signal 
(Figure 3A). Negative controls consisted of plasmid pcDNA3 coding for 
H171R, a known structural viral protein of ASFV, instead of the I329L gene, 
and a CD4-TLR1 construct instead of CD4-TLR3 (Figure 3A). As the 
synthetic dsRNA analogue polyinosine-poly-cytidylic acid (poly (I:C)) 
activates cells via TLR3, in the second system, we also tested the 
effect of I329L on TLR3-dependent NFkB activation induced by poly (I:C). 
Cells (HEK-293T) were co-transfected with a construct encoding 
TLR3, the luciferase reporter containing the NFkB (PRD2) binding 
sequence, and the plasmid containing the cloned ASFV I329L gene. 
The cells were stimulated with increasing concentrations of poly (I:C) 
(0, 5, 25, and 50ug/ml). The vector of the I329L gene without an insert 
(pcDNA3) was used as negative control. 
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Figure3. I329L inhibits NFkB activation by TLR3.
3A. I329L inhibits activation of NFjB. HEK-293T cells were transfected 
with constitutively active CD4-TLR plasmids (50ng CD4-TLR1 or CD4-TLR3) 
in the presence of 300ng of I329L plasmid (pcDNA3-I329L), 100 ng of 
NFkB reporter plasmid (NFkB) and 25ng of β-gal reporter plasmid (β-gal) 
(black bars) and incubated for 48 h prior to reporter assays. The negative 
controls were the plasmid vector without insert (pcDNA3) (white bars) or with the 
control H171R insert (pcDNA3- H171R) (grey bars). 3B. I329L inhibits 
poly (I:C)-dependent activation of NFkB. HEK-293T cells were co-transfected with 
plasmid vectors encoding 50 ng TLR3 (TLR3), 100ng NFkB reporter plasmid (NFkB), 
300 ng ASFV I329L gene (pcDNA3-I329L) and 25ng of β-gal reporter plasmid (β-gal) 
(black bars). Negative and positive controls were the plasmid vector of I329L gene 
without an insert (pcDNA3) and TLR3 (grey bars), and the TLR3 plasmid alone 
(white bars). The cells were stimulated with poly (I:C) at the concentration indicated. 
Luciferase activity was normalized to the β-galactosidase activity obtained with the co-
transfected β-gal plasmid internal control. Standard deviations are shown by error bars. 
A B
CD4-TLR 1 CD4-TLR 3
0
5
10
15
20
25
30 Empty
H171R
 I329L
Lu
ci
fe
ra
se
 U
ni
ts
0 5 10 25
0
500
1000
1500
2000
TLR3
TLR3 + Empty vector
TLR3 + I329L
Poly I:C ( µg/mL)
Lu
ci
fe
ra
se
 u
ni
ts
NFκB NFκB
This TLR3-dependent activation of NFkB in HEK-293T cells expressing 
TLR3 was inhibited by the ASFV gene I329L at all concentrations of 
the ligand, poly (I:C), that were tested (Figure 3B). Thus, I329L was 
shown by two independent approaches to inhibit the TLR3-mediated 
activation of NFkB.
The I329L gene mediates MyD88-independent induction of 
poly (I:C)-stimulated activation of NFkB and IRF3
To confirm and further explore the mechanisms of I329L-mediated 
inhibition of TLR3 activation, human embryonic kidney fibroblasts 
(HEK-293T) stably expressing TLR3 (HEK-TLR3) were transfected 
together with an NFkB luciferase reporter plasmid (NFkB) and 
stimulated with poly (I:C) or IL-1β. As can be seen, the poly (I:C)-stimulated 
activation of NFkB via the established TLR3 pathway was inhibited 
by expression of I329L (Figure 4A). Activation of NFkB can occur ei-
ther dependently or independently of the MyD88 adaptor molecule. 
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However, the absence of an effect on the IL-1 receptor pathway excludes 
 the possibility that I329L modulates TLR signalling by interacting with 
the adaptor molecule MyD88. Finally, we failed to find any inhibitory 
effect of I329L on NFkB activation stimulated by TNF-α, indicating 
that I329L does not have impact on the NFkB activation pathway via 
molecules other than those downstream of TLR ligation. Taking these 
results together suggests that I329L acts upstream of the IkB kinase 
complex, which in the case of TLR3 signalling could be TRIF, a 
possibility explored below. 
Figure 4. I329L inhibits NFkB and IRF3 activation through a MyD88-independent 
pathway. 
4A. I329L inhibits activation of NFkB via Poly I:C but not TNF-α or IL-1. HEK-TLR3 
cells were co-transfected with 300ng of empty plasmid vector (pcDNA3) or 300ng 
of the same plasmid vector encoding I329L (pcDNA3-I329L), together with 100ng of 
the NFkB luciferase reporter plasmid (NFkB) and 25ng of β-galactosidase reporter 
plasmid (β-gal), and cultured for 48h. At 6h before harvesting, cells were not stimu-
lated (white bars), or stimulated with IL-1β (100ng/ml) (grey bars), TNF-α (100ng/
ml) (hatched bars) or poly (I:C) (25μg/ml) (black bars). The NFkB reporter gene 
activity was then measured. 4B. I329L inhibits activation of IRF3. HEK-TLR3 cells were 
transfected with 300ng empty vector (pcDNA3) or 300ng of the same plasmid encoding 
I329L (pcDNA3-I329L) together with 100ng of IRF3 (IRF3) and 25ng of β-galactosidase 
reporter plasmids (β-gal), and 6h before harvesting, cells were stimulated extracellularly 
with 25μg/ml poly (I:C). Luciferase activity was normalized to the β-galactosidase 
activity given by the co-transfected β-gal plasmid internal control. Standard deviations 
are shown by error bars.
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Signal transduction initiated through TLR3 ultima-
tely diverges into two signalling branches, leading 
to activation of NFkB and IRF3. 
In order to determine whether I329L also inhibits activation of IRF3, 
HEK-TLR3 cells were co-transfected with I329L (pcDNA3) and a 
reporter plasmid containing the promoter of IRF3 (IRF3) and then 
stimulated with poly (I:C). As can be seen (Figure 4B), in the 
presence of I329L, activation of the IRF3 promoter was significantly 
reduced. I329L ASFV ORF inhibition of activation of IRF3 
and subsequent expression of IFN-β and CCL5 responses. 
As TLR3 activates and  programs interferon and chemokine 
expression through the coordinated activation of IRF3 and 
NFkB (Melchjorsen et al., 2003; Takeuchi et al., 2004), we next 
examined the effect of I329L on the activation of CCL5 expression 
using an appropriate reporter plasmid. We also extended 
the previously presented I329L-mediated inhibition of the 
NFkB-restricted PRD2 by using a reporter plasmid containing the 
entire IFN-β sequence. The rationale for this was that inhibition of 
activation of NFkB and IRF3 is predicted to inhibit induction of 
IFN-β and chemokine responses, two major effectors of the antiviral 
response induced by TLR3. As can be seen, poly (I:C)-induced CCL5 
activation from HEK-293T cells stably expressing TLR3 (HEK- TLR3) 
was inhibited by I329L (Figure 5A). Moreover, poly (I:C)-induced IFN-β 
activation was also inhibited by I329L in HEK-TLR3 cells (Figure 5B). 
Both results are consistent with an I329L-mediated inhibition of a 
MyD88-independent activation pathway (Fitzgerald et al., 2003) and 
raise the possibility that I329L targets TRIF, as TRIF is the only known 
adaptor protein that interacts with TLR3 and mediates induction of 
IFN-β through activation of NFkB and IRF3. The CCL5 promoter is 
under the control of the PRD2 and ISRE domains (binding NFkB and 
IRF3, respectively), the cAMP responsive element (CRE), AP-1, the 
gamma interferon activation site (GAS), the nuclear factor of activated 
T-cells (NFAT) and CCAAT/enhancer-binding protein (C/EBP) 
domains (binding proteins c-Jun/activating transcription factor 2 (ATF2), 
Fos/c-Jun, signal transducer and activator of transcription (STAT), 
NFAT and C/EBPb. In our experimental system, the induction of 
CCL5 and IFN-β is the consequence of a poly (I:C)-stimulated 
MyD88-independent activation of TLR3. Thus, the possibility of a 
MyD88-dependent, IRF5-mediated activation of CCL5 transcription 
can be excluded.
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The possibility that I329L inhibits IFN-β activation induced intracellularly 
via a receptor other than TLR3 was investigated by introduction 
of poly (I:C) into HEK-TLR3 cells. Interestingly, there was no effect 
of I329L on IFN-β activation via an intracellular poly (I:C) stimulus 
(Lipofectamine-mediated poly (I:C) transfection) (Figure 5C), and we 
therefore exclude the hypothesis that the effect of I329L is mediated 
via intracellular receptors such as melanoma differentiation associated 
gene 5 (MDA-5) or retinoic-acid- inducible protein I (RIG-1). Taken 
together, these results suggest that I329L inhibits induction of 
promoters that are known to contain NFkB or IRF3 binding sites via 
the TLR3 pathway and not via intracellular receptors like MDA-5 and 
RIG-I. Reversal of ASFV-ORF-I329L-mediated inhibition of the activation 
of NFkB and IFN-β promoters by overexpression of TRIF. Activation 
of the TLR3-TRIF signalling pathway not only induces cytokines, 
co-stimulatory molecules and antimicrobial peptides that are induced 
by all TLRs but also antiviral type I interferon and specific chemokines 
including IP-10 and CCL5 (Melchjorsen et al., 2003; Takeuchi et al., 
2004). A direct effect of I329L on TRIF signalling was demonstrated 
using HEK-TLR3 cells transfected with TRIF as, in the presence of 
Figure 5. I329L inhibits activation of CCL5 and IFN-β promoter. 
5A. I329L inhibits activation of CCL5. HEK-TLR3 cells were transfected with 300ng 
empty plasmid vector (pcDNA3) or 300ng I329L plasmid vector (pcDNA3-I329L) 
together with 100ng of CCL5 reporter plasmid vector (CCL5). 
6h before harvesting, cells were stimulated extracellularly with 25μg/ml poly 
(I:C). 5B. I329L inhibits activation of IFN-β. HEK-TLR3 cells were transfected 
with 300ng empty vector (pcDNA3) or 300ng of I329L plasmid vector 
(pcDNA3-I329L) together with 100ng of IFN-β plasmid vector (IFN-β). 6h before 
harvesting, cells were stimulated extracellularly with 25μg/ml poly (I:C). 
5C. I329L does not inhibit intracellular IFN-β activation independently of TLR3. HEK-
293T cells were transfected with 300ng empty vector (pcDNA3) or 300ng I329L plasmid 
vector (pcDNA3-I329L) together with 100ng of IFN-β plasmid reporter (IFN-β). Six 
hours before harvesting, cells were stimulated intracellularly using Lipofectamine 2000 
with 0.5μg/ml poly (I:C). Luciferase activity was normalized to the β-galactosidase 
activity obtained with the cotransfected β-gal plasmid internal control. Standard deviations 
are shown by error bars.
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I329L, the IFN-β signalling pathway was inhibited (Figure 6A). To further 
investigate the possible impact of I329L on TRIF signalling, HEK-TLR3 
cells were simultaneously transfected with I329L (pcDNA3-I329L), the 
IFN-β luciferase reporter plasmid (IFN-β) and increasing quantities of 
TRIF plasmid (TRIF) and then stimulated with poly (I:C). As can be seen, 
overexpression of TRIF reversed the inhibition of reporter activation 
induced by I329L in a dose-dependent manner, consistent with the 
hypothesis that the ASFV gene I329L targets TRIF signalling (Figure 6B). 
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Figure 6. I329L inhibits activation of the IFN-β promoter at the level of TRIF. 
6A. I329L inhibits TRIF-mediated activation of IFN-β. Activation of the IFN-β promoter 
reporter plasmid was induced via ectopic expression of TRIF in HEK-293T cells 
through transfection with the TRIF plasmid vector. Transfections were performed 
with equal amounts of DNA comprising 25ng of TRIF plasmid vector (TRIF) in the 
presence of increasing amounts of I329L plasmid vector (100–300ng) (pcDNA3-I329L) 
jointly with IFN-β-reporter plasmids (IFN-β). 6B. Overexpression of TRIF reverses 
I329L-mediated inhibition of IFN-β activation. TRIF was ectopically expressed in 
HEK-293T cells with increasing amounts of TRIF plasmid vector (25–100ng) (TRIF) 
in the presence of 200ng of the plasmid vector coding for I329L (pcDNA3-I329L) 
simultaneously with 100ng of IFN-β-reporter plasmid vector (IFN-β) plus 25ng of β-gal 
plasmid vector (β-gal) and after stimulating for 6 hours with 25μg/ml of poly (I:C) where 
indicated, before harvesting the cells. In all cases, luciferase activity was measured 
after 48h. Luciferase activity was normalized to the β-galactosidase activity obtained 
with the cotransfected β-gal plasmid internal control. Standard deviations are shown 
by error bars. 
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Discussion
The necessity to recognize and destroy invading pathogens has 
played a crucial role in the evolution of the immunesystem of both 
vertebrates and invertebrates. At the same time, pathogens and, in 
particular, viruses have evolved reciprocal strategies to manipulate 
the immune system. Here, we describe a novel gene from African 
swinefever virus (ASFV), I329L, which is able to modulate one of the 
most critical steps of the innate immune response by interfering with 
TLR3-stimulated activation. This may constitute an advantage for the 
virus with an impact on both its vertebrate and invertebrate hosts, 
pigs and ticks, respectively. Conventional bioinformatic analysis of the 
sequence of I329L predicted a putative type 1 transmembrane 
protein with an intracellular domain followed by a transmembrane region 
and an extracellular domain with nine potential glycosylation sites and 
leucine-rich repeats (LRRs). Both TLR3 and I329L are type I 
transmembrane proteins with 20% of their sequence intracellular and 
more than 70% in a highly glycosylated extracellular domain with LRRs. 
Interestingly, more detailed analysis revealed that the intracellular 
domain of I329L contains a region of homology with BOX1 and BOX2 of 
TLR3-TIR domain (Figure 1A-C). In addition, the putative intracellular 
domain contains a number of intracellular signalling sequences such 
as SH2 and SH3 domain binding motifs, a major TRAF2- binding 
consensus motif and a CK2 phosphorylation site (data not shown). In 
the work mentioned above, we con- firmed that ORF I329L codes for 
a highly glycosylated protein (Figure 2C). Significantly, TLR3 is one 
of the most heavily glycosylated of the TLRs (Bell et al., 2006), and 
ORF I329L was demonstrated to be expressed in the cell membranes 
(Figure 2A, B) and at the cell surface (Figure 2D), locations 
where many receptor and adaptor molecules involved in innate 
immunity have been identified (Fan et al., 2008). Consistent with this, we 
showed that I329L inhibited double-stranded- RNA-stimulated activation 
 of NFkB (Figure 4A) and IRF3 (Figure 4B), two key players in the 
innate antiviral response. As might be predicted, expression of I329L 
protein also inhibited the activation of CCL5 (Figure 5A) and IFN-β 
(Figure 5B). Finally, IRF3 activation mediated by expression of TRIF 
was inhibited by I329L (Figure 6A), whereas over- expression of TRIF 
reverted the inhibition of reporter activation induced by I329L in a 
dose-dependent manner (Figure 6B). Thus, I329L may be targeting at 
the level of TRIF, a key adaptor molecule in the MyD88-independent 
pathway. Direct biochemical proof of this has not been possible, 
despite many attempts. Although this is the first ASFV gene manipulating 
TLRresponses to be described, vaccinia virus has evolved two 
proteins, A46R and A52R, that are inhibitors of the TIR- mediated 
5
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immune response (Bowie & Unterholzner, 2008).
Based on our experimental data and the bioinformatic data 
presented above, some hypothetical models for the ASFV TLR-βased 
strategies to evade the host defence by targeting TLR3 were considered. 
The most immediate explanation focuses on the intracellular domain 
of I329L, with its abundance of signalling motifs in particular, the 
putative TIR homologous region and the reversion of I329L-mediated 
inhibition by overexpression of TRIF. The later experiment suggested 
that the cytoplasmic tail of I329L might interfere with recruitment of 
TRIF, an important adaptor protein involved in the MyD88-independent 
pathway. Similarly, a direct interaction between the cytoplasmic tail of 
I329L and TLR3 was suggested by the observed sequence homology 
between BOX1 of the TIR domain and the intracellular region YIPLIPSY 
sequence of I329L (Figure 1B). This conclusion is supported by the 
experimental data showing I329L-mediated inhibition of IRF3 and NFkB 
activation and the predicted inhibition of induction of expression of 
CCL5 (Figure 5A) and IFN-β (Figure 5B) induced by externally, but not 
by internally, delivered poly (I:C) (Figure 5C). Finally, the observation 
that increasing amounts of I329L were able to inhibit TRIF-mediated 
NFkB (Figure 4A) and IRF3 (Figure 4B) activation is consistent 
with the hypothesis that I329L acts at the level of TRIF in the signal 
transduction pathway. Thus, the possibility that I329L protein interacts 
with the specific intracellular area responsible for TLR3 homodimerization 
cannot be excluded, although in most but not all cells, TLR3 is 
localized to the endosome and not on the cell surface. It is worth adding 
that when the intracellular domain of ORF I329L is aligned to several 
TIR domains, it shows a higher homology to the TLR3-TIR domain 
than to other TIR-domain-containing molecules. The absence of I329L 
RNA in ASFV-infected cells until20 hours post infection, as shown by 
northern blot analysis (Rodriguez et al., 1992), is difficult to reconcile 
with our findings; that is, a virus mechanism such as I329L, evolved 
to inhibit IFN and chemokine induction, might be predicted to be 
expressed early in virus infection. Thus, it will be important to measure 
expression of I329L by a method that is more sensitive than northern 
blotting. In conclusion, the results presented show that ORFI329L is 
able to impair the cellular responses controlled by TLR3 that lead to 
both IFN-β production and NFkB activation. The precise mechanism 
for this inhibition remains to be elucidated, but our current working 
hypothesis based on our observations and the current literature is that 
the ORF-I329L-mediated inhibition is intracellular and might be related 
to an interaction with TRIF. In view of the major impact of I329L on 
innate immunity, its deletion may provide a rational strategy for 
construction of an attenuated deletion mutant vaccine.
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Abstract
To elucidate the role of the M2 protein of the MHV-68 virus in vivo, 
B lymphocyte restricted M2-transgenic mice were constructed. M2 has 
been implicated in the establishment, maintenance and reactivation of 
latency in B cells. Interestingly, M2 also interacts with the VAV signalling 
system, suggesting that it may modulate B-cell receptor-mediated 
signalling events through Vav to influence B-cell activation, proliferation 
and/or survival. The analysis of surface markers expression of 
these transgenic mice demonstrated that M2 transgene made no 
impact on the development of B cells, as there was no difference in the 
development of B-cell subsets, either in the bone marrow or in the 
spleen. However, transgenic mice immunized with the T dependent 
antigen (DNP-KLH) produced significantly higher levels of both IgM 
and IgG2a antibodies. This work shows that virus host evasion genes 
can be used as valuable tools to manipulate the genetic program of 
mammalian cells in vivo. Thus B-cell restricted transgenic expression 
of a virus host modification gene has interfered with the production of 
antibodies and the numbers of germinal centre.
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Introduction
The availability of genetically modified mice lacking components of 
the innate and adaptive immune system, together with genetically 
manipulated MHV-68 viruses, has provided useful tools to explore 
the pathogenesis and the role of specific viral genes in the virus-host 
interaction. The construction of transgenic mice is also a powerful 
strategy to study mechanisms of immunity in vivo. The use of specific 
promoters to restrict cellular transgene expression to a defined cell 
type is an additional strategy, which may overcome the undesirable 
effects of whole body transgenesis. Interestingly, cell specific transgenic 
expression of virus host modulatory genes is an alternative approach 
to study the role of a viral protein in the context of the homologous virus 
infection. This system allows an evaluation of the function of a given 
virus gene expressed in a specific cell type in physiological conditions 
and in context of infection during acute and latent phases. 
This work focuses on the role of the latency-associated M2 gene. 
The M2 open reading frame is located at the left end of the MHV-68 
genome and shares positional homology with latency-associated 
genes in other gammaherpesviruses. Functional studies performed 
in vitro indicated that M2 is a latency-associated protein that has an 
important role in B cell activation, proliferation and survival (Jacoby et al., 
2002). In vivo experiments using mutant M2 viruses have shown that M2 
protein is critical for establishing latency, following intranasal 
inoculation, and for virus reactivation, following intraperitoneal inoculation 
(Herskowitz et al., 2005; Jacoby et al., 2002). In the absence of M2, 
infected B cells are unable to efficiently transition from the germinal 
centre to the follicles (Simas et al., 2004). Early in latency, there is 
an accumulation of latently infected naïve B cells in the absence of 
the M2 protein, indicating a role for the M2 protein in affecting B cell 
development during infection (Herskowitz et al., 2005). B cell proliferation 
is necessary for the establishment of MHV-68 latency, and, similar 
to Epstein-Barr virus (EBV), memory B cells are the primary latency 
reservoir (Moser et al., 2005; Willer & Speck, 2003). In addition, 
M2 protein correlates with high serum IL-10 levels and an increased 
frequency of virus-specific CD8+ T cells during MHV-68 infection 
(Siegel et al., 2008). This is consistent with previous data that indicated 
that M2 is a major target for the host cytotoxic T lymphocyte response 
(Husain et al., 1999).
This part of our work reports the construction of a B-cell restricted 
M2-transgenic mouse and focuses on the impact of the M2 transgene 
on the B cell physiology in vivo, analyzing the B cell compartment 
and the effect of different challenges in an M2-transgenic mouse and 
respective controls.
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Materials and methods 
Mice 
FVB/N mice were bred and kept at the IGC. The transgenic M2 
founder mice were produced at the Transgenic Facility of IGC by 
Dr. Moises Mallo. 
All the animal work was conducted in compliance with Portuguese 
and European laws and was performed at the IGC animal house, 
licensed by the Direcção Geral de Veterinária (Laboratory permission 
520/000/000/2518/99 and Portaria 1005/92 and Directive 86/609/EEC, 
respectively) following the FELASA recomendations.  
Gene amplification and Plasmid construction 
The M2 gene was amplified by PCR using Pfu DNA polymerase, from 
template DNA of MHV-68. The primers used were the following: Up 
5’-atgaggtttcgttttcagg-3’, Low 5’-ttactcctcgccccactccac-3’. PCR was 
conducted on a PTC-100 Peltier-Effect Cycling apparatus and conditions 
were dNTPs 200M, primers 1M, MgSO4 3mM, 95º-2’, 30X (95º-1’, 44-1’, 
74º-2’), 74º-5’. The gene was cloned into pMSCVneo, subcloned 
as a 5’ EcoRII -3’ XhoI fragment into the pCS2+ vector, and then 
subcloned with a downstream SV40 poly A tail as a 5’ Cla I -3’ Apa I 
fragment into the ps vector. This vector, constructed by Joanna B. 
Wilson, and provided by Dr. Pedro Simas (who cloned the M2 gene 
in the pS plasmid), is based on the plasmid backbone of pBluescript 
(SK) and incorporates the promoter (150bp) and enhancer (700bp) 
sequences of the mouse Ig  heavy chain, upstream of the mouse 
APRT intron (150bp). The recombinant vector was digested with 
KpnI and SacI to release the expression cassette from the bacterial 
backbone vector. After being purified from an agarose gel, the expression 
cassette was microinjected into FVB/N fertilized eggs. These were 
then transferred into pseudo-pregnant foster females, producing the 
founder mice. These founders were crossed with wild-type FVB/N mice 
to obtain hemizygous mice. Subsequent crossing of hemizygous mice 
yielded homozygous animals. Control animals were littermates without 
the transgene.
Sequencing
The cloned M2 gene was sequenced using primers derived from the 
sequence of the ps plasmid upstream and downstream of the ClaI and 
XhoI sites, respectively: Up 5’-ctgcccggccacacgcgggtcactctc-3’ and 
3.1
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Low 5’-cgatatcaagcttatcgataccgtcgacc-3’. The kit used was BigDye 
terminator v1.1, Part Nº 4336776, Applied Biosystems and the cycling 
conditions were 96º-1’ and 25X (96º-10’’, 50º-5’’, 60º-4’). The PCR 
products were analysed on a 377 DNA Sequencer and 3130xl Genetic 
Analyser, Applied Biosystems.
Mouse genotyping by Southern Blot and PCR 
Founder mice were analysed by Southern blot to assess integrity of the 
expression cassette injected into the fertilized eggs and discriminate 
between positive and negative mice. Genomic DNA (10g) isolated from 
tail biopsies was digested with KpnI and SacI and electrophoresed on 
a 0.8% agarose gel. Tails were digested overnight with Proteinase K 
(100g/ml) at 56ºC and then DNA was precipitated with isopropanol 
(0.7 volumes) at room temperature. Treatment of the gel, transfer to 
the membrane Hybond-N+ and hybridization were done according to 
the instructions of Hybond-N+ (Amersham, U.K.). The M2 probe was 
labelled with 32P-dCTP using the Random Primers DNA Labelling 
System, Gibco, according to the manufacturer’s instructions. 
Unincorporated probe was removed using G-50 Sephadex Quick Spin 
Columns, Gibco. 
Mice were then genotyped by PCR using DNA from tail biopsies 
obtained at the time of weaning (3 week-old). Detection of the M2 gene 
in the DNA by PCR was performed using Taq DNA Polymerase and 
the previously described primers. PCR was conducted on a PTC-100 
Peltier-Effect Cycling apparatus and conditions were dNTPs 200M, 
primers 1M, MgCl2 2mM, 95º-2’, 30X (95º-1’, 54-1’, 72º-2’), 72º-5’.
Determination of transgene copy number by real time 
quantitative RT-PCR (qRT-PCR) 
The amount of amplified M2 transgene estimated by LightCycler 
Fast Start DNA Master SYBR Green I (Roche) (primers Up, 
5’-atgaggtttcgttttcagg-3, Low, 5’-ttactcctcgccccactcc-3’) was normalized 
against the amount of amplified mouse β-Globin (primers Up, 
5’-ccaatctgctcacacaggatagag-3’, Low, 5’-ccttgaggctgtccaagtgattca-3’). 
Conditions were MgCl2 4mM, primers 200nM. Program for M2 was: 
pre-incubation 95º-10’, amplification 45X (95º-10’, 70º-5’’, 72º-30’’), 
Melting Curve Analysis (65º-15’’); program for β-Globin: 
pre-incubation 95º-10’, amplification 45X (95º-10’, 70º-5’’, 72º-20’’), 
Melting Curve Analysis (65º-15’’). Analysis with the Roche supplied 
software and calculations on the amount of amplified product were 
based on the determination of the second derivative maximum and on 
an arithmetic adjustment of the baseline.
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Demonstration of transgene expression by qRT-PCR
 
Total RNA was extracted from tissue homogenates of thymus, spleen 
and lymph nodes from transgenic and control littermates using Trizol 
Reagent, Sigma. Samples of RNA were digested with DNase I 
(Invitrogen) and cDNA synthesis was performed with MMLV-Re-
verse Transcriptase (Invitrogen), according to the manufacturers’s 
instructions.  Detection of the M2 gene in the cDNA by PCR 
was performed by RT-PCR using LightCycler Fast Start DNA Master 
SYBR Green I (Roche) as described above. 
Flow cytometry analysis of lymphocyte surface proteins
Cell suspensions of bone marrow and spleen were incubated with titrated 
concentrations of the antibodies used in the staining combinations 
given in the text, washed in Phosphate Buffered Saline (PBS)-2% 
Foetal Calf Serum (FCS)-0.02% sodium azide and subsequently 
analyzed in a FACScalibur (Becton Dickinson, Palo Alto). The following 
rat anti-mouse monoclonal antibodies (BD Pharmingen, San Diego, 
CA) were used: Anti-IgM-Alexa488, anti-B220-APC, anti-CD23-PE, 
anti-CD21-FITC and anti-IgD-PE. Except for the four colour staining, 
propidium iodide (PI) was always used to exclude dead cells from 
the analysis. Data were processed using CellQuest software (Becton 
Dickson Immunocytometry Systems, San Jose, CA). Live lymphocyte 
counts were deduced from the acquisition of a fixed number of 10-μm 
latex beads (Coulter) mixed with a known volume of unstained cell 
suspension.
Stimulation and measurement of germinal centre formation 
Mice were injected intraperitoneally with 200μl of 2% sheep red blood 
cells, and 7 to 10 days later spleens were collected, frozen in tissue-tek 
O.C.T. compound (Sakura Finetechnical), and 8μm cryostat sections 
were fixed (absolute ethanol, 5’-RT, followed by acetone, 5’-RT) and 
air-dried. Quantification of the germinal centres was performed by 
immunofluorescence using a titrated concentration of rat anti-mouse Ig 
coupled to Alexa 488 (BD Pharmingen, San Diego, CA) counterstained 
with biotinylated Peanut Agglutinin (PNA) (Vector Laboratories) 
followed by streptavidin-TexasRed (BD Pharmingen, San Diego, CA). 
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Immunizations with T-dependent (TD) antigens and Ig 
isotype-specific ELISA 
Mice aged 16 to 20 weeks were injected intraperitoneally with DNP-KLH 
(TD) (100μg) (Biosearch Technologies) in PBS on day 0, re-challenged 
on day 21 and sacrificed on day 28. Blood was collected for serum 
on days 0, 7, 14, 21 and 28. Determination of DNP-specific serum 
antibodies was done by Ig isotype-specific ELISA. Flat-bottomed 
96-well ELISA plates (Nunc Maxisorp, Naperville, IL) were coated 
with DNP-bovine serum albumin (BSA) (Biosearch Technologies) for 
1h at 37ºC at a concentration of 5 μg/ml in K2HPO4 0.5M, KH2PO4 
0.5M, pH=8.0. After washing three times with PBS (no Ca2+ or Mg2+) 
containing 0.1% Tween-20, blocking was performed at 37°C for 1h 
using 200µl/well of PBS containing 1% gelatine (PBS-G). 
Serial dilutions of serum samples in PBS-G were added to the plates 
and left O/N at 4ºC. Plates were washed 5 times and bound isotype 
-specific antibodies were detected with biotinylated subclass-specific 
horseradish peroxidase (HRP) conjugated antibody (Southern 
Biotechnology Associates, Birmingham, AL), incubating at 37°C 
for 1h. The plates were washed 5 times and developed with freshly 
prepared 0,5mg/ml orto-phenylenediamine (OPD), 0.03% H2O2 
in Na2HPO4 0.2M, Citric acid (H8C6O7) 0.1M, pH=5.6 at RT and 
protected from light. The enzymatic chromogenic reaction was stopped 
with H2SO4 0.1 M and A492nm determined. 
The initial dilution of the serum varied according to the Ig isotype 
and was empirically determined. The relative concentrations of 
DNP-specific antibodies are shown as A492nm values and for each 
isotype a single dilution factor that fell in the linear part of the curve is 
presented for all time-points (1:6400 for IgM, 1:3200 for IgG1, 1:1600 
for IgG2a and IgG2b and 1:400 for IgG3).
Statistics 
Statistical significance between the groups was determined by a 
two-tailed Mann-Whitney t test and no correction was made for 
multiple comparisons. Data were analysed using GraphPad Prism v5.0 
statistical software. Statistical significance was accepted at a two-tailed 
P of <0.05 (*).
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Results
Construction of transgenic mice, determination of the 
number of copies and expression of the M2 transgene 
Selective B lymphocyte transgenic M2 expression in FVB/N mice was 
obtained from a litter of nine mice, after injection of fertilized eggs with 
the expression cassette of the pμs plasmid containing the M2 transgene. 
Southern blot analysis revealed two females and one male with a transgenic 
DNA fragment of the expected size. The two female founders 
were crossed with wild-type FVB/N male mice. The resulting F1 mice 
were further crossed to yield the F2 generation. Southern blot analysis 
of both founder mice of the M2 B cell restricted transgenic line revealed 
the presence of the injected expression cassette of the plasmid pμs 
(data not shown). The number of copies of the transgene incorporated 
in the genome of the two founders, as assessed by the Light Cycler 
technology, varied between 10 and 30. In all of the F1 and F2 mice 
bred from the two selected founders that were analyzed, expression 
was confirmed by RT-PCR (Figure 1). The amplification of β-globin 
was used as a control for the quality of the RNA in both of the two 
founder lines. Besides that, protein expression was confirmed by 
fluorescent staining of spleen cells from SRBC immunized M2-transgenic 
 mice (Figure S1).
4.1
4
Spleen Thymus
M2
β-globin
Figure 1. Seletive B lymphocyte expression of the M2 transgenic protein. 
RT-PCR for the M2 gene in transgenic splenic (positive) and thymocyte (negative) 
cell suspensions. β-Globin loading controls in splenocytes and thymocytes below. The 
results are representative of at least 5 mice per founder. 
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B cell-specific expression of M2 does not affect subpopula-
tions of B cells 
To assess the role of M2 during B cell development, flow cytometric 
analysis of lymphocyte suspensions prepared from bone marrow and 
spleen were performed.
4.2
Figure 2. FACS analysis of B cells in control and M2 B cell restricted transgenic 
mice in bone marrow. 
Cells were stained with B220 and IgM. The analysis was performed gating on 
B-lymphocytes and after exclusion of dead cells by incorporation of PI. The 
white and black bars represent the control and M2-transgenic mice, respectively. 
Representative FACS profiles (2a.) and the relative numbers of B cell sub-
populations (2b.) are presented. The results (n=5, mean ± s. d) are 
representative of at least three independent experiments (P>0.05, not significant).
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The frequency of bone marrow B-cell subpopulations, which define 
successive stages of B-cell development, was determined on the 
basis of IgM and IgD surface markers on B220+ cells pro or pre B 
cells B220low IgM-, immature B-cells, B220lowIgM+ and mature B cells 
B220hiIgM+ (Figure 2).  
The IgM: IgD ratios were similar in both control and transgenic mice 
immature B-cells, IgM+IgD-, transitional B cells IgM+IgDlow and mature 
recirculating B-cells, IgM+IgD+ (Figure 3). The IgM:IgD ratios were si-
milar in both control and transgenic mice (Figure 3). 
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Figure 3. FACS analysis of B cells in control and M2 B cell restricted transgenic 
mice in the bone marrow. 
Cells were stained with IgM and IgD. The analysis was performed gating on 
B-lymphocytes and after exclusion of dead cells by incorporation of PI. The FACS 
profiles are presented (3a.). Relative numbers of B cell subpopulations. The white 
and black bars represent the control and M2-transgenic mice, respectively. (3b.). The 
results are for groups of 5 mice per genotype and are representative of at least three 
independent experiments. P>0.05 (not significant).
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Similarly, there was no difference between control and transgenic 
mice in Marginal Zone (B220+CD23-CD21bright) and Follicular B cell 
(B220+CD23+CD21+) subsets in the spleen (Figure 4).
Collectively, these findings indicate that expression of M2 did not 
affect B-cell bone marrow development and splenic maturation. Similar 
results were also observed in the lymph nodes (results not shown). 
Figure 4. FACS analysis of B cells in control and M2 B cell restricted transgenic 
mice in the splenocytes. 
Cells were stained with B220, CD21 and CD23 antibodies. The analysis was performed 
gating on B-lymphocytes and after exclusion of dead cells by incorporation of PI (4a.). 
Pooled data (4b.). The white and black bars represent the control and M2-transgenic 
mice, respectively. The FACS profiles are presented on the top and the relative 
numbers of B cell subpopulations on the bottom. The results are for groups of 5 mice 
per genotype and are representative of at least three independent experiments. P>0.05 
(not significant).
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M2 expression in B cells induces higher levels of secondary 
IgM and IgG2a antibody and increased numbers of germinal 
centres in response to T-dependent (TD) 
To determine if the B cell restricted M2-transgenic mice can mount antigen 
-specific antibody responses, M2-transgenic and control wild-type 
mice were immunized with T-independent (DNP-LPS and DNP-Ficoll) 
and T-dependent (DNP-KLH) antigens. Similar anti-DNP antibody 
responses to DNP-LPS and DNP-Ficoll were observed in control and 
transgenic mice 10 and 21 days post immunization (data not shown). 
Levels of DNP-specific IgG1, IgG2a, IgG2b, IgG3, and IgM antibodies 
were measured 10 days after primary immunization and 7 days 
after the secondary immunization, (day 21) with DNP-KLH. There 
was no significant difference between control and transgenic titres of 
DNP-specific IgG1 and IgG2b antibodies, whereas titres of 
DNP-specific IgM and IgG2a were significantly elevated (*P<0.05) in the 
secondary response of the M2-transgenic mice at day 28. The higher 
levels of these antibodies to the T-dependent antigen (Figure 5a and 5c) 
are in agreement with the increased numbers of germinal 
centres determined by the number of peanut agglutinin (PNA) positive 
areas in the spleen sections, which reinforces the idea of an increased 
expansion of B cells during the germinal centre reaction in the 
M2-transgenic mice.
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Figure 5. Response of M2 B cell transgenic mice to TD antigen DNP-KLH and the 
formation of germinal centres in M2 B cell transgenic mice are increased. 
Control and M2 B cell restricted transgenic mice were immunized with the TD 
antigen DNP-KLH. The relative amounts of DNP-specific IgM, IgG1 , IgG2a and 
IgG2b (5a.-5d. respectivelly) antibodies were determined by ELISA. Serum was 
collected before immunization and 7 and 14 days after primary immunization (day 1). 
Mice were then re-immunized at 21 days, bled at day 28 and the secondary 
immune response measured. The arrows represent the days at which mice 
were immunized (day 1 and day 21). 
White and black circles represent mean ±S.D. for control and transgenic mice, 
respectively. Each circle represents one mouse. Results of the ELISA are 
shown as absorbance at 492nm (Y-axis) versus day of serum collection 
(X-axis). Similar results were observed in the lymph nodes (results not shown). 
Germinal Centre (GC) Formation in the M2 B cell restricted transgenic mice. Dual-colour 
immunofluorescence to visualize GC (5e.). Numbers of splenic GC were calculated 
based on the numbers of B220+ follicular areas and PNA+ germinal centres in fields 
from histological cryostat sections from control and M2-transgenic mice (5f). Data are 
mean ± s.e.m. per microscopic field (18–20 fields were analyzed for each genotype). 
*P<0.05 in comparison indicated by horizontal line on chart. 
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Discussion 
Virus host evasion strategies provide ready-made tools for genetic 
manipulation of cell biology and immune responses. The M2 gene 
of mouse herpes virus 68 (MHV-68) is known to be involved in the 
establishment, maintenance and reactivation of latency in B cells 
(Herskowitz et al., 2005; Macrae et al., 2003; Rodrigues et al., 2006). 
Here, as an approach to better understand the biological role of M2, 
we have successfully constructed M2-transgenic mice with expression 
restricted to B cells. The construction of transgenic mice is a 
powerful alternative strategy to study mechanisms of immunity in vivo. 
The use of specific promoters to restrict cellular expression to a certain 
cell type is an additional refinement, which may overcome the undesirable 
effects of whole body transgenesis. Our findings reinforce the idea that 
the increased physiological expansion of B cells during the germinal 
centre reaction could increase the size of the memory B cell pool, the 
reservoir for virus in vivo. The data is consistent with previous works 
suggesting that M2 may manipulate the activation, proliferation and 
survival of B cells. 
The validity of the model was justified by the generation of two founder 
lines with similar characteristics and with RT-PCR assays demonstrating 
 expression of M2 in splenocytes but not in thymocytes. The first step 
in the characterization of the M2-transgenic mice was the analysis of 
surface markers. There were no differences between the wild-type 
and the M2-transgenic mice in their B cell subpopulations in the bone 
marrow, spleen and lymph nodes (Figure 2-4). Therefore, the B cell 
restricted expression of the MHV-68 M2 protein in vivo did not impact 
on B cell development, a finding consistent with the absence of a strong 
in vivo phenotype for the VAV1, VAV2 and VAV3 triple knockout mice 
(Pearce et al., 2004). As the downstream target for M2 is VAV 1/2, we 
may conclude that the VAV proteins are redundant and overlapping in 
their function. 
We then performed functional assays to assess the impact of the trans-
gene on the serological immune response. Transgenic mice immuni-
zed with the T- dependent antigen (DNP-KLH), produced statistically 
higher levels of IgM and IgG2a anti-DNP antibodies than normal mice 
(Figure 5a-5d). The predominant subtype observed following MHV-68 
infection, as well as in other viral infections, is IgG2a, suggesting a 
preferential class switching (Coutelier, 1987). Similarly, when 
M2-transgenic mice were challenged with a T-dependent antigen, 
there was a significant increase of IgG2a, especially in the secondary 
challenge. 
Particularly significant was our observation of increased germinal centre 
formation in mice immunized with sheep red blood cells (Figure 5e-5f). 
5
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Together with the previous described data with M2 transfected 
WEHI-231 B cell lines in vitro (Madureira et al., 2005), our results 
suggest that M2, perhaps through its interaction with Vav (Madureira 
et al., 2005; Pires de Miranda et al., 2008) increases the sensitivity 
of the latently infected B cells to activation via the immunoglobulin 
receptor (BCR), and thus might favour reactivation and consequent virus 
transmission. In addition, these experiments suggest that M2 
might function to promote the survival of activated and memory 
B cells, thus expanding the reservoir of host cells for the establishment 
of latency.
Several studies with M2 deletion mutant viruses have shown reduced 
levels of acute splenic latency (Herskowitz et al., 2005; Jacoby et al., 
2002; Macrae et al., 2003), an effect attributed to a reduced number 
of infected splenic B cell follicles, rather than a reduced expansion of 
latently infected germinal centre B cells (Simas et al., 2004). In 
addition, the M2 protein alone can drive plasma cell differentiation 
in a B lymphoma cell line (Liang et al., 2009), perhaps providing a 
novel viral strategy to regulate gammaherpes virus reactivation from 
latently infected B cells. Thus, M2 has been postulated to be a new 
class of herpesvirus gene products (reactivation conditioners) that does 
not directly participate in virus replication, but rather facilitates virus 
reactivation by manipulating the cellular milieu to provide a reactivation 
competent environment (Liang et al., 2009). Accordingly, a crucial role 
of M2 in the establishment of latency may be its impact in signalling 
the end of the expansion of the viral load in germinal centres with the 
associated differentiation of latently infected B cells into long-lived 
memory B cells, the main reservoir for the virus (Rodrigues et al., 2006). 
In conclusion, M2 does not affect the distribution of B cell subsets in 
the bone marrow and spleens of the M2-transgenic mice but it affects 
B cell responses to thymus dependent protein antigens. 
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129Figure S1. Expression of M2 by B-cells in spleen cell sections from SRBC 
immunized M2-transgenic mice. 
Mice were immunized with SRBC and cryostat sections of spleen 
were fixed as described in Materials and Methods. Control (S1a. and S1e.) 
and transgenic (S1b. and S1f.) spleen sections were stained 
with a mouse-anti-recombinant M2 serum followed by biotin anti 
-mouse IgG2a (Biolegend) and streptavidin-Texas Red (Southern Biotechnology) 
(S1a. and S1b.) and counterstained with FITC-monoclonal-anti-mouse B220 
(Ebiscience) (S1e and S1f). As a specificity control for the anti-M2 
staining, spleen sections were stained with normal mouse serum followed 
by biotin anti-mouse IgG2a (Biolegend) and streptavidin-Texas Red 
(Southern Biotechnology) (S1c. and S1d.) and counterstained with 
FITC-monoclonal-anti-mouse B220 (Ebiscience) (S1g. and S1h.). 
Note the low background in the staining with the biotin anti-mouse IgG2a 
(Biolegend) and streptavidin-Texas Red (Southern Biotechnology) (S1c. and 
S1d.). The recombinant M2 was expressed in E. coli transformed with a pGEX-M2 
construct and purified by GST-affinity chromatography according to the 
manufacturer’s instructions (GE Healthcare).
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Abstract
Some important features of M2 protein in the murine herpesvirus 
strain-68 (MHV-68) pathogenesis were already indicated by in vitro 
and in vivo analysis by using M2 mutant virus, but the precise function 
of M2 and its specific role in MHV-68 latency remain to be clarified. 
In order to investigate the immunological and virological aspects of 
this specific protein in the MHV-68 pathogenesis, we combine the use 
of our M2 B-cell restricted transgenic mice with the use of MHV-68 
knockout to ORF M2 viruses. This approach provides an alternative 
system model to explore the impact in vivo of a single virus protein in 
the context of the latent phase of infection, 
Here we show that the pathogenesis of M2-transgenic mice infected 
with the M2-deficient mutant virus did not revert to that observed upon 
infection of normal mice with Wt virus. However, the higher reactivation 
levels late after M2-transgenic mice were infected with Wt virus 
reflected the importance of M2 as a target for the immune response, 
and thus with an impact on the establishment of latency. Finally, 
there was markedly less apoptosis in B cells from M2-transgenic mice 
infected with either Wt or M2FS mutant, than from similarly infected 
wild-type mice, coherent with the published inhibitory influence of M2 
on apoptosis in vitro. Thus M2 plays a role in both the humoral and 
cellular anti-virus immune response and provides a strategy to increase 
the pool of germinal centre B cells through inhibition of apoptosis in the 
infected cell.
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Introduction 
The murine herpes virus (MHV)-68-infected mice are well known as a 
model for studies of gammaherpesvirus infection. Intranasal inoculation 
of mice with MHV-68 results in a productive infection in the lungs, with 
maximal viral titres observed between days 5 and 10-post infection 
(p.i.), and viral clearance on days 9-15 post infection. During the 
subsequent viremia, MHV-68 spreads to the spleen where it becomes 
latent, mainly in B lymphocytes located in the germinal centre and in 
the memory B lymphocyte pool (Flaño et al., 2003; Thorley-Lawson & 
Babcock, 1999; Thorley-Lawson, 2001; Willer & Speck, 2003). B cells 
are required for trafficking of infected cells to the spleen, leading to 
the establishment of splenic latency  (Stewart et al., 1998; Weck et 
al., 1999). During latent infection, there is no virus replication and the 
viral genome is present as a nuclear episome (Clambey et al., 2002). 
Initial establishment of latency in the spleen is associated with a marked 
splenomegaly and mononucleosis. The splenomegaly is driven by 
CD4+ T cells and is dependent on the presence of MHV-68-infected 
B cells in the spleen (Usherwood et al., 1996). The resolution of 
splenomegaly is achieved by CD8+ T cells, which are also important 
in the long-term control of persistent infection (Ehtisham et al., 1993). 
This work focuses on the role of the M2 gene; a gene transcribed during 
latency, with a pivotal role in the establishment, maintenance and 
reactivation from latency in B cells (Herskowitz et al., 2005; Jacoby et 
al., 2002; Macrae et al., 2003) and a major target for the host cytotoxic 
T lymphocyte response (Husain et al., 1999). Studies with M2-deficient 
viruses indicate that M2 does not have an impact on the acute phase 
in the lung (Jacoby et al., 2002; Macrae et al., 2003). 
Several studies with M2 deletion mutant viruses have shown reduced 
levels of acute splenic latency (Herskowitz et al., 2005; Jacoby et al., 
2002; Macrae et al., 2003), an effect attributed to a reduced number 
of infected splenic B cell follicles, rather than a reduced expansion 
of latently infected germinal centre B cells (Simas et al., 2004). In 
addition, the M2 protein alone can drive plasma cell differentiation in 
a B lymphoma cell line (Liang et al., 2009), perhaps providing a novel 
viral strategy to regulate gammaherpes virus reactivation from latently 
infected B cells. Thus, M2 has been postulated to be a new class of 
herpesvirus gene product (reactivation conditioners) that does not 
directly participate in virus replication, but rather facilitates virus 
reactivation by manipulating the cellular milieu to provide a reactivation 
competent environment (Liang et al., 2009). Accordingly, a crucial role 
of M2 in the establishment of latency may be its impact in signaling 
the end of the expansion of the viral load in germinal centres with the 
associated differentiation of latently infected B cells into long-lived 
2
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memory B cells, the main reservoir for the virus (Rodrigues et al., 2006).
M2 has been shown to interact with a number of cellular proteins in 
vitro. M2 co-immunoprecipitates with Vav1 and Vav2 proteins in 293T 
and inhibits cell cycle arrest and apoptosis in WEHI-2931 B-cells 
(Madureira et al., 2005). In fibroblast cultures, M2 interacts with DDB1/
COP9/cullin repair complex and ATM to suppress DNA-damage induced 
apoptosis (Liang et al., 2006). However, to date the impact of M2 
expression in vivo has not been reported. Thus the main goal of 
this part of the work was to assess the in vivo role of M2 in the host 
response to MHV-68 virus infection during the latency state, using the 
B-cell restricted M2-transgenic mouse. 
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Materials and methods 
Cell culture 
BHK-21 cells were cultured in 5% CO2 at 37
oC in complete GMEM, 
(cGMEM) consisting of Glasgow’s modified Eagle’s medium (GMEM) 
supplemented with 10% FCS, 10% (w/v) tryptose phosphate broth, 
100U/ml penicillin-G, 100μg/ml streptomycin and 2mM L-glutamine. 
 
Virus production and titration
MHV-68 clone G2.4 used (Efstathiou et al., 1990) in this work was 
provided by Dr. Pedro Simas. The MHV-68 recombinant virus (M2FS) 
(provided by Dr. Heiko Adler and Dr. Stacey Efstashiou) contains a 
frameshift in the ORF M2 created by insertion of a single guanine 
between nucleotides 4603-4604, immediately downstream of the 
translational start codon (Husain et al., 1999), creating a novel Apa I 
site and premature stop codon 78 nucleotides downstream. Virus 
working stocks were grown by low multiplicity infection of semi-confluent 
BHK-21 cells (0.001 PFU/cell) in 150cm2 culture flasks, with MHV-68 
or with M2FS. After 4 days, supernatants were centrifuged (30000g, 
2h, 4oC, Beckman type 19 rotor) and pelleted virus was re-suspended 
in 2ml GMEM medium and ultrasonically disrupted for 30sec. Aliquots 
were stored at -80oC. To determine the virus titre sub-confluent BHK-21 
cells were incubated with 10-fold serial dilutions of virus in GMEM. 
Following a 1h adsorption, the medium was replaced with cGMEM 
medium containing 0.32% carboxymethyl cellulose and incubated 
at 37oC for 4 days. After removal of this medium, cells were fixed 
with 10% formaldehyde in PBS and then stained with 0.1% toluidine 
blue in formal saline. Viral plaques were counted under a Stermi SV6 
microscope (Zeiss) and virus titres were calculated from numbers in 
duplicate dishes. 
Infection of mice with MHV-68 or M2FS 
After genotyping, 6-8 week old mice were transferred from the standard 
animal house to quarantine. Animals were inoculated intranasally 
under the effect of light halothane anaesthesia with 104 PFU of MHV-68 
or M2FS virus in 20μl of PBS. At different time points after infection, 
mice were killed by inhalation of CO2. The entire experiment was 
performed twice, with comparable results. 
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Infectious centre assay 
Spleen cell suspensions were 10-fold serially diluted, starting with 
107cells/ml. BHK-21 cells (5x105) were added to each sample and the 
final volume was adjusted to 5ml with cGMEM. The mixture incubated 
for 1h at 37oC with gentle shaking and then plated out in 60mm cell 
culture Petri dishes, was then incubated at 37oC in a humidified incubator 
for 5 days. Monolayers were fixed with 10% formaldehyde in PBS and 
stained with 0.1% (w/v) toluidine blue in formal saline. Plaques were 
counted under a Stemi SV6 microscope (Zeiss) and the number of 
infectious centres per 108 splenocytes was calculated. 
Estimation of apoptotic cells 
Splenic cell suspensions were stained with a titrated concentration of 
a monoclonal FITC labeled rat anti-mouse B220 (BD Pharmingen, San 
Diego, CA) to allow B cell selection. Then, these suspensions were 
fixed in 90% ethanol (20’ at RT), washed with PBS, permeabilized 
(PBS containing 0.05% (v/v) triton X-100 and 50 units of RNaseA) for 
30’ at RT. After this, samples were re-suspended in PBS with propidium 
iodide (PI), at a final concentration of 25μg/ml and analysed in a 
FACScalibur (Becton Dickinson, Palo Alto). Apoptotic B cells were 
determined accounting cells in the hypodiploid sub-G1 peak after 
gating on the B220+ splenic B cell population. 
Statistics  
Statistical significance between the groups was determined by a 
two-tailed Mann-Whitney t test and no correction was made for 
multiple comparisons. Data were analysed using GraphPad Prism v5.0 
or SPSS v17.0 statistical software. Statistical significance was 
accepted at a two-tailed P of <0.05 (*).
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Results
Pathogenesis of normal and B cell restricted M2-transgenic 
mice to infection with MHV-68 and M2 deficient (M2FS) 
virus 
To study the pathogenesis of MHV-68 infection in the M2-transgenic 
mice, groups of M2-transgenic and wild-type mice were infected 
intranasally with 104 PFU of MHV-68 or M2FS viruses and monitored 
by infectious centre assays over a period of 90-days post infection (p.i.) 
to determine levels of latent viruses in the spleen. 
First, comparing wild-type FVB/N mice infected with MHV-68 
or M2FS virus, at day 14 p.i. there was an approximately 
10-fold reduction in the number of  infectious centres in mice 
infected with M2FS virus, as compared with mice infected 
with MHV-68, which is in agreement with similar work 
in BALB/c mice (Simas et al., 2004) (Figure 1a). At later 
time-points, days 43 p.i.  (Figure 1c) and 71 p.i. (Figure 1d), 
the number of infectious centres was consistently higher in the 
M2FS virus infected mice, when compared with mice infected with 
wild-type MHV-68, as previously described in BALB/c mice 
(Marques et al., 2008; Simas et al., 2004). Importantly, even 
at 90 days p.i. (Figure 1e), the long-term latency of MHV-68 in 
FVB/N mice was not significantly affected by the disruption of 
the M2 protein, also as previously described for BALB/c mice. 
Thus, we confirm that the acute latency deficit and long-term 
latency of M2 deficient MHV-68 virus observed in BALB/c mice (Simas 
et al., 2004) also occurs in FVB/N mice. 
Second, comparing infection of M2-transgenic and wild-type mice 
infected with MHV-68 virus, reactivation levels were significantly 
higher at later times [day 43 (Figure 1c) and day 90 
(Figure 1e)] in M2-transgenic mice infected with wild-type virus, 
consistent with the proven importance of M2 as a target for the 
protective immune response and thus with an impact on the 
establishment of latency. 
Third, comparing infection of wild-type and M2-transgenic mice 
with M2FS there were no major differences between the FVB/N 
wild-type and the M2-transgenic mice, apart from day 71 p.i.; 
where a higher number of latent reactivation-competent 
virus was observed in the wild-type mice infected with M2FS mutant 
virus (Figure 1d). 
Fourth, and finally, comparing wild-type and M2-transgenic 
mice infected with MHV-68 and the M2FS mutant virus, 
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infection of the M2-transgenic mice with the M2-deficient 
virus (M2FS) did not result in a restoration of the latency 
deficiency seen in wild-type mice infected with the M2FS virus. 
Thus, at day 43 p.i. similar numbers of infectious centres 
were observed, and therefore a similar latency deficiency, 
recovered from both wild-type and M2-transgenic mice infected with 
the M2 deficient virus (Figure 1c). 
Surprisingly, the latency deficiency observed upon infection of 
normal mice with the M2 deficient virus was not reversed upon infection 
of M2-transgenic mice with the M2 deficient virus (Figure 1a). An 
explanation for this is not immediately obvious, but one possibility 
could be the impact of the M2 transgene on the physiology of the B 
cell. For example, it is known that M2 drives B cell proliferation and 
differentiation in an IL-10 dependent manner (Siegel et al., 2008). For 
this reason, we measured the IL-10 levels in sera from naïve and SRBC 
stimulated normal and M2-transgenic mice. Although the levels of IL-10 
were low, they were, nevertheless, significantly above background 
(p<0.05), and there was no significant difference between the wild-type 
and M2-transgenic mice (p>0.05, not significant) (Figure S2). 
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Figure 1. Numbers of latent reactivation-competent virus in control 
and M2-transgenic mice infected with MHV-68 or M2FS virus.
Control and M2-transgenic mice were infected intranasally with 104 PFU of either 
MHV-68 or M2FS and the spleens were assayed for latent virus at the days from 14 to 
90 days post-infection (p.i.). Wild-type mouse with MHV-68  virus (white circles), Wild-
type  mouse with M2FS virus (black circles), M2-transgenic infected with MHV-68 virus 
(white circles), or  M2-transgenic infected with M2FS virus (black circles). Results were 
compiled from two independent experiments, and the results for these four groups are 
presented as the numbers of latent reactivation-competent virus measured on days 14, 21, 
43 , 71 and 90 (1a. to 1e., respectivelly) post-infection. The continuous horizontal 
dashed line indicates the limit of detection of the assay and the short 
horizontal line in each group of circles represents the arithmetic mean (ND, denotes 
that virus was not detectable). Each circle represents an individual mouse. *P<0.05 in 
comparison indicated by horizontal line on chart.
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Expression of the M2 protein protects against apoptosis 
induced by infection with MHV-68
To study the impact of the M2 transgene in the context of infection, 
groups of 8 week old wild-type and M2-transgenic mice were infected 
intranasally with wild-type (MHV-68) and M2 deficient recombinant 
(M2FS) viruses. Spleen cell suspensions prepared 21 days 
post-infection were stained with Propidium Iodide (PI) and apoptosis 
was assessed by the magnitude of the hypodiploid sub-G1 peak. In 
contrast to the abundant apoptosis in the normal mice infected with 
either of the two viruses, (Wt 38,3±11% and M2FS 49,2±4,32%), there 
was little or no apoptosis with either virus, (Wt 0,08±0,08% and M2FS 
0,00±0,05%) in the B-cell from M2-transgenic mice (Figure 2a and 2b), 
a finding consistent with observations in vitro (Madureira et al., 2005).
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Figure 2. Transgenic expression of the M2 transgene protects B-cells from 
apoptosis. 
Suspensions of splenocytes from control (left hand side) and M2-transgenic 
(right hand side) mice infected with 104 PFU of either MHV-68 or M2FS virus were 
stained with a FITC monoclonal rat anti-B220 to identify the B cells, permeabilized, 
stained with Propidium Iodide (PI) and examined by FACS. Apoptotic cells were 
determined by the presence of a hypodiploid sub-G1 peak after gating on 
the B220+ splenic B-cell population. 2a. Results are presented as the per-
centage (%) of apoptotic cells for the control (white circles) and the M2-
transgenic mice (black circles). Each circle represents an individual 
mouse. 2b. Representative FACS profiles are also shown. 
The results are for groups of 5 mice per genotype and are representative of at least 
three independent experiments. *P<0.05 in comparison indicated by horizontal line on 
chart.
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Discussion
The M2 gene of mouse herpes virus 68 (MHV-68) is known to be 
involved in the establishment, maintenance and reactivation of latency 
in B cells. The work presented here complements the work presented 
in Chapter 3 challenging the M2 B-cell restrict transgenic mice with 
wild-type and mutant virus infections to further clarify the role of M2 in 
host-virus interaction. 
Previous studies, conducted with female BALB/c mice, demonstrate 
that recombinant viruses, deficient in M2, show no replication deficit, 
neither in tissue culture nor during the acute phase in the lungs of 
infected mice (Jacoby et al., 2002; Macrae et al., 2001). Thus, before 
investigating the pattern of establishment and maintenance of latency 
in the FVB/N M2-transgenic mice infected with MHV-68 and M2FS 
deficient viruses, we analyzed the infection in the wild-type FVB/N 
background. Indeed, we observed that FVB/N wild-type mice infected 
with M2FS revealed the same phenotype as BALB/c, namely, an acute 
latency deficit and an elevated long-term latency. Therefore control of 
infection through recognition of M2 peptides by CD8+ T-cells might 
not be restricted to the H-2Kb haplotype, as previously suggested 
(Marques et al., 2008). 
In order to explore the role of M2 in the establishment of latency 
M2-transgenic and wild-type mice were infected with wild-type MHV-68 
and M2 deletion mutant (M2FS) viruses. Then the numbers of 
reactivation-competent virus plaques in the spleen were measured 
as an indication of latently infected B-cells (Figure 1a-1e). The yield 
of virus recovered in normal mice infected with the M2 deficient virus 
increased at the late, but not at earlier phase of infection. This 
phenotype was not observed in the M2-transgenic mouse, where 
the response to wild-type and M2 deficient viruses was similar. The 
observation of higher reactivation centres in the late phase of latency 
in the M2-transgenic mice infected with wild-type viruses is consistent 
with the role of M2 in expansion of germinal centre B cells, on the one 
hand. On the other hand, the higher virus yield in M2-transgenic mice 
may be attributed to tolerance to M2 and the consequent loss of a 
major immunodominant CD8+ T-cell epitope with an expected impact 
on the establishment of persistence (Husain et al., 1999).  
In conclusion, the B-cell restricted transgenic expression of the MHV-68 
ORF M2 provides a novel approach to explore the mechanism and 
possible exploitation of the M2 gene. It has the merit of being relevant 
in the context of an MHV-68 infection, providing a good platform to 
study the impact in vivo of a single virus protein during acute and latent 
phases of virus infection. Although we have not found an effect on the 
distribution of B-cell subsets in the bone marrow and spleens of the 
5
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M2-transgenic mice (described in chapter 3), we have found a relevant 
phenotype when these mice were challenged with a thymus dependent 
protein antigen, or when infected with MHV-68 or an M2 deficient 
recombinant virus. Infection of normal mice with M2 deficient MHV-68 
resulted in an increased reactivation in the late, but not the 
earlier phase, of latency, an observation not seen when the 
M2-transgenic mice were similarly infected. More importantly, we have 
demonstrated in vivo that the host evasion M2 protein not only 
contains an immunodominant CD8+ T cell response, but also protects 
B-cells from apoptosis in vivo, thereby providing a viral strategy for 
increasing the pool of potential host cells for the establishment of 
latency. 
In contrast to our expectation, the latency deficiency phenotype 
associated with the M2 deficient virus was not reversed by similar 
infection of M2-transgenic mice. The possibility that this might be 
related to the known impact of M2 on IL-10 expression (Siegel et 
al., 2008) was not supported under our experimental conditions, as 
there was no significant difference between levels of serum IL-10 in 
control and SRBC immunized normal and M2-transgenic mice. Another 
possibility is that the impact of expression of the M2 transgene on the 
physiology of B cells might in some, as yet unexplained, way have 
been responsible for the failure to reverse the latency deficiency 
phenotype. 
Our findings not only confirm the importance of the M2 protein as 
an immunodominant determinant of cellular immunity, but also shows 
that M2 is a key regulator of apoptosis in the germinal centre. Based on 
these results we suggest that M2 might function to promote the survival 
of activated and memory B cells, thus expanding the reservoir of host 
cells for the establishment of latency. 
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Figure S2. No significant difference of IL-10 levels in control and SRBC 
immunized normal and M2 transgenic FVB/N mice. 
Mice were immunized as described in materials and methods and the sera were 
assayed for IL10 using murine IL-10 ELISA Development Kit  (Peprotech) according 
to the manufacturer’s instructions. The values are given for each mouse individually. 
P>0.05 (not significant).
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Viral evasion research
Coexistence of viruses and their hosts imposes an evolutionary 
pressure on both virus and the many defensive possibilities of the 
innate and adaptive host immune systems. On the one hand, the host 
has developed an extraordinarily versatile immune system able to 
recognize pathogens, extracellular and intracellular whereas pathogens 
on the other hand, viruses have reciprocally evolved a wide range 
of strategies to manipulate the host cell biology and immune system. 
Although the study of viral genes has been intensively explored, much 
more investigation is still required for a complete understanding of the 
role many various host evasion proteins in the complete scenario of 
host-pathogen interaction. In this context, our lab sees the study of 
virus-host evasion genes as a genuine source of ready-made tools 
for future therapeutics. Therefore our focus is first to identify and then 
exploit host evasion mechanisms of assigned and non-assigned viral 
evasion genes, which the former can be identified through bioinformatics 
the latter can only be detected through functional assays. Previously, 
our lab demonstrated the importance of host-evasion mechanisms 
of some non-assigned viral evasion proteins from large DNA 
viruses, such as MHV-68, HCMV and AFSV, for example, the inhibition of 
cytokine and interferon responses (Correia, 2008) and the manipulation 
of cell cycle/apoptosis (Nascimento et al., 2011). One in particular 
(A238L) was used for the construction of a T cell restricted “evasion 
gene” transgenic mouse to explore mechanisms operating in the 
development of the lymphoid system (Almeida et al., 2012). 
In this thesis, we have elucidated the mechanism of two other different 
viral immunomodulatory genes, ORF I329L (ASFV) and ORF M2 
(MHV-68). These were identified through functional and bioinformatics 
analysis and their impact as transgenes was evaluated in vitro and 
in vivo, respectively. 
African Swine Fever virus gene I329L, a TLR3 antagonist  
in vitro
In the second chapter of this thesis, we have systematically analysed 
an unassigned gene from African SwineFever Virus, ORF I329L, 
characterizing its biological role as an inhibitor of TLR3 signalling. 
This research was motivated by the hypothesis that inhibition of TLR 
signalling may constitute an advantage for ASFV which must not 
only survive in both vertebrate and invertebrate hosts, but 
which is restricted to macrophage, the ‘motor’ of innate immunity, in both 
1
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hosts. We have identified through conventional bioinformatics a marginal 
sequence homology between I329L and TLR3. Subsequently, by 
biochemical analysis, we have characterized this unassigned 
gene as a highly glycosylated protein expressed in the cell 
membranes and on its surface, locations where many receptor 
and adaptor molecules involved in innate immunity have been 
identified (Fan et al., 2008).
Significantly, TLR3 is described as one of the most heavily glycosylated 
TLRs (Bell et al., 2006). Functional assays revealed that I329L 
inhibited dsRNA-stimulated activation of NFkB and IRF3, two key 
players in innate immunity. Consistent with this, expression of 
I329L protein also inhibited the activation of interferon-b and CCL5. 
Finally, overexpression of TRIF reversed I329L-mediated inhibition of 
both NFkB and IRF3 activation, suggesting that TRIF, a key MyD88- 
independent adaptor molecule, is a possible target of this viral 
host immunomodulation gene. Although this is the first ASFV gene 
manipulating TLRresponses to be described, the Vaccinia virus has 
evolved three proteins, A46R, A52R and N1L, that are inhibitors of the 
TIR-mediated immune response (Bowie & Unterholzner, 2008). Both 
A46R and A52R are able to inhibit signaling via multiple TLRs although 
the specificity varied showing that they are not redundant (Bowie et al., 
2000; Harte et al., 2003). In vivo loss of either protein caused a mild 
attenuation in a murine intranasal model of infection. The third protein, 
N1L, is a small intracellular protein that contributes to virus virulence in 
a more profound manner (Bartlett et al., 2002), targeting the I-kappaB 
kinase complex and inhibiting signalling via TLRs and tumor necrosis 
factor family of receptors (DiPerna et al., 2004).
Our early experimental results together with a bioinformatic approach, 
inspired a theoretical co-related work performed by Elsa Henriques in 
collaboration with our team (Henriques et al., 2011). Using comparative 
 structure modelling of the TLR3 and ORFI329L we hypothesized that 
I329L may function as a TLR3 decoy, showing that the viral protein 
could hinder TLR3 dimerization and inhibit the downstream signalling 
pathway. Our preliminary experimental data using FACS analysis of 
HEK-293T cells transfected with TLR3 and stimulated with Poly I:C 
indicated that I329L does not bind to dsRNA, but inhibits recognition 
of dsRNA by TLR3 intracellularly (unpublished data). Although our 
experimental data indicates that ORF-I329L-mediates intracellular 
inhibition through interaction with TRIF, the possibility that I329L 
protein interacts with the specific intracellular area responsible 
for TLR3 homodimerization, cannot be excluded. Based on our 
experimental data and the bioinformaticdata presented, some 
hypothetical models for the ASFV TLR-based strategies to evade the 
host defence by targeting TLR3 were considered. 
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B cell restricted transgenic expression of M2 MHV-68 
protein in vivo
In the third and fourth chapter of this thesis, we have reported the 
successful construction a B cell restricted transgenic mouse, as an 
alternative approach to explore the mechanism and exploitation of a 
specific virus host evasion protein on a single cell level. Previous work 
from our team already validated this approach to study the impact 
of another viral evasion gene from African Swine Fever Virus, ORF 
A238L (Almeida et al., 2012). An innovation of this work in particular, is 
that it allows the assessment of the biological effect of a specific virus 
transgene in association with the pathogenesis, during concomitant 
infection with the same virus, both wild-type and viral gene deficient, 
thus providing a good platform to study the impact in vivo of a single 
virus protein during acute and latent phases of virus infection. In this 
case, the selected M2 viral transgene is an already characterized viral 
host manipulation gene, implicated in the establishment, maintenance 
and reactivation of latency in B cells (Herskowitz et al., 2005; Macrae 
et al., 2003; Rodrigues et al., 2006) .
Although we have not found an effect on the distribution of B cell 
subsets in the bone marrow and spleens of the B-cell restricted M2 
transgenic mice, we have found an interesting phenotype, either 
when the transgenic mice were challenged with a thymus dependent 
protein antigen (DNP-KLH and SRBC), or when they were infected with 
MHV-68 or an M2 deficient recombinant virus. The latter findings 
are consistent with previous works describing M2 as a critical viral 
protein for B cells during the establishment and maintenance of latency 
in MHV-68 pathogenesis.
The predominant subtype observed following MHV-68 infection, as 
well as in other viral infections, is IgG2a, suggesting a preferential 
class switching (Coutelier, 1987). Interesting, in our hands, transgenic 
mice just immunized with the T-dependent antigen (DNP-KLH) also 
produced significant higher levels of IgG2a anti-DNP antibodies 
than normal mice, especially in the secondary challenge. This may 
be due to the increased germinal centre formation observed in M2 
transgenic mice immunized with sheep red blood cells. It is possible that the 
increased germinal centre formation was the result of the significant 
lower levels of apoptosis in the virus infected transgenic splenic 
B-cells. In view of these findings it would be interesting to determine 
the affinity of the IgG2a antibodies in wild-type and M2-transgenic 
mice, the prediction being lower although (with less apoptosis) in the 
transgenics. 
Infection of normal mice with M2 deficient MHV-68 resulted in an 
increased reactivation in the late, but not the earlier phase, of 
1.2
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latency, an observation not seen when the M2 transgenic mice were 
similarly infected. More interesting, the observation of higher reactivation 
centres in the late phase of latency in the M2 transgenic mice infected 
with wild-type viruses is consistent with the proven importance of M2 
as a determinant of protective cellular immunity, and thus with an 
impact on the establishment of persistence (Husain et al., 1999). 
Together these data provide strong evidence that M2 manipulate the 
activation, proliferation and survival of B cells in vivo. These findings not 
only confirmed the importance of the M2 protein as an immunodominant 
determinant of cellular immunity, but also demonstrated in vivo that 
the M2 protein protects B cells from apoptosis in vivo validating 
previous described data with M2 transfected WEHI-231 B cell lines 
in vitro (Madureira et al., 2005), thereby providing a viral strategy for 
increasing the pool of potential host cells for the establishment of 
latency. Thus M2 might function to promote the survival of activated 
and memory B cells, thereby expanding the reservoir of host cells 
for the establishment of latency. We hypothesized that M2, perhaps 
through its known interaction with Vav (Madureira et al., 2005; Pires de 
Miranda et al., 2008) increases the sensitivity of the latently infected 
B cells to activation via the immunoglobulin receptor (BCR), and thus 
might favour reactivation and consequent virus transmission. 
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2 Final remarks
The results of this work have contributed to the understanding of the 
impact of two different viral immunomodulatory proteins at the cell and 
whole animal level. At the cell level, we demonstrated in this thesis 
the major impact of I329L on innate immunity, which has never been 
described before. Besides adding to our understanding of the ASFV 
genes involved in immune evasion, these findings may contribute to 
the development of new and rational therapeutic approaches. The 
I329L gene may constitute a good candidate for development of 
therapeutics for autoimmunity and chronic inflammatory disorders or 
creation of an attenuated deletion ASFV mutant vaccine.At the animal 
level, we demonstrated an approach relevant to study the impact in 
vivo of a single virus protein during MHV-68 latency. Here, our data 
not only confirmed data that M2 is able to manipulate the activation 
and proliferation of B cells in vivo but also validate the effect M2 on the 
inhibition of apoptosis in vivo for the first time through an innovative 
approach. Without doubt this work contributed to better understanding 
of M2 role in the physiopathology of infection as well the immune 
response at the cellular level. In the future, it would be interesting 
to validate our results in a mouse with controlled gene expression 
system where the gene of interest is expressed temporally as well as 
spatially controlled manner.
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